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Motor neurone disease refers to a group of neurological disorders that result from 
progressive degeneration of the motor neurones leading to death from respiratory 
failure within 3-5 years from the onset of symptoms. Amyotrophic lateral sclerosis 
(ALS) is one of the most common forms of motor neurone disease, and can be 
described as entailing the involvement of both upper and lower motor neurones. 
Usually, the disease is obvious and presents as asymmetrical weakness in the limbs 
and progressive muscular atrophy.  
Over the last two decades more than 30 genes have been identified as involved in ALS 
pathology. These include PARK7 and FUS (Fused in sarcoma) which are the subject 
of this thesis. FUS is a multifunctional protein that has ubiquitous expression and is 
involved in different steps of RNA processing such as mRNA and miRNA. 10% of 
ALS cases are heritable and mutation of the FUS gene is found in 3-5% of familial 
forms of ALS. Therefore the FUS gene is important for it association as a candidate 
gene that is postulated to be important for ALS, in addition to various types of cancer. 
Mutations with FUS gene have been found in autopsy samples from the brain and 
spinal cord of patients with ALS. Understanding the regulation of FUS gene 
expression may, therefore, give insights into how its stimulus inducible expression 
may be associated with neurological disorders. 
My hypothesis is that the evolutionary conserved regions (ECRs) and primate specific 
retrotransposons of the SINE-VNTR Alu (SVA) are regulatory domains from the 
human FUS gene and PARK7 genes. Consequently, the aim of this thesis was to 
develop an in vivo model to validate their regulation. Comparative genomic analysis 
was used between distant species, utilizing the ECR browser and UCSC browser to 
identify conserved regions from the FUS gene. It is demonstrated that ECR and SVA, 
 xviii   
 
which can drive reporter gene activity in vitro (in the neuroblastoma cell line), are also 
capable of driving reporter gene expression in the chick embryo neural tube and brain 
at embryonic day 5. 
In conclusion, these identified important ECRs from human FUS gene act as 
regulatory domains. In addition, the SVAs, representing the most recent 
retrotransposon to enter the human genome also was showed to have regulatory 
properties in FUS and PARK7 genes. Furthermore, the thesis demonstrates that these 
elements regulate gene expression in vitro and in vivo. This supports the idea that 
employment of the chick embryo as a useful and informative model system to analyse 
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1.1 Overview  
To understand nerve cell gene regulation, a description of both the embryonic 
development of the nervous system and adult nervous system is required. In the first 
part of the introduction, I describe the development of the human nervous system from 
the ectoderm. After that, the definition of Motor Neurone disease and classification of 
motor neurone disease is clarified. Next, a commentary on the genes implicated in 
motor neurone disease, including FUS and PARK7 and how they are implicated in 
ALS and neurodegenerative disease.  I have focused specifically, on the elements that 
regulate gene expression. These regulatory elements are evolutionary conserved 





1.2 Differentiation of neurons in the central nervous system 
At the early embryonic stages, the human nervous system is developed from the 
external germinal layer of the blastula called the Ectoderm (Strominger et al., 2012). 
The ectoderm is induced by the trophic factors derived from the mesoderm and 
notochord to differentiate to neuroectoderm and form neural tissue. The neural tissue 
in the midback region will differentiate and thicken to form the neural plate which 
itself will develop into the central nervous system (Yuan et al., 2006). The neural plate 
will elongate and enlarge at the anterior region and form the brain, while the lateral 
edge of the neural plate will develop and enlarge to form the neural tube. The 
establishment of the neural plate is governed by the expression of four types of 
proteins that bind to the bone morphogenetic protein 4 (BMP-4): noggin, follistatin, 
chordin and bone morphogenetic protein (BMP) (Strominger et al., 2012). Molecular 
genetic studies of the development and establishment of the nervous system have 
revealed the role of genes in initiating the patterns and regions of the nervous system 
(Hatten, 1999). The differentiation of the neural tube and central nervous system 
(CNS) are under the control of a number of genomic transcription factors. Indeed, 
these factors within the regional differences in the underlying mesodermal somites 
have a role in the initiation of the anterior posterior axis (AP) and the formation of the 
forebrain, midbrain, hindbrain and spinal cord, while the development of the pattern 
of the dorsal-ventral axis is induced by different transcription factors. These factors 
will divide the neural tube into the dorsal and basal plates, for example the sensory 
neurones are produced from the dorsal plate while the motor neurones are produced 
from the basal plate. The development of lower motor neurons within the neural tube 
is influenced by factors from the notochord. These factors, including Sonic hedgehog 
 4   
 
(Shh), fibroblast growth factor (FGF) and retinoic acid, play an important role in the 
process of dorsal and ventral neural tube specification. Shh originates and is 
synthesized in the notochord and can function in the ventral specification of the neural 
tube. In contrast, FGF originates from the dorsal ectoderm. Both of these factors can 
induce a second signal centre located within the neural tube (Pierani et al., 1999). 
Initially, Shh can influence the medial hinge cells to form the floor plate of the neural 
tube (see Figure 1.1)(Placzek et al., 1990). In turn these floor plate cells can also 
secrete Shh, with the most ventral part of the neural tube having the highest 
concentration of Shh (Liem et al., 1995, Sander et al., 2000). Cells that are located 
next to the floor plate are exposed to the highest concentration of Sonic hedgehog and 
will develop to form the ventral (V3) neurons and the second set of cells, which receive 
a lower concentration of Sonic hedgehog protein, concentration will develop into 
motor neurones. The other two sets of cells, meanwhile, which are exposed to even 






















Figure 1.1: A newly formed vertebrate neural tube with two cell types 
of chick embryo neural tube. Those cells located near to the notochord 
develop into ventral floor plate and those in the ventrolateral sides are 
called the motor neurone region. Figure has been adapted from Placzek et 
al. (1990).  
 
 











The basic organization of the neural tube into a brain, meanwhile, is a result of the 
expression of particular genes encoding protein factors that regulate the transcriptions 
of other genes and control brain differentiation. HOX genes are one such example. 
These control the hind brain cell identity and initiate the segmental pattern of the spinal 
cord and spinal ganglia. HOX gene expression is regulated by retinoic acid (RA) and 
has an important role in the establishment of the AP axis in both the spinal cord and 
the hind brain. Another example is Otx2 transcription factors, which are expressed in 
the anterior region of the forebrain to the border between midbrain and hindbrain. 
wnt1, meanwhile, is in control of the AP axis of these regions, the Pax6 gene is 
expressed in rostral (motor) regions of the cortex, and the Emx2 gene is expressed in 
the posterior part of the motor region of the developing cortex. 
 
Figure 1.2: In vitro experimental illustration of the importance of Sonic hedgehog 
in the patterning of the ventral portion of the vertebrate neural tube. The 
relationship between the Sonic hedgehog gradient concentration, the development of 
specific neuronal types in vitro, and the space in nM from the notochord. This Figure 




1.3 Classification of neurones 
Neurones can be classified into sensory neurones, motor neurones and association 
neurones (Kaye and Davis, 2014). Sensory neurones have a role in transmitting the 
impulses to the central nervous system and can be in two subtypes; somatic sensory, 
which transmit the impulses from sensor receptors in the skin, bones and joint muscles 
to the central nervous system (CNS); and visceral sensory, which transmit the 
impulses from visceral organs. Motor neurones, however, transmit impulses away 
from the central nervous system and are divided into two subtypes, somatic motor 
neurons, which innervate the skeletal muscles, and visceral motor (autonomic motors), 
which innervate cardiac and smooth muscles and glands. The third subtype, associated 
neurones, or interneurones, transmit information, directly and indirectly, from sensory 
neurones to motor neurones and it is this type that account for most neurones in the 
brain (Stifani, 2014). 
1.4 Motor neurones (MNs) 
Motor neurones can be defined as a group of neuronal cells located in the central 
nervous system (CNS). These cells can regulate both voluntary and involuntary 
movements (Kaye and Davis, 2014). Motor neurones (MNs), generally, can be 
classified into two main categories according to the location of their cell body: upper 
motor neurones and lower motor neurones (Stifani, 2014). Despite the fact that both 
types share the same nomenclature, upper motor neurones and lower motor neurones 
are fundamentally different in terms of the location of their cell body, 
neurotransmitter, lesion symptoms and cell targeting (see Table 1.1) and finally 
clinical symptoms upon lesion (Talbot and Marsden, 2008). Furthermore, upper MNs 
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activate lower motor neurons, while lower MNs (except for visceral MNs) are 
connected to the target muscles directly.  
 
Table 1.1: Comparison between the upper and lower motor neurones regarding, 
location, symptoms upon lesion neurotransmitters and targeting (Redrawn from 
(Stifani, 2014)). 
 Upper MNs Lower MNs 
Location Cortex and Brainstem Brainstem and spinal 
cord 
Neurotransmitter Glutamate Acetylcholine 
Targeting Within the CNS Outside the CNS 
Symptoms upon lesion Spasticity Paralysis 
 
1.4.1 Upper motor neurones 
Upper motor neurones originate from either the motor region of the cerebral cortex or 
from the brain stem (Figure 1.3) (Purves et al., 2001, Kenneth, 2003). Upper motor 
neurones can transmit motor information to the downstream target (lower motor 
neurones) through glutamatergic neurotransmitters. They are mainly initiators of 
voluntary movement, and reside in the fifth layer of the grey matter primary motor 
cortex, where they are called Betz cells. Betz cell or (pyramidal cells of Betz) are a 
type of giant pyramidal cell that have the largest cell bodies in the brain and are 
approximately 0.1 mm in diameter. In fact the Betz cells are located precisely in the 
precentral gyrus. The precentral gyrus is considered the most important region of the 
frontal lobe. Upper motor neurones project their axons away from the precentral gyrus 
and end in the brainstem. In the brainstem, they form synapses with the lower medulla 
oblongata and form the lateral corticospinal tract that is located on both sides of the 
spinal cord. Those fibres that do not form synapses, will pass into the corticospinal 




Figure 1.3: Illustration of the location of upper and lower motor neurones according to 
the anatomical pathways controlling movement. Upper motor neurones originate from the 
motor region of the cerebral cortex; they are located in the motor cortex and are responsible 
for voluntary movements. These neurones contribute their axons to the corticospinal tract. 
Then, the corticospinal tract passes the through the medulla (brain stem). After that, most 
fibres decussate and enter the lateral corticospinal tract and the remaining fibres that not cross 
will enter the ventral corticospinal tract directly. Then, the axons extend to reach their target 
in the spinal cord. These are the lower motor neurones, whose bodies are located in the grey 
matter and whose axons innervate the muscle fibres directly. This Figure has been adapted 
from; Damjanov (2000).   
1.4.2 Lower motor neurones  
Lower motor neurones cell bodies are located in specific nuclei in the brainstem and 
ventral horn of the spinal cord. Similar to the upper motor neurones, they reside within 
the CNS but, in contrast to upper motor neurones, they project their axonal extension 
and connection outside of the nervous system (Figure 1.3). Lower motor neurones 
receive neurotransmitter inputs from upper motor neurones, sensory neurones and 
interneurons. Furthermore, injury to lower motor neurones can cause paralysis since 
the damaged pathway cannot be replaced by other pathways to transport the 
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information to the downstream target in the periphery (Stifani, 2014). Lower motor 
neurones can be classified into three categories: I) Somatic motor neurones, ii) 
Visceral motor neurones and iii) Special visceral motor neurones (Kandel et al., 2000). 
Somatic motor neurones are located in the midbrain, hindbrain and ventral horn of the 
spinal cord. Somatic motor neurones innervate and control eye and tongue muscle 
movement and innervate limb muscles. The visceral motor neurones, or general 
visceral motor neurones, are located in the hindbrain and innervate the 
parasympathetic neurones that in turn innervate the tear and sweat glands, pulmonary 
glands, the cardiovascular and gastrointestinal system and, finally, the smooth 
muscles. Branchial motor neurones, or special visceral motor neurones, are located in 
the hindbrain and innervate the skeletal muscles that derive from the branchial arch 





1.5 Motor neurones rely on motor proteins  
When axons are viewed by quick-freeze-deep-etch electron microscopy their 
cytoskeletal structure (ultra-structural inclusions) shows three different types of 
filaments i.e. actin microfilaments, microtubules and intermediate filaments (IFs). The 
intermediate filaments, or neurofilaments, are abundant in many axons. The axonal 
cytoskeleton provides a mechanical route to transport the secreted molecules (in 
vesicles) produced in the cell body which is necessary for the synapse transmission in 
the axonal terminal (Yuan et al., 2006). 
The highly specialised morphology of these neurones depends on a dynamic system 
that can transport the vesicles’ protein and organelles, including mitochondria and 
secretory vesicles, from the cell body towards the axonal terminal by a mechanism 
called fast axonal transport. Slow axonal transport, meanwhile, can convey other 
cytoskeletal proteins towards the axonal terminal (Dillman III et al., 1996, Hirokawa 
and Takemura, 2004). The inner environment of the neurones has a machinery system 
which can be characterised by two main elements: the microtubules, which act as 
tracks and the molecular motors that can transport cargo along the microtubules. The 
microtubules have two ends, one called the plus end that is localised towards the 
synapse, while the minus end is towards the cell body. In the cell cytoplasm, dynein 
is considered to be a major motor protein, and is a retrograde transport that moves 
towards the minus end of the microtubules. A member of the kinesin motor family, 
meanwhile, moves the cargo towards the plus end of the microtubules (Rao et al., 
2011). Microtubule motor proteins have an essential role in neurones and other cell 
types (Figure 1.4). There are several types of microtubule binding protein, including: 
kinesin and the kinesin superfamily, dyneins, dynactin and tau protein.  
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1.5.1. Kinesin superfamily proteins (KIFs) and Kinesin 
Molecular motors have an essential role in transportation of the protein complexes, 
organelles and mRNA to a particular location. This family have more than 45 members 
known as kinesin superfamily proteins (KIFs), all these members have been identified 
in the human genome (Xia et al., 2003) and share homology with the 340 amino acid 
motor domain of conventional kinesin (Miki et al., 2001). KIFs are a microtubule 
motor protein and have an essential role in the anterograde transport in axons and 
dendrites. Kinesin can use the energy from ATP hydrolysis to convey the protein 
complexes, organelles and mRNA along the microtubules to target destinations 
(Goldstein and Yang, 2000). A mutation in the kinesin gene expressed in neurons can 
cause hereditary spastic paraplegia type 10 (SPG10) (Reid et al., 2002). Similar 
mutations were observed in other kinesin superfamily proteins, which also caused 
defects in motor activity, and resulted in axonal degeneration of motor and sensory 
neurons in patients with these mutations. 
1.5.2 Dyneins 
Cytoplasmic dynein in neurones has a major role in retrograde axonal transport but 
also has a variety of other cellular functions including neurofilament transport, mRNA 
localisation and endoplasmic reticulum-to-Golgi vesicular transport. Dyneins use the 
energy from ATP hydrolysis in order to move their cargo towards microtubule minus 
ends (Holzbaur, 2004, Yuan et al., 2006). Cellular studies have demonstrated that 
mutations in the cytoplasmic dynein heavy chain can cause progressive motor neuron 
degeneration in heterozygous and homozygous mutant mice and perturb neuronal 
function of dynein. These mutations can lead to inclusion of the Lewy-like body, 




Dynactin may also be called dynein-activator complex and has a major role in the 
cellular function of cytoplasmic dynein. Dynactin can act to raise the efficacy of the 
motor and to pair it with its vesicular cargos (Holzbaur, 2004). Work by Puls et al 
(Puls et al., 2003) demonstrated that a substitution mutation in a single base pair can 
cause misfolding of dynactin’s binding domain and lead to human motor neuron 
disease.  
1.5.4 Tau protein 
Tau was identified in 1972 for its function as a promoting factor in tubulin 
polymerisation (Weingarten et al., 1975). Tau is a neuronal protein and is located 
primarily in axons. Tau has an important role in stabilising and organising the 
dynamics of microtubules (Rao et al., 2011). The pathophysiology of tau protein was 
studied by Orozco et al (Orozco et al., 2012) which showed that tau transcripts 
including exon 10 can cause frontotemporal dementia and Parkinsonism. 
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Figure 1.4: Microtubule motor proteins shuttling the cargo in the neuronal axon. In 
neurones, the microtubule motor protein can transport the material toward the axon 
presynaptic terminal by anterograde transport powered by kinesin and proteins of the kinesin 
super family (KIF). Retrograde axonal transport requires both cytoplasmic dynein and 
dynactin in order to transport the material back to the cell body for degradation. This Figure 
has been adapted from; Holzbaur (2004). 
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1.6 Motor Neurone Diseases (MNDs)  
Motor neurone disease (MND) is a progressive neurodegenerative disease, ultimately 
leading to death with respiratory failure, commonly five years from the onset of the 
symptoms (Aoun et al., 2012) . The terminology MND is typically used in the UK and 
represents an umbrella that collects all types of motor neurone disease, while the term 
Amyotrophic Lateral Sclerosis or Lou Gehrig’s disease is commonly used in the USA. 
For this reason MND and ALS are often used interchangeably although in this thesis 
MND is used as an umbrella term and ALS as a specific type, as defined here. The 
symptoms associated with MND can be characterised by motor weakness and bulbar 
dysfunction (Bäumer et al., 2014). 
The existence of a disease associated with degeneration in the motor neurones was 
first observed in the 19th century, and the neurologist Jean-Martin Charcot was the first 
person to identify the combination between upper and lower motor neurone 
dysfunction (Vejjajiva et al., 1967). The incidence of motor neurone degeneration in 
the UK population is about 1 in 50 000 (Bäumer et al., 2014), with currently between 
5000 and 6000 people living with diagnosed MND in the UK. MND is therefore 
considered to be a relatively rare disease (Fisher et al., 2012). MND is also an age-
related disease, with most affected individuals being between 50 and 65 years old; 
however, 5-10% of patients are below 40 years (Bäumer et al., 2014) . Men are usually 
more susceptible to MND (one and a half times more so than women). MND is caused 
by a combination of genetic and environmental factors and many theories have tried 
to explain the role of dietary factors in MND. For example lathyrism in India and 
konzo in Africa are examples of neurotoxic disorders mainly caused by the intake of 
the neurotoxic plant products Lathyrus sativus and Manihot esculenta (Spencer and 
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Palmer, 2012). These toxins can affect the Betz cells specifically. Environmental 
poisons such as pesticides and heavy metals, in combination with genes that have risk 
factors for disease susceptibly may also be involved (Trojsi et al., 2013) . 
1.7 Classification of motor neurone disease  
In general, MNDs are considered to be a syndrome that involves various clinical 
phenotypes, which share features of progressive motor neurone degeneration. Many 
criteria are used to classify MNDs including: degree of involvement of upper motor 
neurones (UMN) or lower motor neurones (LMN). It can be classified into sub forms 
for example: a) Amyotrophic lateral sclerosis (ALS), b) Progressive bulbar palsy 
(PBP), c) Progressive muscular atrophy (PMA), d) Primary lateral sclerosis. e) 
Pseudobulbar palsy, f) Hereditary spastic paraplegias. Other criteria that can be used 
to classify MNDs include: rapidity of the disease progression, e.g. slow or rapid. 
Diffuse MND or regional spread e.g. flail arm, bulbar (PBP). Age at onset: younger 
than 45 years or older, familial or sporadic, cognitive involvement: Frontotemporal 
dementia (FTD) or loss of executive function (Ludolph et al., 2015) . There is no 
precise test for MND and it is known that MND has variable characteristics that might 
affect people in different ways. These include the distribution of the disease in the 
body and also the rate of  disease progression (Ludolph et al., 2015). Clinical diagnosis 





1.7.1 Amyotrophic lateral sclerosis (ALS)  
ALS is the typical or classical form of MND. It can be described as having 
involvement of both upper and lower motor neurones (Figure 1.5). Initially, symptoms 
start in the hands and feet as asymmetrical weakness, then the muscles tend to become 
stiff and weak, followed by wasting in the limbs due to damage in the motor neurones 
located in the brain, brainstem and corticospinal tract for instance. It can also present 
as spinal onset with limb weakness or bulbar onset with difficulty with speech and 
swallowing (Kelly, 2012, Xia et al., 2003, Agosta et al., 2015) finally leading to death 
from respiratory failure. 
1.7.2 Progressive bulbar palsy (PBP)  
This form of MND involves both upper and lower motor neurones (Cerero Lapiedra 
et al., 2002). At first, the motor neurone cells that are located in the motor cortex, 
spinal cord, brain stem and pyramidal tracts degenerate (Cerero Lapiedra et al., 2002). 
Then, it affects the bulbar muscles, including the muscles used for talking, chewing 
and swallowing. Patients with this form of the disease exhibit bulbar and cortico-
bulbar symptoms, which include dysphagia, dysarthria, tone wasting and brisk jaw 
jerk. 
1.7.3 Progressive muscular atrophy (PMA)  
This is an uncommon form of MND, about ~ 4 % of people with MND have this type. 
This condition is also known as lower motor neurone syndrome. The muscles of the 
hands and feet are usually first affected or it might affect just one of either. This form 
is applied when there is no involvement of upper motor disease and usually has a better 
prognosis (Riku et al., 2014). 
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1.7.4 Primary lateral sclerosis  
This is a rare type of MND and accounts for 1% of all cases. It can mainly be diagnosed 
as weakness and spasticity in the leg muscles and spastic bulbar weakness (Figure 
1.5). Typically, symptoms start in one leg and then diffuse over time to involve the 
arms, speech and swallowing muscles (Turner et al., 2013). In fact, in most types of 
MND, the symptoms start in a certain location and spread out as they progressively 
affect neighbouring neuronal cells (Talbot, 2002). 
 
1.7.5 Pseudobulbar palsy  
This condition is characterised mainly by failure to control facial muscles, specifically 
the muscles which control the movements needed for chewing and speaking. People 
affected with this disorder can show difficulty in chewing and swallowing. This 
condition results from degeneration of motor neurones located in the brain stem and 
corticobulbar tract (Steele et al., 2014). 
 
1.7.6 Hereditary spastic paraplegias (HSP)  
This is a group of conditions mainly characterised by pyramidal weakness and 
presence of spasticity in the lower limbs and hyper-reflexia with extensor plantar 
responses (Fink, 2013). HSP has been found in all types of inheritance (autosomal 







Figure 1.5: Illustration of the location of motor neurone cells in the nervous system with 
relation to the MND form. The upper motor neurones which are located in the motor cortex. 
In the case of ALS and PLS these cells will be affected and eventually damaged. The fibres 
descending from the upper motor neurones will pass through the corticospinal tract and 
synapse with lower motor neurones; in ALS cases these neurones are also affected and 
eventually become damaged. This Figure has been adapted from; Stifani (2014). 
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1.8 Genes implicated in ALS. 
Over the last two decades more than 30 genes have been identified and characterised 
for their role in ALS pathology. This section will explore several mutant genes that 
have been implicated in familial amyotrophic lateral sclerosis (FALS). These include 
Superoxide Dismutase 1 (SOD1), TAR DNA binding protein (TARDBP), Elongation 
Protein 3 (ELP3), Kinesin-associated protein 3 (KIFAP3), chromosome 9 open 
reading frame 72 (C9orf72) and Fused in sarcoma (FUS). Along with these genes, the 
PARK 7 gene was also studied due to its association with both motor neurone disease 
and neurodegenerative diseases more generally. 
1.8.1 Superoxide Dismutase 1 (SOD 1). 
Mutations in the SOD1 gene were first identified in relation to ALS in 1993 (Rosen et 
al., 1993). They are implicated in 20% of autosomal dominant cases of FALS and are 
also found in all types of motor neurone disease (Dion et al., 2009). In addition, a few 
cases of ALS related to SOD1 mutation show a recessive inheritance (Dion et al., 
2009). SOD1 is an abundant and ubiquitously expressed gene, encoding for the 
copper/zinc superoxide dismutase enzyme that functions as an active homodimer 
cytosolic enzyme. The main role of this enzyme is to reduce the production of reactive 
oxygen species (ROS) by catalysing the conversion of toxic superoxide radicals to 
molecular oxygen and hydrogen peroxide. The protein consists of 153 amino acids 
and changes in more than 125 distinct amino acids have been linked to ALS cases. 
Mutations within this gene might disrupt the highly-stable native SOD1 enzyme, 
leading to protein misfolding and then aggregation. Generally, oxidation and mutation 
of SOD1 can lead to misfolding of the SOD1 protein producing toxic gain-of function 
(Grad and Cashman, 2014). As a result of SOD1 misfolded protein, SOD1 has been 
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implicated in ALS pathology in the form of excitotoxicity, mitochondrial dysfunction, 
endosomal trafficking, oxidative stress and axonopathy (Beckman et al., 1993, Boxer 
et al., 2011). 
 
1.8.2 Transactive response DNA binding protein (TARDBP coding for TDP-43)  
The transactive response DNA binding protein (TDP-43) is encoded by the TARDBP 
gene. This protein has ubiquitous expression and is a 43 kD nuclear protein that 
translocates between the nucleus and the cytoplasm. TDP43 plays an important role in 
gene regulation, including in transcription, RNA splicing, mRNA stability and micro 
RNA biogenesis (Dion et al., 2009). Deletion of TARDPB results in embryonic 
lethality and loss of function of TDP-43 in neuronal cell culture, causing mRNA 
missplicing and neuronal defects (Mutihac et al., 2015). Mutations in the gene coding 
for TDP-43 have been identified as having a significant causative link for ALS and as 
accounting for 4% of FALS and some cases of FTD, as well as involvement in all 
types of motor neurone disease (Kabashi et al., 2008). TDP-43 consists of 414 amino 
acids, is encoded by six exons and has two RNA recognition motifs and a C–terminal 
that is enriched with a glycine region and that interacts with heterogeneous nuclear 
ribonucleoproteins (hnRNPs) (Buratti et al., 2005).  Dominant mutations in the 
TARDBP gene have been found in ALS cases (Lagier-Tourenne and Cleveland, 2009, 
Gitcho et al., 2008, Kabashi et al., 2008, Sreedharan et al., 2008, Van Deerlin et al., 
2008). These studies have demonstrated that the aberrant form of TDP-43 can cause 
neurodegeneration. Most mutations are located in the C-terminal which is encoded by 
exon six of the TARDBP gene. Patients with  mutation in TDP-43 develop ALS, and 
over 50% also developed cognitive impairment (Colombrita et al., 2009). 
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Furthermore, TDP-43 inclusions were found in the cytoplasm or nucleus of neurone 
and glial cells from the spinal cords and brains of ALS patients (Neumann et al., 2006, 
Van Deerlin et al., 2008). Neuropathy caused by TARDBP mutations can be 
characterized by hyper-phosphorylation and ubiquitination with the generation of a 
25 kD C-terminal fragment that is missing the nuclear localised domain. In 2008, 
dominant mutations in the TARDBP gene were identified as a major cause of ALS 
and represent approximately 3% of familial ALS cases and 1.5% of sporadic cases 
(Dion et al., 2009). Inclusion bodies associated with mutation in the TDP-43 are seen 
in the cytoplasm of both the upper and lower motor neurones and both the frontal and 
temporal cortex of the central nervous system (Al-Chalabi et al., 2012). 
  
1.8.3 Elongation protein 3 
ELP3 gene codes for an RNA processing protein(Simpson et al., 2009). It has an 
essential role in the construction of the Elongator complex, called holo-Elongator, and 
is a component associated with RNA polymerase II, which is essential for RNA 
binding (Greenwood et al., 2009, Kristjuhan and Svejstrup, 2004, Tanner and Linder, 
2001). Two loss-of-function mutations were identified in Drosophila ELP3 which can 
cause abnormality in axonal targeting and synaptic development. Knockout of ELP3 
in zebra fish resulted in a shortening the motor neurone branching and other abnormal 
features of the nervous system (Simpson et al., 2008). Added to that in an association 
study of 1483 individuals, ELP3 was found to have an association with human motor 





1.8.4 Kinesin Associated Protein 3 
KIFAP3 gene codes for kinesin associated protein. This gene, located in the 
chromosome1 q24.2, is involved in chromosome movement and has an intracellular 
function as part of the transport machinery. Genomic wide association studies by 
(Landers et al., 2009) have demonstrated that the CC genotype of the single nucleotide 
polymorphisms (SNP) rs1541160 located within intron 8 of the KIFAP3 gene is 
associated with a survival advantage of 18 months among 1014 patients with ALS. 
Further analysis of this study showed that there is a linkage disequilibrium between 
rs1541160 and rs522444 in KIFAP3 promoter region and these alleles are favourable 
in correlation with the decreased level of KIFAP3 expression in brain tissue and 
lymphoblast of ALS patients. 
 
1.8.5 Chromosome 9 open reading frame 72  
The gene termed Chromosome 9 open reading frame 72 (C9orf72) was discovered by 
(Gijselinck et al., 2012) through its linkage to ALS, which is achieved through a large 
hexa-nucleotide coded for GGGGCC repeat expansion mutations residing in the non-
coding region of the C9orf72 gene that has a correlation with neurodegenerative 
disease including fronto-temporal lobar degeneration (FTLD) and ALS. Mutations in 
C9orf72 account for approximately 20-30% of FALS patients. The pathology 
associated with this gene can result from the loss of function of the C9orf72 protein. 
Alternatively, it can be caused by  gain of function mechanisms including sense or 
antisense repeats of RNA (Mizielinska et al., 2017). Another mechanism may  be  the 
formation of RNA aggregates  in the neuronal nuclei which might sequester important 
RNA-binding proteins and form a toxic dipeptide repeat (DPR) protein in order to 
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mediate the RNA repeat translated with the absence of an ATG initiation codon 
(Gijselinck et al., 2012, Van Mossevelde et al., 2017). 
 
1.8.6 PARK7 
The PARK7 gene is located on the distal part of the short arm of the chromosome 
1p36.2-p36.3 and the gene is also called DJ-1. It was first identified as a protein that 
has a potential oncogenetic role by working in cooperation with ras oncogene to 
transform mouse NIH-3T3 cells (Nagakubo et al., 1997). PARK7 protein is 
ubiquitously expressed in over 22 human tissues and is also found to be expressed in 
both cell nuclei and the cytoplasm of the HeLa cell line (Nagakubo et al., 1997, Singh 
et al., 2015). PARK7 is highly expressed in brain and cerebral tissues. The product of 
this gene has 189 amino acids. The protein can act as a positive regulator of androgen 
receptor-dependent transcription AR, and thus it can interfere with the binding of the 
PIASxα with AR (Takahashi et al., 2001). 
PARK7 has an important role in the human cell lines, as an antioxidant and or a 
molecular chaperone. Many studies have suggested that PARK7 may function as a 
redox-sensitive chaperone, and can protect the neurons from oxidative stress and cell 
death. Defects with the PARK 7 gene can cause several diseases, including 
Parkinson’s disease 7, autosomal recessive early onset familial Parkinson’s disease 
(PD), juvenile type 2se (Dawson and Dawson, 2003, Alvarez-Castelao et al., 2012). 
Furthermore, PARK7 can cause breast cancer and non-small cell lung carcinoma (Le 
Naour et al., 2001, MacKeigan et al., 2003b). PD  is known as a heterogeneous disease, 
with most cases appearing to have sporadic origins, although mutations with specific 
genes can cause familial PD (Macedo et al., 2003). PD symptoms can have general 
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features, such as resting tremor, postural instability with muscular rigidity, and 
akinesia (Jankovic, 2008). 
1.8.7 Fused in Sarcoma Protein (FUS). 
The FUS gene was selected to be the focus of the investigation in this thesis for a 
number of reasons. At the beginning of this study, the FUS gene had recently been 
discovered to be implicated in ALS (Kwiatkowski et al., 2009) and it was therefore 
clearly an important next step to know the role of the FUS gene in ALS; secondly, 
FUS mutation had been shown to represent more than 3-5% of cases of FALS 
(Kwiatkowski et al., 2009). Thirdly, we identified an SVA with central VNTR located 
upstream of the FUS gene that might have an important role in the regulation of the 
FUS gene (Savage et al., 2014a). 
The FUS/TLS gene was identified twice; first in human myxoid liposarcoma, where 
it was named FUS (Fused in sarcoma) since the gene was found to be disrupted in the 
chromosomal translocation, t(12;16) (q13;p11) and fused to CHOP gene (GADD153), 
which acts as a transcriptional repressor (Rabbitts et al., 1993) and later in human 
myeloid leukaemia, when the gene was fused with the transcriptional activator, ERG 
and seen in the recurrent chromosomal translocation, t(16;21) (p11:q22) . FUS gene 
coding for Fused in Sarcoma Protein is located on chromosome 16. FUS/TLS and 
hTAF1168 are known as RNP-motif-containing proteins and are present in the Pol II 
transcription complexes and involved in Pol II transcription (Bertolotti et al., 1996). 
The collection of human FUS/TLS, with EWS protein and TAF 15 (TATA-binding 
protein associated factor) with Drosophila Cabeza/SARFH protein comprise a sub-
family of RNA binding proteins, known as the TET or FET family (TLS/FUS, Ewing’s 
sarcoma, TATA-binding protein-associated factorII-68) (Bertolotti et al., 1996). 
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Previous studies have determined that the FUS/TLS, EWS, RBP56/hTAFII68 genes 
have conserved domain structure proteins and similar genomic structures, which might 
indicate that these genes originated from the same ancestor gene (Morohoshi et al., 
1998). FUS/TLS protein has been reported to form a ternary complex with other 
proteins such as hnRNP A1 and hnRNP C1/C2 (Zinszner et al., 1994). It is also worth 
noting that FUS/TLS protein was identified by (Calvio et al., 1995) as hnRNB P2 
assembled on pre-mRNA. While FUS/TLS-like protein was isolated from HeLa cell 
as a TATA-binding protein associated factor (Khokha and Loots) by (Bertolotti et al., 
1996). Added to that it was demonstrated by (Bertolotti et al., 1996) that EWS protein 
was correlated with TFIID and the RNA polymerase II complexes. Drosophila 
Cabza/SARFH protein also has a similar structure to EWS protein, containing active 
transcription units through RNA polymerase II (Immanuel et al., 1995). These data 
suggested that FUS/TLS, EWS and Drosophila Cabeza/SARFH with 
hTAFII68proteins are involved in the transcription and metabolism of mRNA. In the 
TET family, the RNA binding domain of most of its members is encoded by three 
exons; the exception is the Cabeza/SARFH protein where the RNA binding domain is 
encoded by two exons. The TET family, therefore, contains the only RNA binding 
domain that has a strongly conserved exon structure, and this conservation is not seen 
in other families of RNA binding proteins (Morohoshi et al., 1998).  
The FUS/TLS gene consists of 15 exons that span 12 kb of human genomic DNA. The 
translation initiation codon is located in the first exon, the promoter sequence has no 
TATA box-like sequence but does have a GC rich region and multi binding site for 
transcription factors like Activator Protein (AP2), specificity protein 1 (Sp1) and GC-
rich sequence DNA-binding factor (GCF) located in the promoter region (Åman et al., 
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1996). The FUS/TLS consists of 526 amino acid proteins. Figure 1.6 illustrates the 
main characteristics of this gene, including an N-terminal domain that has four protein 
domains; a region SYQG, which consists of serine, tyrosine, glutamine and glycine 
and a RNA recognition motif (RRM); a multiple RGG region that is implicated in 
RNA binding; a C terminal repeat which consists of a zinc finger motif; and a highly 
conserved C-terminal region located at the very end (Figure 1.6) (Pérez-Mancera and 




Figure 1.6: Schematic view showing the structure of the FUS gene together with the 
associated FUS protein structure. The FUS gene contains 15 exons, while the FUS protein 
comprises 526 amino acids. The FUS protein is including in an N-terminal domain that is 
enriched in four types of amino acid: serine, tyrosine, glutamine and glycine (the SYQG 
region), a glycine rich region, one RNA recognition motif (RRM), a multiple RGG-rich region 
that is implicated in RNA binding, a C-terminal repeat which consists of a zing finger motif 
and a highly conserved region located at the very end of the C-terminal region. This Figure 
has been adapted from; Perez-Mancera and Sanchez-Garcia (2004).  
 
1.8.8 FUS mutational analysis  
In a previous study conducted on multi-generational British kindred linked with a 
FALS study exons from the FUS gene were sequenced (Waibel et al., 2010). This 
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study identified a single base pair change in  exon 15 of the FUS/TLS gene, with this 
change leading to a substitution of arginine to cysteine at location 521(R521C), a 
residue at the very C-terminal end of the protein, which is a highly conserved region, 
functioning in the area of nuclear localisation signals (NLS).  
The vast majority of FUS mutations that have been identified in the FALS cases are 
missense mutations. There is also, however, a novel nonsense mutation (R495X) in 
the C-terminal and it has been predicted that this mutation may lead to production of 
truncated TLS/FUS and the deletion of the sequences that encode the NLS domain 
(Waibel et al., 2010). This results in TLS/FUS mislocalisation and the formation of 
the cytoplasmic inclusion which is a pathological hallmark of neurons that have been 
affected by FUS mutation. Most FUS/TLS mutations are dominant, however a rarer 
recessive mutation (H517Q) was found in a family of Cape Verde origin (Sproviero 
et al., 2012).  
Investigation of the autopsy samples of brains and spinal cords from patients with 
FUS/TLS mutations has shown abnormal FUS/TLS to be present in the cytoplasm of 
neurons and glial cells, and lower motor neurones in the spinal cord (Sproviero et al., 
2012, Urwin et al., 2010, Deng et al., 2010). Mutant human ALS FUS was found to 
be overexpressed in adult transgenic rats, causing a loss in neurones in both the cortex 
and hippocampus leading to learning and memory deficits (Huang et al., 2011).  
A number of mutations residue in the 3’UTR of the FUS gene in ALS patients at a rate 
of 1.2%, as demonstrated by (Sabatelli et al., 2013b). These mutations increase the 
level of the FUS protein in a limited number of cases and since such protein over 
abundance has been correlated with the disease severity, it is proposed that the level 
of FUS protein has a crucial role in the cell phenotype and in the development of 
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neurological disorders, including ALS (Mitchell et al., 2013, Neumann et al., 2009, 
Mackenzie et al., 2010). Over expression of the wild type of the FUS gene in a 
transgenic mouse model has in fact been shown to cause degeneration in motor 
neurones in an age and dose-dependent fashion (Mitchell et al., 2013, Mackenzie et 
al., 2010). 
1.8.9 Implication of FUS mutation for ALS and FTLD  
ALS and FTLD are related neurodegenerative diseases. ALS can be considered 
degeneration of the upper and lower motor neurone cells, causing skeletal muscle 
weakness and limb paralysis, while FTLD affects cortical neurones leading to cortical 
dementia (Forman et al., 2006). ALS symptoms can overlap with FTLD pathology 
and, in some cases; ALS patients can develop sporadic FTLD. Both conditions also 
have ubiquitin-positive inclusion (Deng et al., 2010, Neumann et al., 2009, Urwin et 
al., 2010). In a cell line, FUS knockdown appears to cause preferential inclusion of tau 
exons 3 and 10 and result in disruption of tau’s role. A similar study by (Orozco et al., 
2012) has demonstrated that the inclusion of tau exon 10 can also lead to 
frontotemporal dementia and Parkinsonism (Hutton et al., 1998). Tau splicing is 
therefore a potential target of FUS function in neurones (Orozco et al., 2012). All these 
studies have demonstrated that there are several mechanisms that have a major role in 
controlling FUS expression; these mechanisms can be at the level of the FUS 
expression or the expression of isoforms, or might take place post transcription or 
translation, but these all have their role to play in neurological disorders. For example, 
the mutant form of FUS protein or the regulation of the gene transcription or 
translation process results in misplaced of the FUS protein. Result in accumulation in 
the cytoplasm rather than in the nucleus of the cell. This was happen due to FUS 
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mutants in  a damaged or missing nuclear localization sequence (NLS) (Gal et al., 
2011). The pathological accumulation of the mutant form of the FUS gene in stress 
granules or the formation of the globular and skein-like inclusions of the wild type of 
FUS gene can cause the death of motor neurones (Gal et al., 2011). For more than two 
decades researchers have focused on identifying the mutations and polymorphisms 
(Breen et al., 2008b) in the exonic sequences of proteins in order to define the 
functional associations with disease. Over 95% of these studies have demonstrated the 
relationship of the polymorphisms and mutations. Mutations can be defined as a 
polymorphism when they occur in at least 1% of the population affecting the coding 
regions of the associated genes with the risk of disease. Many mutations and 
polymorphisms that have a strong correlation with the progression of neurological 
disorder, however, can occur in genes in the regions of noncoding DNA sequence and 
even at some distances from the transcriptional start site. Most previous studies have 
focused on mutations in the FUS protein and relatively little is known about FUS gene 
regulation. Therefore, the regulation of the FUS and PARK7 genes were the main 
theme of this thesis. Evolutionary conserved regions (ECRs), and SINE-VNTR-Alu 
(SVA) at the FUS locus were studied as potential regulatory domains. In addition, the 




1.8.10 Involvement of FUS/TLS in gene regulation  
FUS/TLS is considered to be a multifunctional protein and has an association with 
multiple steps of gene regulation transcription and RNA splicing. From proteomic 
study it has been identified that the FUS/TLS is associated with specific and general 
factors in order to initiate the transcription  (Law et al., 2006) also interact with nuclear 
hormone receptors (Powers et al., 1998). Added to that FUS can interact with gene 
specific transcription factors for example Spi-1 or NF-kappaB implicated in the 
spliceosome mechanism (Hallier et al., 1998, Uranishi et al., 2001). In vitro studies, 
meanwhile, demonstrate FUS/TLS is correlated with large transcriptional splicing 
complexes which bind to both the 5’and 3’of pre mRNA splice site. FUS/TLS is 
involved  with several splicing factors, such as YB-1, serine-arginine proteins (SC35 
and TASR) (Chansky et al., 2001, Göransson et al., 2002), hnRNP A1 and C1/C2 
(Zinszner et al., 1994) FUS/TLS is involved in various mechanisms such as 
transcription and RNA processing for both mRNA and micro-RNA (Figure 1.7). For 
example FUS/TLS and TDP-43 have been found (by mass spectrometry) to play roles 
in micro-RNA processing by association with Drosha, the RNase III- type protein 
known for its function as a mediator of the first step of micro-RNA maturation (Kim 
et al., 2009) Figure 1.7. In addition, TDP-43 has been implicated in the cytoplasmic 
cleavage step of micro-RNA by Dicer complex, through its association with argonaute 
2 and DDX17 proteins, which have known roles in these functions (Freibaum et al., 
2010). 
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 Figure 1.7: Schematic diagram demonstrating the involvement of the TDP43 and 
FUS/TLS genes in the metabolism of the RNA. FUS/TLS and TDP-43 both associated with 
DROSH and TDP-34 involved in Dicer. This Figure has been adapted from; Verma (2011). 
 
1.9 Elements that regulate gene expression. 
Regulation of gene expression is a complex process and controlled spatially and 
temporally by interaction of signals that act on regulatory elements such as promoters 
and enhancers. These elements can recruit transcription factors which allow cells to 
control the rates of processes involved in gene expression such as chromatin 
decompaction, initiation of transcription and then elongation.  
Previously, identification of the putative regulatory region in non-coding DNA was 
difficult for researchers because these regions were small and often widespread. The 
wealth of genomic data information now available from genomic browsers, however, 
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can accelerate identification using information about the genomic data of humans, 
rodents and pufferfish (fugu). Analysis of the potential regulatory element through 
genome homology serves to highlight sequences that might act as a putative regulatory 
element. Furthermore, these databases can hold information on the transcription 
factors across several cell lines (and species), along with the chromatin state, and can 
aid in the identification and analysis of the potential regulatory elements. The UCSC 
genomic browser (http://genome.ucsc.edu/index.html) is one useful and freely 
available application in the encyclopaedia of DNA elements, and can give a huge 
amount of information specifically about the functional elements of the human 
genome. This project is a collaboration between different research groups and is 
funded by the National Human Genome Research Institute (NHGRI). This tool is 
useful and can assist in identifying and analysing the putative regulatory elements in 
the genome. 
1.9.1 Evolutionary conserved regions (ECRs)  
Evolutionary conserved regions (ECRs) are regions of DNA sequences that have 
strong conservation across diverse vertebrate species. These ECRs can highlight 
important regions that might have a role in gene regulation (Drake et al., 2006) and 
can also assist in the discovery of novel genes (Pennacchio and Rubin, 2001). Exons 
are also strongly conserved between vertebrates, and some fraction of the non-coding 
sequences can have strong evolutionary conserved regions when observed between a 
ranges of species. These ECRSs that are located in the non-coding DNA sequence can 
pinpoint an important role of these sequences that has been conserved through 
evolution between a range of vertebrate species, for example human, mouse, fish (Lein 
et al., 2007, MacKenzie and Quinn, 2004). The potential role of the ECR can act as a 
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cis regulator for gene expression and can determine the spatial and temporal aspects 
of gene expression. In general, ECRs have been recognised as functioning as 
enhancers and repressors of gene expression (Pennacchio et al., 2006, Loots and 
Ovcharenko, 2007). Their role in gene expression has been identified and 
characterized in vivo by Pennacchio et al. 2006. As they tested 167 of a large group of 
non – coding elements from human chromosome 16 for enhancer activity in a 
transgenic mouse. These regions, are conserved between human and pufferfish or/and 
extremely conserved sequences in human –mouse-rat. Furthermore, 45% of the tested 
regions showed to act as enhancers at embryonic day 11.5. Furthermore, work by 
Paredes et al. 2011 studied the regulation role of the ECR from DRD4 gene, a key 
gene involved in regulating human social behaviour and cognition were demonstrated 
to act as transcriptional activity in primary cultures derived from rat cortex.  
Identification of ECRs has been made much easier with aid of the ECR browser (Loots 
and Ovcharenko, 2007, Hillier et al., 2004). The ECR browser is a tool that has been 
developed to aid identification of novel genes, the distance of regulatory elements and 
putative transcription factor binding sites. In general, regulatory elements might be 
also located in different regions other than ECRs and might be resident in regions 
containing genetic variation. Genetic variation in human genome important as 
considered for differences between individuals of the same species. These 
polymorphic regulatory domains can have different form and categories for example 
variable number tandem repeats (VNTRs), transposable elements inserted into our 





1.9.2 VNTR (Variable Number Tandem Repeats)  
VNTRs can be defined as a nucleotide sequence repeats greater than 6 bp that act as 
recognition motif for protein such as transcription factors and act as a regulatory 
domain. VNTRs always show variations in length between individuals (Haddley et al., 
2008). VNTRs are considered to be a type of genetic variation and to have a role in 
gene regulation. 
There are 600,000 VNTR candidates that are distributed in the human genome (Breen 
et al., 2008a). VNTRs can occur in functional positions, for example when they are 
located in splicing junctions between intron- exon and when they located within a first 
50 base pairs of the promoters, enhancers and functional intronic regions. VNTRs can 
function when present in the recognition sequence to a protein DNA interaction, and 
provide various transcription binding sites through their repetitive features (Ferreira et 
al., 2008, Breen et al., 2008c, MacKenzie and Quinn, 1999). 
VNTRs can have various copy number repeat, differing in their number of repeats 
between individuals. For instance, the serotonin transporter gene has a polymorphism 
within the intron 2, located in the promoter region. This polymorphism, consist of a 
VNTR, which differs in the number copies of repeats, containing 9, 10, and 12 copies 
of a 17 –bp elements (Heils et al., 1997). These variations in the number of repeat have 
been linked to unipolar and bipolar disorders. The 10 and 12 copies can act as strong 
positive transcriptional regulatory elements, in the hindbrain of E10.5 of mouse 
model(Heils et al., 1997). Meanwhile these two regions differs in the level of 
transcriptional activity in vitro as  12 copy polymorphism was showed to have stronger 
gene expression than the 10 copy polymorphism (Krueger, 2009).   
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The dopamine transporter gene (DAT1), meanwhile, has nine polymorphic versions 
of VNTRs located in the 3’UTR (Haddley et al., 2008). VNTRs have been shown to 
regulate gene expression, different alleles can drive expression in different locations 
and different alleles can respond to a stimulus differently in vitro and in vivo 
(MacKenzie and Quinn, 1999, Vasiliou et al., 2012, Roberts et al., 2007). 
VNTRs have also been implicated in genetic predisposition to disease (De Luca et al., 
2006, Munafò and Johnstone, 2008, Herman et al., 2005, Buhnik-Rosenblau et al., 
2012). For example, the serotonin transporter gene (5HTT/SLC6A4) has two VNTRs, 
one located within the promoter region and the other located in intron 2. Thus the 
serotonin transporter gene has been implicated in alteration of the level of serotonin 
secretion between the synaptic cleft and neurones. Added to that the VNTR, which is 
located in the promoter region of the 5HTT gene has a long polymorphic region (LPR) 
and consists of two alleles, either 14 copies or 16 copies that have a 22=23 bp repeat, 
while the VNTR which is located within intron 2 has three different alleles that have 
9, 10, or 12 copies and consist of 16-17 bp repeat (Stin2).  
VNTRs have various regulatory classes but in general can share the important property 
that they are mostly located within non-coding sequences of the genome. VNTRs 
found in the genome emerge through evolution and are subject to evolutionary 
conservation between humans and primates, although they are not conserved in the 
lower mammals. They are implicated in the gene expression by possessing cis-
regulatory elements or can have one or more transcription factor binding site. Many 
VNTRs are localized within the gene enriched region rather than non-genic regions, 
which supports the hypothesis that VNTRs can alter gene expression. VNTRs have 
been implicated in many diseases, such as diabetes, through the large non-coding 
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VNTRs located in the insulin gene (Ong et al., 1999) or depression (Caspi et al., 2003), 
attention deficit hyperactivity disease (Brookes et al., 2006), and addiction to cocaine 
(Guindalini et al., 2006). 
1.9.3 Mobile DNA or transposable elements  
Mobile DNA elements were first identified in 1950 by Barbara McClintock when 
studying gene regulation in maize (McClintock, 1950). Mobile DNA can be divided 
into two major classes; first major class the DNA transposons, which were, discovered 
in maize and are not actively mobile in humans and mice. They mobilise through a 
mechanism by which the DNA sequence that encodes for the transposon is cut out 
from its normal location in the genome and pasted into an alternative position. The 
second major class is the retrotransposons, this class are actively mobilised in humans 
and mice through an RNA intermediate by a mechanism called copy and paste, 
through which the retrotransposon is transcribed. In the transcription it will employ 
the intermediate RNA to act as a template for the synthesis of the cDNA by the RNA 
dependent DNA polymerase and this DNA can then integrate back into the genome 
and make a complete or a partial copy of the retrotransposon. The retrotransposons 
can be further classified into two subclasses: long terminal repeat (LTR) and non-LTR. 
This non-LTR class is still active in human genomes (Beck et al., 2011) and comprises 
long interspersed elements (LINEs), short interspersed elements (SINE) and SINE-
VNTR-Alus (SVAs) and processed pseudogenes these transposable elements have 
recently become known for their activity in the human genome. Long interspersed 
elements (LINES) are the only elements that can move through the DNA. The majority 
of these elements are represented by the LINE-1 elements and comprise 18% of the 
human genome with about 500,000 copies (Goodier and Kazazian, 2008). LINE-1 has 
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two open reading frames (ORF) which encode for two proteins required for 
retrotransposition (Feng et al., 1996). This retrotransposition of the LINE1 can happen 
by a process called target primed reverse transcription (TPRT), in which this process 
itself can lead to 5’truncation, 3’transductions and target site duplications (TSD), 
internal rearrangement and inversions. LINE-1 have two important roles in the human 
genome; first they can cause expansion and proliferation and, second, they can provide 
mobility to non-autonomous retrotransposon elements such as SINEs, SVAs and 
processed or retro pseudogenes (RNA that has been produced by reverse transcription 
and inserted into the genome LINE-1 machinery by the process of ‘copy and paste’) 
(Pavlicek et al., 2006). Processed pseudogenes have no introns and no promoter and 
regulatory element in their structure but have a 3’ poly A tail (Ding et al., 2006). 
More than 120 families of Short Interspersed Elements (SINEs) have been found in 
the eukaryotic genome. They originated from the cellular RNA that has been 
transcribed by RNA polymerase III, which vary in length from 150-300 bp (Ding et 
al., 2006) The Alu element is the most popular form of SINE in the human genome. 
The Alu element is primate specific and has more than 1 million copies. These 
elements are named according to the Alu1 restriction enzyme site in their sequences 
(Ullu et al., 1982). Alus are mobilized by the LINE-1 machinery and originate from 
the processed 7SL RNA gene. Alus and can regulate the transcription process by the 
internal RNA polymerase III (Batzer and Deininger, 2002).  
SVA, specifically, is a non-autonomous retrotransposon that relies on the LINE-1 
machinery to enter the genome. The SVA element is named from its main components 
of SINE, VNTR and Alu like sequences. Since SVAs are hominid specific and include 
a VNTR domain in their structure, it may be postulated that they have a role in genetic 
variation and involvement in the human genome. SVAs are the newest of the 
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retrotransposable elements and share the same characteristics as retrotransposon 
elements, for example they are flanked by target site duplications (TSDs) and 
terminate with a poly (A) tail. They can be inverted or truncated through their insertion 
in the genome since they can transduce 3’sequences through their transition in the 
genome. As a result, they are considered to be non-autonomous retrotransposons and 
they can transit through the genome by LINE-1 encoded proteins in trans. SVAs can 
be categorised into six SVA subfamilies (A,B,C,D,E,F) according to the SINE region, 
and their age. For example, the estimated age for the oldest sub type (A) is 13.56 
million years (Myrs) while the youngest sub type (F) is 3.18Myrs old (Wang et al., 
2005). 
A canonical SVA consists of approximately 2 kilobases (Figure 1.8), however the size 
of the SVA insertion in the human genome may vary between 700 to 4000 base pairs. 
A canonical SVA consists of: starting from 5’ sequences, a hexamer repeat ‘ccctct’ 
followed by sequences sharing homology to two antisense Alu like sequences, then a 
GC-rich variable number tandem repeat (VNTR), followed by a sequence sharing 
similarity with the env gene and a long terminal repeat of an endogenous retrovirus 
HERV-K10. It terminates with the canonical polyadenylation signal (polyA) tail. 
There are approximately 2700 copies of SVAs in the human genome and account for 
0.13% of the human genome these may have been inserted in the human genome 
recently through SVA retrotansposons. 
  





Figure 1.8: Schematic representing the structure of a canonical SVA. This image is taken 
from (Konkel and Batzer, 2010). The image shows the canonical SVA structure, consisting of 
target site duplications (TSDs), a full-length of elements containing from 5’ to 3’a hexamer 
repeat (CCCTCT), a homology region of two antisense Alu sequences, a variable number of 
tandem repeat (VNTR) regions and a SINE region from HERV-K10 and human endogenous 
retrovirus, ending with a polyA-tail. Figure adapted from Konkel and Batzer (2010). 
 
SVA elements have remained active in the human genome and play a role in cancer 
through various mechanisms by which SVA affects the regulation of gene expression. 
SVA, can mediate alternative splicing and might lead to the production of an abundant 





1.9.4 The impact of the SVA on the human genome  
Mainly, the insertion of the SVA has affected the gene regulation process as there are 
2700 insertions of the SVAs in the human genome represent as a key feature for the 
polymorphisms and modulation of gene expression of specific genes that have a 
relationship with certain diseases. Moreover, SVA types have increased their number 
in the human genome at different stages of hominoid evolution, and their propagation 
has been associated with changes in human cognitive behaviour. (Vasieva et al., 2016) 
SVAs insertions have been linked with several disease, including, Duchenne muscular 
dystrophy, cystic fibrosis, haemophilia and several types of cancers (Hancks and 
Kazazian, 2010, Kaer and Speek, 2013). To date eight SVA insertions have been 
implicated with disease through several processes, such as exon skipping, insertions 
and decreases in the level of mRNA production. 
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1.9.5 Identification of the regulatory elements using the ECR Browser and UCSC 
Browser  
The ECR Browser (http://ecrbrowser.dcode.org) is a dynamic tool that can provide the 
user with a wealth of information about the genomic structure of several compared 
species such as humans, dogs, rodents and fish, and can pinpoint important conserved 
regions. It is possible within the tool manually to manipulate the threshold and thus to 
generate, retrieve and display the data in a very easy way to define the sequence length 
of the base and compare the length and the percentage of conservation similarity. It 
can also provide the number and type of species whose genome has been compared 
with the desired sequence  One of the useful application of this tool is that the 
generated data can be exported to the UCSC browser to identify the sequence 
homology between closely related species, such as humans and mice through using 
the BLAST tool or by using BLAST to search for distant species, for example rodents 




1.9.6 Development of a chick model for identification of the regulatory elements 
that regulate FUS and PARK 7 genes implicated in motor neurone disease  
Many studies have advanced current knowledge by attempting to interpret the genome 
and characterise the varied associations of gene expression patterns with disease. In 
order to analyse the transcriptional activity of gene flanking sequences, it is essential 
to use cellular-based in vitro (Tanaka et al., 2010) (Trojsi et al., 2013)or whole 
organism-based in vivo models (Farley, 2013). Initially, in vitro models such as clonal 
cell lines or isolated primary cells were used to analyse the transcription activity of 
gene flanking regions. Typically, the potential regulatory element is cloned into a 
suitable plasmid vector along with a marker or reporter gene in order to visualise or 
quantify the effect of the element on transcriptional regulation. In cell line assays one 
of the most frequently used reporter genes is luciferase. Using this approach allows 
rapid analysis of regulatory elements to generate a robust data set and gives 
quantitative results on the relative efficiency of different sequences. In vitro models, 
however, do not reflect the tissue specific, spatial, or temporal gene regulation 
observed in vivo. Since many genes involved in human diseases show tissue-specific 
expression, in vitro cell lines might lack the relevant factors for tissue-specific gene 
expression, e.g., the human brain has a three-dimensional structure comprised of 
different cell types that would be difficult to recapitulate in a cell culture dish. 
Furthermore, neuronal interactions occur between different brain regions and include 
different cell types, and these interactions might have implications for gene 
expression. In vitro cultures containing only a few cell types in a monolayer, therefore, 
may not be an appropriate model (Uchikawa, 2008, Tanaka et al., 2010). 
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To circumvent some of the disadvantages of cell line models, in vivo animal models 
have been developed to address gene expression in an appropriate anatomical location 
for comparison with that seen in humans. For a suitable in vivo model certain criteria 
must be considered follows: (1) duration of life span, (2) wealth of knowledge about 
the organisms and degree of genomic comparison with the organisms that they are to 
be compared to, (3) ease of manipulation of the tissue, organs and DNA, (4) cost. A 
wide range of organisms have been started just from using a single cell, such as yeast 
and bacteria through to multicellular organisms such as C. elegans, D. melanogaster, 
fish, avian species, rodents and primates.  
1.9.7 A mouse model can be used as an experimental model. 
Mouse models can offer several advantages for the investigator. There is a well-
established technique and a well-documented protocol for manipulating mouse 
embryos (Sambrook et al., 1989)  and the mouse genome has been entirely sequenced 
(Chinwalla et al., 2002, Church et al., 2009). Mice have a brain structure and cell types 
that are similar to human (Bier and McGinnis, 2004). There are also a number of 
disadvantages, however, generating the transgenic mice protocol is: (1) Complex, (2) 
time consuming and cost 20 time more than chick model, (3) transgenic mice have a 




1.9.8 Advantages of the chicken embryo in vivo model compared with murine 
models. 
The generation of a transgenic mouse protocol was found to be quite complicated, 
time consuming and labour intensive. In contrast, chicken embryos have many 
advantages that can be employed in order to identify and characterise the Cis 
regulatory element of the gene of interest (Kondoh et al., 2004, Uchikawa et al., 2003, 
Matsumata et al., 2005, Uchikawa, 2008). Fertilised eggs are cheap and can be 
obtained easily from the commercial hatcheries which produce fertilised eggs in large 
quantities for farming or pharmaceutical industry. Maintenance costs are very low as 
there are no animals to feed and animal houses to run equipment for. Chicken embryos 
have some disadvantage for use as an animal model instead of a mouse model, 
however. For example, the chick genome (International Chicken Genome Sequencing, 
2004) has not yet been as well characterised as the mice genome as mice have been 
used more extensively by scientists. In the past, analysing gene regulation using 
chicken cells was only done through transfection of tissue cultured cells. This situation 
has now changed, however, with the successful application of the electroporation 
technique. In ovo electroporation can be defined as a technique to introduce DNA into 
living chicken embryos, thus potentially manipulating gene activities with high 
efficiency (Funahashi et al., 1999, Muramatsu et al., 1997). This technique has opened 
up a new field for the study of gene regulation (Uchikawa et al., 2003).  
In order to predict the potential regulatory sequences, the application of the genomic 
comparison of the chicken and other species is used frequently (Uchikawa, 2008). One 
of the useful elements of the genome project is the ease of comparison of the entire 
genome sequences between vertebrate species, with the regulatory regions always able 
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to be recognised as non-coding DNA sequence blocks that show a very strong 
conservation among vertebrate species (Hardison, 2000). It is accepted that chickens 
are at an appropriate distance from mammals on the phylogenetic tree. This means that 
chicks and mammals can share strong conserved regions (Khokha and Loots, 2005), 
In addition, chickens and mammals belong to the same amniotes and might share 
various regulatory elements. The study of the gene regulation elements in chicks, 
therefore, can highlight important and universal paths that are conserved between 
vertebrates. 
1.9.9 The electroporation technique can used in order to define the regulatory 
regions of a gene using reporter gene constructs. 
Many methods have been used to transfer the reporter gene vector to cells or tissues 
in chicken embryos. Some of these methods are viral based, for example retroviral 
vectors have been used to identify genes that have a major role in the development and 
differentiation of myocytes in chicken embryos (Muramatsu et al., 1997). Viral 
methods are a typical approach for generating stable gene expression, while non-viral 
methods are considered only when transient gene expression is the aim. There are 
different transient transfection methods for chick embryos in-ovo. In ovo lipofection 
(LP) is a suitable method for gene transfection and shows expression in transfected 
tissues with a reporter gene vector. In addition to the LP method, there is another 
method called micro particle bombardment. This method has been used constantly in 
gene transfection in tissues of various animal species in vivo. Finally, electroporation 
or electro-transfection is a very simple and popular method, which can work on most 
types of cells, is cheap, and can direct the cloning to a particular location for example 
the forebrain and neural tube. Electroporation involves a sequence of electrical pulses 
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that allows cells to take up the DNA.  This was successfully applied  to chick embryos 
by (Neumann et al., 1980). With this method it is possible to observe reporter gene 
expression only 2 hours after transfection of DNA into chick embryos by in Ovo 
electroporation. A comparison study between the three mentioned non-viral protocols 
(MPB, LP and EP) was conducted by (Muramatsu et al., 1997) based on the expression 
intensity and the transfection efficiency of a LacZ reporter gene in chick embryos in 
ovo. The EP technique was found to have the strongest reporter gene expression 
among the three methods and, indeed, EP scored a peak transfection rate of 50.0% 
(15/30) and a peak survival rate of 53.6% (30/56) (Muramatsu et al., 1997). 
Electroporation techniques have many advantages that make them the most suitable 
approach to be employed for in ovo gene transfection to chicken embryos. These 
advantages includes: (1) Simple and cheap, (2) transfection that can be done directly 
to the specific tissue, for example, neural tube, or brain, (3) it has become possible to 
transfect DNA to the cells in deeply located target tissue, for example motor neurone 
cells that are located in the ventral part of the neural tube (Timmer et al., 2001), (4) 
electroporation has been successful in achieving transfection of DNA into most cells 
and it can be done in-ovo in the developing chicken embryos (Muramatsu et al., 1997, 
Yasuda et al., 2000). In fact all three non-viral methods were first used in the 1990s 
and have been developed continually, but the development of electroporation 
techniques have superseded the others to a large degree (Uchikawa et al., 2003, 
Uchikawa et al., 2004, Burke et al., 2005, Tanaka et al., 2010, Farley, 2013). For these 
reasons, electroporation was considered to be the most appropriate transfection 
method for use in this thesis. 
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Electroporation entails the application of electric field pulses to cells or tissues. This 
is known to form some type of structural rearrangement to the cell membrane. These 
rearrangements consist of two main stages, the electroporation or 
electropermeabilisation stage, during which the cell’s membrane produces temporary 
aqueous pathways, called pores, followed by the electrophoresis stage, which provides 
a dynamic force that causes the DNA, ions and molecules to be transported through 
these pores. Many theories have attempted to explain the events that occur within the 
membrane during the electroporation. For instance, the electric field should produce a 
potential difference of a critical value across the cell. After this critical value has been 
reached, it facilitates the molecules’ entry across the cell membrane. Another theory 
is that the electroporation might raise the surface tension that leads to a change in the 
balance of two opposing forces of tension and line tension. Since surface tension can 
cause pore formation the line tension works as an opposing force and can overcome 
this pore formation (Weaver, 1995). Another theory claims that the electroporation 
creates an electric field that has the effect of compressing the membrane bilayer. While 
others believe that the polar head of the phospholipids is reorganised, which might 
cause awakening in the hydration layer (Chen et al., 2004, Ryttsen et al., 2000). 
Although the complete mechanism has not yet been elucidated, however, these 
theories do demonstrate that electroporation is asymmetrical, with the maximum effect 
being on the sides facing the electrodes and being most marked on the side facing the 
positive electrode (Hibino et al., 1993). 
To produce electroporation there is a critical value, at an exact point on the cell. This 
critical value is normally between 200mV-600mV (Teissie and Rols, 1993, Gabriel 
and Teissie, 1997). Moreover, the electric field required to reach the critical value 
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works inversely according to the cell size; for example, small cells like bacteria require 
up to 200KV/cm whereas large cells only need 200V/cm (Teissie and Rols, 1993). 
Electrically connected cells such as those in a developing chick neural tube (Sheridan, 
1968) perform electrically as if they were one big cell thus decreasing the electrical 
energy necessary for electroporation to 15-20 V. Beside the electric field strength there 
are another two elements, the duration and number of electric pulses, which regulate 
the electroporation level, elevating the field strength and increasing the area of the 
electroporation (Gabriel and Teissie, 1997). Too great a field strength will result in 
irreversible electroporation or joule heating, both resulting in cell death. A square 
wave pulse is now more favoured than that with an exponential decay as it reduces the 
amount of time thee electric field is applied and thus reduces the joule heating and risk 
of damage, i.e. burning (Uchikawa et al., 2003). Electroporation’s disadvantages stem 
mainly from the nonspecific transport, of for example, calcium and sodium into the 
cell and, for example, potassium, out of the cell when the membrane has been 
permeabilised. In addition, there may be incomplete penetration such that only some 
cells are electroporated. 
1.10 Aim of the project. 
 The aim of the project was to establish a chick embryo based model in order 
to address the regulatory elements of gene expression in the form of ECR, 
VNTR, and SVA.  
 In this thesis we test the hypothesis that DNA sequences that regulate FUS 
gene expression in motor neurones might be have a crucial role in the 
development of motor neurone disease. Mutations within 3’UTR of FUS gene 
were found in patients with ALS (1.2%) (Sabatelli et al., 2013b). This might 
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result in elevation in levels of FUS protein being crucial for cell phenotype and 
initiation or progression of ALS (Mackenzie et al., 2010), since FUS over 
expression in a mouse model led to progressive degeneration of motor 
neurones (Mitchell et al., 2013).  Our laboratory has identified two regulatory 
elements, ECR and SVA, within this gene and showed them to have strong 
activity in vitro. Therefore regions of noncoding sequences from FUS gene, 
might have a crucial role in the regulation of gene expression.   
 PARK7 gene was also addressed in this project due to implication of this gene 
in neurodegenerative disease and it was identified a regulatory domain in the 
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2 Materials and Methods  
All chemicals were supplied by the Sigma-Aldrich unless indicated otherwise. Kits 
were supplied by manufacturers as indicated in the text.  
2.1 Bacteriological Media  
2.1.1 Luria Broth  
25 g of Luria broth (Fluka Analytical) base was added per litre of distilled water and 
autoclaved at 121 ºC for 15 minutes. 
2.1.2 Luria Agar  
40 g of Luria broth (LB) (Fluka Analytical) Agar base was added per litre of distilled 
water and autoclaved at 121 ºC for 15 minutes, then cooled to 55 ºC. 10 mL of 
ampicillin stock was added. The LB agar was then poured into petri dishes (~25 mL 
per 100 mm plate). 
2.1.3 Antibiotic   
                            Stock                             Working concentration 
Ampicillin          100µg/ml                          50µg/ml                           
2.2 Electrophoresis Buffer for Agarose Gel Electrophoresis 
5X Tris-Borate-EDTA. 
Tris (TRIZMA base)              108 g 
Boric acid                               55 g 
EDTA                                     5.84 g  
Distilled water                        Volume made up to 2 litres. 
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pH was adjusted to 8.3 if required. 
T E buffer  
10 mM Tris-HCl, pH 8.0, 1 mM EDTA. 
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Elution buffer  
50 mM Tris-HCl, pH 8, 1 mM EDTA, 1% SDS, 50 mM NaHCO3, 2.5 M NaCl. 
2.3 Sources of cell lines  
SK-N-AS Human neuroblastoma cell line, CRL- 2137 from the American Collection 
of Cell Culture. 
 
2.4 Complete media for SK- N- AS cell line  
Human neuroblastoma SK- N- AS cells were maintained in Dulbecco’s Modified 
Eagles medium (Sigma, D5672), with 4500 mg/L of  high glucose medium, 10% (v/v) 
foetal bovine serum (Thermo Scientific/Hyclone), 100 units per ml of penicillin, 100 
µg/ml streptomycin (Sigma P0781), 1% (v/v) non- Essential Amino Acids (Sigma, 
M7145) and 200 mM L-glutamine (Sigma, D7513), in 5% CO2 at 37 ºC  
 
2.5 Freezing media  
90% Foetal bovine serum, 10% DMSO. 
2.6 Millonig’s Phosphate Buffer  
Sodium phosphate, monobasic NaH2 PO4. H2O   12.68 g/L 
Sodium phosphate, dibasic Salt NaH2 PO4    43.8 g/L 
NaH2PO4.H2O and NaH2PO4 were dissolved in 900 ml of distilled water and pH 
adjusted with HCl or NaOH to pH 7.4 at room temperature. The volume was made up 




2.7 Millonig’s Phosphate Buffer pH 7.4 (0.125M)  
0.4 M Phosphate Buffer Diluted (Millonig’s: water, 3:7)  
2.8 4% Paraformaldehyde  
Distilled water       35 ml 
Paraformaldehyde       2 g  
NaOH         4-5 drops 
Phosphate Buffer 0.4 M      15 ml 
35 ml of distilled H2O was added to 2 g paraformaldehyde and stirred constantly whilst 
being heated gently to 65 ºC. 5 M NaOH was added dropwise until the solution 
cleared. When the solution had cooled to room temperature the volume was made up 
to 50 ml using 15 ml of 0.4 M Phosphate Buffer. pH was assayed and adjusted to pH 
7. Ten ml aliquots were stored at -20 ºC. 
 
2.9 Embryo staining  
Sodium azide 10% stock solution 
10 g of sodium azide in 100 ml of distilled water. This was stored at room temperature   
 
2.10 Embryo staining solution  
Phosphate Buffer   0.1 M pH 7.3 
MgCl2     2 mM 
Sodium deoxycholate   1%  
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Potassium ferrocyanide  5 mM  
Potassium ferricyanide  5 mM 
NP-40     0.02% 
X- gal     1 mg/ml (added prior to use). 
 
2.11 Detergent Rinse  
Phosphate buffer   0.1 M 
MgCl2     2 mM 
Sodium Deoxy cholate  0.01% 
NP-40     0.02% 
 
2.12 Diluent solution  
1% BSA, 
0.12 M (Diluted Millonig’s)  
0.1% Triton 
0.1% NaN3 
2.13 Analysis of endogenous gene expression  
2.13.1 Tissue extraction  
Chick embryonic day 5 (E5) neural tube, E15 forebrain and E17 cerebellum were used 
to purify total RNA. Chick eggs were incubated for 5-17 days at 38 °C. The egg shell 
was cut in order to obtain the embryo which was placed on a petri dish. The petri dish 
was then placed under a dissecting microscope and the neural tube tissue and the 
forebrain region of the developing embryo or the cerebellum was separated from the 
rest of the chick embryo. The dissected tissue was sliced into pieces less than 20 mg, 
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and then further sliced into slices less than 5 mm thick. This step was done as quickly 
as possible to prevent RNA degradation and was performed at room temperature.  
2.13.2 Purification of total RNA from Animal Tissue  
The RNeasy Mini Kit (Qiagen, Germany) was used to extract total RNA from the 
chick E5 neural tube, E15 forebrain and E17 cerebellum. 
After harvesting, the tissue pieces were submerged completely in a collection vessel 
containing 600 µl RLT buffer. 10 µl of reducing agent β-mercaptoethanol (β-ME) was 
added to 1 ml of RLT Buffer prior to use. The RLT buffer consists of a highly 
denaturing guanidine isothiocyanate. This buffer can inactivate RNases in order to 
facilitate isolation of intact RNA. In order to disrupt and completely release all RNA 
contained in the sample, a mortar and pestle was used initially and subsequently the 
sample was homogenised using a handheld glass homogenizer. Following 
homogenisation, the lysate was passed through a 23-gauge needle fitted to an RNase-
free syringe five times. The lysate was then centrifuged for 3 min at 8000 x g (10,000 
rpm).The supernatant was transferred into a new microcentrifuge tube and one volume 
of 70% ethanol was added to the lysate and mixed immediately by pipetting. 
700 µl of the sample was transferred to an RNeasy spin column placed in a 2 ml 
collection tube and centrifuged for 15 s at 8000 x g (10,000 rpm). The RNeasy spin 
column was washed with 700 µl of Buffer RW1 to remove the contaminants from the 
sample and centrifuged for 15 s at 8000 x g. The spin membrane was then washed 
twice with 500 µl of Buffer RPE and centrifuged for 15 s at 8000 x g to remove the 
contaminants; in the second wash, however the centrifugation was increased to 2 
minutes. RNA was eluted by pipetting 30-40 µl of RNase–free water directly onto the 
RNeasy membrane, then centrifuging for 1 min at 8000 x g. 
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2.13.3 Design of primers for detection of mRNA expression  
PCR was used to identify the expression of the FUS, ELP3, KIFAP3, and PARK7 
genes, the primers were designed to bridge adjacent exons in order to avoid/distinguish 
any PCR product from contaminating gDNA which had acted as the template. The 
whole gDNA sequences of FUS, ELP3, and KIFAP3 PARK7 were taken from the 
UCSC genome browser (Hg19) (http://genome.ucsc.edu/index.html). 
The exonic sequences were then used to design PCR primers using the Prime3 
programme (http://frod.wi.mit.edu/). The potential set of primers were analysed in the 
in-silico PCR tool of the UCSC genomic browser to confirm they were unique to the 
target region of interest and that there were no other PCR amplicons. Primers were 
produced according to various criteria such as the product size, Tm, length of the 
primers, non-complementarity at 3’ ends (Table 1 Appendix). Primers were 
synthesised by Eurofins (MWG primers, Eurofins Genomics Anzinger Str. 7a 85560 
Ebersberg Germany). 
2.13.4 First strand synthesis of cDNA from total RNA  
cDNA was produced from the total RNA extracted in 2.2.1.4 by using either the 
Cloned AMV First-Strand cDNA Synthesis Kit (Invitrogen) or the Go Script Reverse 
Transcription Kit (Promega). The manufacturer’s protocol was followed to convert up 
to 5 µg of total RNA to first-strand cDNA. 
The following components were mixed and briefly centrifuged before use and then 




Table 2.1: Component and the volume used in the reaction mix prepared for each 
sample.  
Component Volume 
Primer(50µM Oligo(dT)20 1 µl 
10 mM dNTP mix 2 µl 
DEPC-treated water to 12 µl 
RNA (5 µg) (The volume of RNA varied 
between samples depending on 
the concentration of RNA)                                                              
                                                                             
 
The mixture was denatured by incubation at 70 ˚ C on a heat block for 5 min and chilled 
immediately in ice water for 5 min, then centrifuged for 10 s and stored on ice. This 
allowed the oligo dT primer to anneal to the polyadenylated RNA and act as a primer 
for the subsequent synthesis reaction. The following reaction mix was prepared for 
each sample. 
 
Table 2.2: The below reaction mix was prepared for each sample. 
Component 1 reaction 
5x cDNA Synthesis Buffer 4 µl 
0.1 M DTT 1 µl 
RNaseOUT  ™ (40 U/ µl) 1 µl 
DEPC-treated water 1 µl 
Cloned AMV RT (15 units/ µl) 1 µl 
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Total Volume 8 µl 
 
8 µl of the mix was pipetted into the reaction tube containing the annealed oligo  20, 
RNA and dNTP mix that had been prepared previously to make a final volume of 20 µl 
of reaction mixture, this was done on ice. The reaction tube was then transferred to a 
thermal cylinder preheated to 50 ˚C (specific temperature for AMV RT enzyme) and 
incubated for 60 min. The termination of this reaction was caused by heating at 85 ˚C 
for 5 min. The cDNA samples were then stored at -20 ˚C. 
 
Alternatively, the Go Script Reverse Transcription Kit (Promega) was used to convert 
up to 5 µg of total RNA into first-strand cDNA. The following components were 













Experimental RNA (up to 5 µg/reaction) 1 µl 
Primer [Oligo15 (0.5 µg/reaction) 1 µl 
Nuclease-Free Water 3 µl 
Final volume 5 µl 
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The primer and RNA were incubated at 70 ºC on a heat block for 5 min and then 
immediately placed on ice for 5 min. The mixture was then centrifuged for 10 s and 
stored on ice until the reverse transcription mix was added. 
Reverse transcription reaction mix was prepared and combined on ice as in Table 2.4 
below. 
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The 15 µl of reverse transcription mix was combined with 5 µl of RNA and primer 
mix and then incubated on a heat block first for 25 ºC for 5 min, and then at 42 ºC for 
up to one hour. The reaction could be stored at -20 ºC or used for PCR immediately. 
  
Component Volume 
Go Scriptᵀᴹ 10X Reaction Buffer 2 µl  
 
MgCl2 (25 mM)                                                                      
 
4 µl  
 
PCR nucleotide mix 











Recombinant RNasin® 0.5 µl 
Nuclease free water                                            5.9 µl 




2.13.5 Polymerase Chain Reaction  
Polymerase chain reaction (PCR) was performed to amplify cDNA for analysis of 
gene expression using Go Taq Flexi DNA Polymerase (Promega) and utilising the 
cDNA that was generated in (2.2.1.4) as a template (Table A1 Appendix)  
 
Table 2.5 The components and reaction volumes used in the PCR reaction Taq 































10X PCR Buffer minus Mg 5 µl  
 




PCR nucleotide mix 












(10 µM)                             
 
1 µl  
 
Taq polymerase (5 U/µl)                      0.4 µl 
Nuclease free water                                            38.1 µl 
cDNA template                                                  2 µl
Final Volume                                                     50 µl 
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Table 2.6: The following PCR program was run for amplification of target cDNA 




















Gradient PCR was performed and optimising annealing temperatures were ranged 
between (55 ˚C - 65 ˚C) with a specific band obtained at 62 ˚C, which was performed 
for the PARK7 primer set specifically. PCR was run in a peqSTAR 2X (peqlab) 
Gradient Thermocycler.   
2.13.6 Polymerase chain reaction using a proof reading polymerase  
PCR was performed for amplification of the DNA template using Phusion High-
Fidelity polymerase enzyme. Restriction enzyme sites were incorporated at the 5’ end 
of each primer in order to facilitate directional cloning. The Phusion DNA polymerase 
master mix was prepared as follows: 
Table 2.7: The components and reaction volumes used in the PCR reaction 
Phusion polymerase was used in PCR reaction  
 
 Activity Time Temperature 
Step 1 (1 cycle) Denature 2 min 94 ˚C 
Step 2_(30 cycles) Denature 1 min 94 ˚C 
 Anneal 1 min 55 ˚C 
 Extend 1 min 72 ˚C 
Step 3 Final incubation 10 min 72 ˚C 


















5 X Phusion High – Fidelity Buffer 10 µl 
10mM dNTPs 1 µl 
10µM Forward primer 2.5 µl 
10µM Reverse primer 2.5 µl 
Template X µl 
Phusion polymerase  0.5 µl 
dH2O X µl 
 Activity Time Temperature 
Step 1(1 cycle) Initial denature 1 min 98 ºC 
Step 2 (25 cycle) Denature 5 s 98 ºC 
 Anneal/extension 20 s 72 ºC 
(1cycle) Final extension 10 min 72 ºC 
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2.14 Agarose gel electrophoresis  
Agarose gel electrophoresis was used to separate DNA fragments by size or for 
restriction digests analyses. By this process, negatively charged nucleic acid molecules 
move through an agarose matrix within an electric field. The shorter the molecule the 
faster it can move through the matrix, thus migrating further than longer molecules. 
Since DNA is a negatively charged molecule it moves towards the positive terminal 
of the electric field. 
Agarose gel 1-2% was made by dissolving an appropriate amount of agarose (Bioline) 
in 0.5X TBE in a conical flask, the flask was heated in a microwave oven and then 
removed and the solution mixed before being returned to the microwave to boil. Once 
the agarose was completely in solution it was cooled at room temperature for 5 min 
and then the nucleic acid stain was added to allow UV visualisation (either 1 µl of 
GelRed per 10 ml (Cambridge Bioscience) or 0.5 µl per 10 ml of ethidium bromide 
(Sigma 10 mg/ml) was added). The percentage of agarose gel used was dependant on 
the size of the DNA fragments that were to be resolved on the gel. The gels were 
poured into casting trays and combs were placed inside. The gel was allowed to set at 
room temperature for 40 min, and, once set, the comb was removed. The gels were 
placed in a gel tank filled with 0.5X TBE running buffer which was part of the 
electrophoresis apparatus. The addition of 5 µl of ethidium bromide was recommended 
for every litre of running buffer if ethidium bromide was used as a nucleic acid stain. 
Prior to loading the sample into the wells, 1 µl of loading dye (Promega 6X) was added 
to each 5 µl sample, this was to enable monitoring of how far the DNA sample 
migrated. Depending on the expected DNA fragment size on the gel a DNA ladder, 
either 100 bp (Promega) or 1 kb (Promega) was loaded, usually in the first gel well. 
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After the samples were loaded into the wells the lid on the gel apparatus was attached 
ensuring the positive (red) terminal was at the bottom of the gel as the voltage was 
applied. The voltage was set at a standard 5 V/cm, with the length of exposure to the 
current being dependent on the DNA fragment size and the percentage of the gel. The 
DNA was left for at least 1 hour to migrate through the gel towards the positive 
terminal. After the electrophoresis was done any bands were visualized on a UV 
transilluminator (BioDoc-it Imaging System) and photographs were taken using a 
digital camera. 
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2.15 Methods for cloning  
2.15.1 Designing primers for detection of endogenous FUS, KIFAP3, ELP3, 
PARK7 genes expression from purified total RNA. 
 
Primers that could be used to amplify the required sequences of chick genome DNA 
of the gene of interest were designed using Primer3 (http://frodo wi.mit.edu/). The 
primers were designed to bridge exon boundaries in order to distinguish the product 
from any other amplicon arising from chick gDNA contamination. First, the chick 
gDNA of the gene of interest was obtained from the UCSC genomic browser (H19), 
then the intron sequences were deleted. The obtained sequences were applied to 
Primer3 software which is available from either the UCSC Genome Browser 
(http://genome.ucsc.edu/index.html) or from the National Centre for Biotechnology 
Information (NCBI) (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The 
generated primers were based on several criteria such as the melting temperatures, 
usually between of 50 °C and 65 °C and a, GC% content between 40-60%, and then 
these primers were applied to the in silico PCR tool of the UCSC genome browser for 
the determination of the primer specification for the area of interest only, and no other 
potential PCR product  
 
2.15.2 Bioinformatic Analysis  
Evolutionary conserved region (ECRs) potentially containing regulatory elements 
were identified by genomic comparison using the ECR Browser (http: 
//ecrbrowser.dcode.org (Ovcharenko et al. 2004)) and the UCSC Genomic Browser 
Hg 19 (http://genome.ucsc.edu/index.html).  
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The ECR Browser is a dynamic tool demonstrating multiple alignments for genomic 
sequences of several vertebrate species including humans, rodents and fish.  
 The ECR Browser was set to highlight only sequences with a length of more than 100 
bp with at least 70% similarity across the species sequences. In addition, the data was 
exported to UCSC Browser and used to search for sequence homology between 
closely related species, for example, humans and mice, using the BLAST tool, or to 
compare sequence homology between more distant species such as rodents and fish 
(Paredes et al., 2011).  The human FUS gene was compared with chimpanzees, dogs, 
rats and mice using 70% identity and a length of 100 bp as the parameter to identify 
conserved sequences. Of the conserved regions, a region 4 kb upstream and 
downstream was analysed and coordinated and were obtained from Hg19 build. 
Typically, regions of interest were identified and were extended by 100-200 bp on 
both sides to facilitate primer design. Primers were designed incorporating restriction 
enzyme sites at the 5’ ends to facilitate construction of the plasmids. 
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2.15.3 Restriction enzyme digests  
Restriction enzyme digests were used to make the specific nucleic acid overhangs 
which allowed the PCR product to be ligated efficiently into the vector in the correct 
orientation, or they were used as an indicator for the presence of the insert and to 
confirm the direction of cloning. Restriction enzymes from both Promega and from 
New England Biolabs were used (approximately 5 unit/1 µg DNA).  
The components of reaction used with restriction enzymes from Promega or New 
England Biolabs were as follows: 
Nuclease free water                                             final volume of 20 µl 
10X specific restriction enzyme Buffer                    2 µl               
Acetylated BSA (10 µg/µl)                                       0.2 µl   
DNA (1µg)                                                               Y µl   
Restriction Enzyme (typically, 10 unit/ µl)            0.5 µl   
 
The digestion reaction was incubated in a water bath for 1-4 hours at the recommended 
temperature and buffer that was specified for each enzyme’s optimum activity. The 
reaction was then purified using a Promega mini column system cat. # A9282, and 
wash buffers, and was recovered from the column using an elution buffer. A fraction 
of the eluate was then run on a 0.8% agarose gel in order to visualise the DNA band 
size, by loading a DNA ladder (100 bp ladder; Promega, Cat. No. G2101 or 1 Kb 
ladder; Promega, Cat. No. G5711). This allowed confirmation that the reaction had 





2.15.4 Extraction of DNA fragments from agarose gels  
Agarose gel containing the required fragment of DNA was illuminated under long 
wave UV translumination. The DNA fragment was excised from the agarose gel using 
a clean blade. The DNA fragments were extracted using Promega Wizard SV Gel & 
PCR clean-up system. 
2.15.5 SV Gel clean-up kit protocol  
Promega wizard SV Gel & PCR clean-up system cat. #A9281 was used to extract the 
fragment DNA from the agarose gel. This kit has a special membrane binding solution 
(MBS) which can dissolve the agarose gel and aid the binding of the DNA to the 
membrane in the minicolumn assembly. A membrane wash solution is provided to 
eliminate contaminations and nuclease free water is used to elute the DNA from the 
membrane. Briefly, the excised gel slice was dissolved at a ratio of 1 µl MBS to 1 mg 
of gel at 50 ºC – 65 ºC or, for a PCR amplification, an equal volume of PCR reaction 
and MBS. The mixture then was centrifuged through a minicolumn assembly at 16,000 
x g for 1 min to allow the DNA to bind to the membrane. The membrane was washed 
with MBS, centrifuging at 16,000 x g twice. Following the evaporation of the residual 
ethanol, the DNA was eluted from the membrane in 50 µl of nuclease-free water. 
2.15.6 Ligation of DNA fragments into plasmid vector  
Two cloning methods were followed, one allowed for directional cloning and the other 
non-directional cloning. 
For directional cloning the inserts were cloned into the vector using the unique 
overhangs produced from two different restriction enzyme digests, located at specific 
ends of the insert. When non-directional cloning was used, the vector was treated with 
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Shrimp Alkaline Phosphatase SAP (Fermentas Catalogue Number EF0511) catalyses 
the release of 5’-phosphate groups from DNA, using the following protocol to reduce 
the risk of vector re-annealing. 
2.15.7 SAP treatment Protocol for dephosphorylation of DNA 5’- termini. 
17 µl of the solution containing the DNA sample, 10 X reaction buffer 2 µl, and SAP 
(1 µl at 1 unit/1 µl) were incubated at 37 ºC for 30 min before the reaction was stopped 
by heating at 65 ºC for 15 minutes. 
2.15.8 Ligation reactions  
Ligation reactions usually followed a molar ratio of vector to insert of 1:3. The 
following equation was usually followed in order to estimate the volume of insert 
required for ligation.  
ng vector x insert size kb x molar ratio of insert = ng insert  
          vector size kb                                   vector  
 
A typical ligation reaction contained: 
Vector DNA                                           1 µl (100ng) 
Insert DNA                                                   Y µl 
10X Ligation Buffer                                    1 µl 
Nuclease free water                                       Z µl 
T4DNA Ligase (1-3 U/µl)                              1 µl 
Final volume                                                 10 µl 
The ligation reaction was incubated for 3 hours at room temperature and then used for 
transformation of the chemically competent cells or stored at -20 ºC. Usually, two 
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control reactions were performed along with the ligation reaction; the first just with 
vector control, and the second with vector control in tandem with ligase control. 
2.15.9 Transformation of chemically competent DH5α E.coli cells  
A vial of chemically competent DH5α E.coli (Invitrogen) stored at -80 °C was 
defrosted on wet ice and 50 µl aliquots were placed in 1.5 ml microcentrifuge tubes. 
10 µl of ligation mixture or 10 ng of plasmid DNA were added to the 50 µl of 
competent DH5α cells, gently mixed and then placed on ice for 30 min. Then the cells 
were placed in the water bath at 37 ºC for 20 s for heat-shock and then incubated on 
ice for 2 min. 950 µl of LB broth which had been pre warmed at 37 ºC was added to 
the transformed cells and they were then incubated in a shaking incubator at 37 ºC and 
225 rpm for 1 hour. The tube containing the cells was positioned at an angle to assist 
gaseous exchange to ensure the mixture was aerobic. 50- 200 µl of transformed cells 
were spread on a pre warmed LB agar plate which contained the appropriate antibiotic 
(100 µg/ml ampicillin) and incubated inverted at 37 ºC overnight to allow growth of 
colonies of bacteria containing plasmid. The rest of the transformed mixture was 
stored at 4 ºC for future use. 
2.15.10 Plasmid DNA isolation from bacterial cultures  
To produce plasmids suitable for electroporation with a 260 nm: 280 nm ratio >1.7, 
overnight cultures of bacteria containing the plasmids were purified using a plasmid 
prep kit (Qiagen). The mini, midi and maxi version of their products were used 
depending on the amount of culture being purified. The manufacturer’s guidelines 
were followed. Overall, the methodology comprises lysis of the bacteria to release the 
plasmid, recovery of the plasmid on a membrane, followed by elution to release the 
plasmid. In order to store the transformed bacteria for long periods of time, glycerol 
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stocks were prepared. 1.4 ml of a fresh overnight culture was transferred to a 
microcentrifuge tube and the bacteria were pelleted by centrifugation at 8000 rpm for 
3 min at room temperature. The supernatant was discarded and the pellet was gently 
resuspended in 0.5 ml of sterile 15% glycerol (v/v in LB broth) and then transferred 
to a cryovial. This was immediately frozen and stored at -80 °C.   
2.15.11 Mini-preparation of plasmid DNA  
To purify up to 20 µg plasmid DNA for screening of colonies to identify the correct 
clones, the Miniprep protocol was followed in accordance with the manufacturer’s 
guidelines (Qiagen, Cat No. 27106). Colonies were selected from the agar plates that 
the transformation mixture was cultured section (2.1.2) and the bacteria grown 
overnight in 5 ml of LB broth media containing the appropriate amount of antibiotic. 
This step will result in expansion of the bacteria containing the plasmid of interest. 
The 5 ml of the overnight culture was pelleted and then suspended in a 250 µl lysis 
buffer in order to lysis the bacteria to release the plasmid. Once the cellular lysis was 
completed and the plasmid was released, the reaction was neutralised and cell debris 
and RNA, proteins and low molecular weight impurities were removed with salt wash. 
Plasmid DNA was eluted in 50 µl nuclease free water or elution buffer and then 





2.15.12 Maxi-preparation of plasmid DNA  
The maxiprep kit protocol was followed in accordance with manufacturer’s guidelines 
(Qiagen, Cat No. 12165). It was designed to purify up to 500 µg of high plasmid DNA 
from E.coli cells cultured in 100 ml selective Luria broth overnight with supplemented 
appropriate antibiotic at 37ºC with shaking (225 rpm). The resulting DNA pellet was 
then resuspended in 200-500µl of a lysis buffer. Once the cellular lysis had been 
achieved and the plasmid was released the reaction was neutralised immediately and 
the cellular debris was removed. The plasmid was purified, washed and eluted through 
the column by gravity flow. The DNA was precipitated from the eluate by the addition 
of 0.7 volumes of isopropanol at room temperature. The DNA pellet was washed with 
70% ethanol in order to remove the excess salt. The ethanol was removed and the 
DNA pellet was air dried and resuspended in 500 µl of elution buffer or nuclease free 
water.  
The concentration of the plasmid DNA, purified by mini or maxiprep methods, was 
measured using either a spectrophotometer or a Nanodrop 8000 and then stored at 
-20 °C for working stocks or stored at -80oC for long term storage. DNA purity ratio 
= OD260/OD280. The recommended ratio for successful transfection was ≥1.7  
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 2.15.13 Analyse of RNA, DNA Measurements, and protein contamination by 
using spectrophotometer  
2.15.13.1 RNA measurement  
The purity of RNA isolated by the RNeasy Mini Kit was measured by the ratio of 
absorbance readings at 260 nm with 280 nm in a spectrometer. DNA and RNA both 
absorb ultraviolet light with a peak in absorbance at 260 nm. Nucleic acids are 
commonly contaminated with different molecules, such as proteins, which have a peak 
absorbance of 280 nm. The spectrophotometer exposed the samples to ultraviolet light 
at 260 nm and a photo-detector measured the amount of light that passed through the 
sample. The spectrometer was then set to expose the sample to a wave length of 
280 nm, the measurements of light that passed through the samples was recorded. The 
ratio of absorbencies was calculated by dividing the 260 nm reading by the 280 nm 
reading. Pure RNA has a 260/280 ratio of 1.9-2.1, meaning that the values expected 
for high quality RNA are ~2.0. 
The concentration of the RNA was also calculated as shown below. 
Concentration µg/µl = Absorbance260  X dilution factor X 40 (co-efficient of RNA)  
An absorbance reading of 1 at 260 nm = 40 µg RNA/ml 
The concentration of the RNA isolated determined the volume of each sample needed 
in cDNA synthesis. The samples of RNA were stored at -20 °C.
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2.15.13.2 DNA measurement  
DNA concentration was measured using the standard protocol of absorbance at 
260 nm using a spectrophotometer. DNA concentration measurements were 
performed by diluting the DNA sample with distilled water to give a concentration in 
a range between 10 µg/µl and 50 µg/µl. First the spectrophotometer was calibrated at 
260 nm using distilled water. Then, the optical density of the DNA sample 
concentration in ng/µl was obtained by OD at 260 nm and the final concentration 
calculated using following formula. 
OD260 X 50 X dilution factor = concentration of DNA (µg/µl) 
OD260 = optical density of sample at 260 nm. 
An absorbance of 1 at 260 nm = 50 µg DNA/ml 
The DNA purity was obtained at 260 nm (OD260) and also at 280 nm (OD280); the 
purity of the DNA was calculated using the following formula. 
DNA purity ratio = OD260/OD280  
OD260 = optical density of the sample at 260 nm. 
OD280= optical density of the sample at 280 nm 
The recommended ratio for successful transfection was ≥1.7  
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2.15.14 Sequencing  
Plasmid samples with the insert cloned in were sequenced externally using either 
Source Bioscience Sanger Sequencing service or Dundee DNA Sequencing and 
Services (see Figure 6.6 in the Appendix). 
2.15.15 Reporter gene construction for in vivo analysis in a chick embryo model  
2.15.15.1 Construction of FUS ECRs phrGFP Reporter gene constructs  
The human FUS gene promoter fragments ECR PP (582) and PP (243) that were 
identified in (Chapter 3 section 3.3.12) were subject to PCR and cloned in pGL3b 
plasmid for use in the in vitro study. For in vivo analysis of the FUS promoter in chick 
embryos the addressed regions above were cut from their original pGL3b plasmid 
using SacI and Bgl II restriction enzymes. These reporter gene constructs were 
prepared by and a kind gift from Dr Thomas P Wilm, (University of Liverpool). 
Subsequently, these fragments were cloned into the SacI/BamHI site of the 
multicloning site of promoter-less vector phrGFP (Stratagene, UK) upstream of the 
GFP reporter gene. These clones were named FUS PP phrGFP and FUS ECR PP 
phrGFP (see Figure 6.11 and Figure 6.12 in the Appendix both these two plasmid 
constructs were constructed and prepared by Dr Vivien J Bubb and Christine Cashman 




2.15.15.2 Construction of INT PP phr GFP and INT ECR PP phrGFP  
In order to clone the putative regulatory element from FUS intron 1 into a location 
upstream of the FUS promoter sequence in ECR PP GFP and PP GFP, a 704 bp 
fragment was amplified by PCR using proofreading Phusion DNA polymerase (NEB, 
UK) and primers  5’-GATGAGATCTATGGCCTCAAACGGTAGGTAAGG and 5’-
AGGTGCTAGCGAAAGAAATTTAGGCGGGAAAAACTCTCGGGC, 
introducing BglII  and NheI restriction sites for directional cloning. The resulting 
constructs were named FUS INT PP phrGFP and FUS INT ECR PP phrGFP, 
respectively (see Figure 6.13 and Figure 6.14 in the Appendix). 
2.15.15.3 Construction of FUS SVA ECR PP phrGFP, FUS SVA PP phrGFP 
and FUS VNTR ECR PP phrGFP, FUS VNTR PP phrGFP  
FUS SVA and FUS VNTR sequences were excised from the original pGL3P vector 
and then amplified by PCR using standard Phusion polymerase conditions. The 
primers used are outlined below and incorporate NsiI and XbaI restriction enzyme sites 
to facilitate directional cloning:  
SVA UP 5’- TTGCATGCATGTGACTATTGCATACCTTGC-3’ and SVA DN 5’-
GACGTCTAGAGGAGAGGTTGTCATGGTACA-3’, and VNTR UP 5’-
TTGCATGCATCATCAGTTTTCCCTCAGACCCAG-3’ and VNTR DN5’-
GACGTCTAGAGTTGGGGGTAAGGTCACAGA-3’.  
The resulting products were cloned into the NsiI/XbaI site of FUS PP phrGFP and FUS 
ECR PP phrGFP respectively. The result product created FUS SVA PP phrGFP, FUS 
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SVA ECR PP phr GFP and FUS VNTR PP phrGFP, FUS VNTR ECR PP phr GFP 
(see Figures 6.15, 6.16, 6.17, 6.18 in the section for chapter 4). 
2.15.15.4 Generation of PARK7 SVA construct in forward orientation 
construct. 
In order to clone the PARK7 SVA forward sequence into the reporter plasmid FUS 
PP GFP, the insert was released from the Zero Blunt PCR vector from Invitrogen with 
Nsi1 a kind gift from Dr Abigail Savage at the University of Liverpool). 
 The reporter plasmid phr FUS PP GFP was digested using the same restriction 
enzyme Nsi1 and then the linearized plasmid was cleaned over a Promega # A9282 
mini elute column to remove all the buffers and then dephosphorylated with shrimp 
alkaline phosphatase. The released fragment was cloned into the Nsil site of the 
reporter plasmid FUS PP GFP and ligated to produce a construct named phr GFP FUS 
PP PARK7SVA (Figure 6.19 in the Appendix) and screened the minipreps with BglI 
as this enzyme cut once with the insert and twice with the backbone and released 
fragments 1229, 1724, 2697.  
2.16 Injection and transfection by electroporation. 
The most appropriate Hamburger-Hamilton (HH) stage of embryos to inject the neural 
tube was found to be at about HH 12-14. Earlier than this, the neural tube has not 
formed a closed central canal of sufficient length, whereas later than this the central 
canal of the neural tube has become too small. The protocols involving Chick embryos 





2.17 Plasmid mixes for the injection  
The plasmid mix contained a mixture of the two plasmids at a maximum concentration 
load of 6 µg/µl. The constitutively active td Tomato plasmid (a kind gift from Marco 
Marcello, University of Liverpool) at final concentration of 1 µg/µl and the phrGFP 
(human recombinant green fluorescent protein) reporter plasmid containing the 
sequence under test (at a DNA concentration adjusted between of 2-5 µg as per 
instruction adopted from Cold Spring Harbor Manual (Sambrook et al., 1989) were 
suspended in PBS +1 mM MgCl2, containing 0.2% (v/v) of fast green (FG) to aid 
visualization during the injection process. 
The injection of the td Tomato plasmid (Figure 3 in the Appendix) acted as a positive 
control for the transfection process and indicated the location of the reporter plasmid. 
2.18 Accessing the Embryos  
It was determined that eggs were normally at 12-14 HH, and thus at the correct stage 
for use, at 48 hr after incubation at 38 °C. The eggs were placed in a petri dish which 
had been prepared previously, with a blue tag button in the centre of the petri dish to 
hold the egg properly for windowing; the egg was then cleaned with tissue immersed 
with ethanol. Then the pointy end of the egg was punched with an egg punch and a 
syringe fitted with a 19G needle was inserted through the hole, directed below the 
equatorial mark to avoid damaging the yolk and used to withdraw 2-3 ml of albumen 
so as to allow the embryo to sink away from the area where the window was to be cut 
to avoid damaging the embryo in the subsequent process. The precise volume removed 
depended on the size and freshness of the egg, the fresher and bigger the eggs the 
greater the amount of albumen that was needed to be withdrawn. Then the puncher 
hole was taped up with a piece of laboratory tape (Shamrock brand) and the egg was 
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prepared for windowing. An oval window was drawn with a pencil on the top of the 
egg, centred on where the embryo should be (normally the embryo floated on the 
highest part of the egg during incubation). A suitable length of Sellotape Magic tape 
(2.5 cm wide) was placed over the marked oval. Using dissecting scissors, the marked 
oval was cut through the shell (Figure 1). The dust from the cutting was removed from 
the egg. A suitable length of the Sellotape Magic tape (2.5 cm wide) was placed over 
the partially cut oval or ‘window’. The tape was stuck down on both its short and long 
ends leaving a piece raised up at one end to aid unsealing the window later. An 
observation of the egg was made to ensure that the embryo had developed to the 
appropriate stage (Figure 2.2) and that an adequate volume of albumen had been 
withdrawn; any bubbles that had possibly formed in the albumen were ruptured with 
a hypodermic needle. The window was then sealed and the Sellotape was pressed 












Figure 2.1: Egg being windowed with dissecting scissor. The chick egg was placed on the 
Petri dish and prepared for windowing with dissecting scissors. 
 
 
Figure 2.2: The windowed egg with the developing embryo visible. The windowed was 
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2.19 pG-td Tomato  
pG-td Tomato sequence was PCR-amplified from pG-td Tomato using the forward 
primer 5’ATAGGAATTCCGTGTACGGTGGGAGGTCTA-3’ and reverse 5’-
GGCCGTCGACATCATTTTACGTTTCTCGTTC-3’. These introduced the Eco RI 
and SalI restriction sites as indicated, for directional cloning into the plasmid pIRES 
eGFP. The pIRES eGFPcassette was removed from the vector using the Eco RI and 
XhoI restriction sites and replaced by the tomato reporter gene, such that the Tomato 
reporter was located downstream of the chick beta actin promoter (this plasmid was a 
kind gift from Dr Vivien J Bubb and Christine Cashman, University of Liverpool), see 
Figure 6.9 map of td Tomato. The td Tomato plasmid was co-injected with a promoter-
less reporter vector phrGFP (Stratagene, UK).  
2.20 IRES GFP  
IRES containing GFP-expressing reporter plasmid was a gift from Dr Jon Gilthorpe 
(Department of Developmental Neurobiology, King’s College London), see Figure 
6.8 map of iresGFP. This is a CMV/ β-actin promoter upstream of the internal 
ribosome entry site (IRES) under the influence of the cytomegalovirus enhancer 
resulting in constitutive expression by the plasmid and high levels of expression of 
the, downstream, enhanced green fluorescent. 
2.21 Marker gene  
In order to demonstrate that transfection had occurred and was located at the site of 
the injection a marker gene was co-injected with the reporter gene. The marker gene 
plasmid can act as a positive control for a successful electroporation. Two marker 
genes were used in developing this thesis, the first marker gene used was IRES GFP, 
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and this was co-injected with a p1229-based vector, see Figure 6.7 Map of P1229, 
which is a modified version of pBLUESCRIPT, with the entire LacZ ORF/cDNA 
under the control of a human βglobin minimal promoter inserted into the polylinker 
area. This vector required an enhancer sequence that is cloned upstream of the 
promoter in MCS, and when the transcription factors bind the cloned enhancer 
sequence, the human βglobin minimal promoter is activated and the LacZ gene is 
transcribed. This results in the expression of the β-Gal by the cell. The β-Gal is later 
visualised by staining. These two marker proteins have been shown to be expensive 
in terms of both time and labour and hence were replaced with other marker proteins.  
IRES GFP was replaced with pG-td Tomato (a kind gift from Dr Marco Marcello, 
University of Liverpool) plasmid and this was used as a marker gene for the 
remaining experiments and the p1229 vector was replaced with the no promoter 
phrGFP reporter gene system.   
2.22 Injection of the plasmid  
The egg was placed under a dissecting microscope and the window shell removed 
(Figure 2). The vitelline membrane was removed using two forceps. A micropipette 
of borosilicate capillary glass tubing, with a filament, (Warner Instruments, G150TF-
3) was pulled (Sutter Instruments Model P-87 Flaming/Brown pipette puller) and 
attached to a plastic mouth pipette aspirator tube assembly for calibrated 
microcapillary pipettes (Sigma). The sealed end of the pipette was snapped off to give 
a needle of the appropriate diameter. These were then loaded with 100 – 200 µl of 
plasmid mixture (Figure 3). The neural tube or brain of the chick embryo, as 
appropriate (Table A2 Appendix), was penetrated with the micropipette tip (Figure 
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2.3) and the plasmid mix was inserted into the central canal of the neural tube or the 
lumen of the brain via a small volume of buccal pressure. 
After the micropipette was removed, gold plated electroporator straight wire 
electrodes of 3 mm or 5 mm length (Harvard Apparatus, Inc. BTX Models 514 (3 mm) 
512 (5 mm)) (Figure 2.4) were used for electroporation of the chick embryo neural 
tube (Figure 2.5) while paddle electrodes (Figure 2.4) were used for electroporation 
of the brain region, specifically the mid brain of the chick embryo (Figure 2.6) were 
positioned on either side of the embryo with a gap of 5 mm and attached to the 
electroporator. A drop or two of Phosphate-Buffered Saline (PBS) (Thermo Fisher 
Scientific) was placed on the electrodes to increase electrical connection.  
Figure 2.3: Microcapillary pipette used for injection of chick embryo. 
2.23 Electroporation  
The embryo was electroporated with five square waves of electric pulses at a fixed 
voltage of 15.5 V with a pulse length of 50 ms duration, and a gap of 100 ms. The 
electric field applied to the tissue caused formation of transient pores in the cells and 
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at the same time the negatively charged plasmid DNA was drawn towards the positive 
charge of the electrode and entered into the cells through the pores. 
As the DNA was drawn towards the anode, the position of the electrodes in relation to 
the tissue altered the location of the tissue that was to be transfected (Figure 2.7). When 
transfecting tissue of the neural tube with DNA injected into the central canal, the 
electrodes were placed on either side of the neural tube (Figure 2.5). If the anode was 
placed or tilted ventrally to the midline, and the cathode placed dorsally, the 
electroporation occurred in the ventral half of the neural tube. This position was used 
specifically when transfection of the motor neurone cells was the target. There were 
two types of electrodes used: the first type for chick neural tube electroporation (this 
was called the ‘straight wire’ electrode), while the second type was used to 
electroporate the chick brain tissue (Figure 2. 6), this was called the paddle electrode 




Figure 2.4: Two types of electrodes were used in chick embryo transfection. The straight 
wire electrode was used for transfecting the chick neural tube; the paddle electrode was used 
for transfecting chick brain tissue. 
 

















Placement of the anode electrode can alter the transfection; when the anode electrode 
was tilted to the ventral region of the neural tube; this anode will be close to the motor 
column and might increase the chance of motor neurone cells being transfected (Figure 
2.7). 
 
Figure 2.7: Illustration of electrode position in relation to the site of transfection of the 
chick embryo neural tube. Electroporation introduces the plasmid DNA to the motor 
neurone cells located to the anode electrode, while the other side acts as a control. 
 
After the electroporation was completed, the window was sealed with the shell 
fragment, which was stuck down, or if the shell piece was missing, the window was 
taped over. The embryo was then allowed to develop in a humidified incubator. This 
specialised incubator was fitted with a specialised humidity system (Brinsea Ova Easy 
380 with H22 Digital Humidity Management Module). This was used to incubate the 
windowed embryo. The temperature was set at 37.8 °C with the active humidity 
system set at 35%. 
Following the incubation period, usually 48 hours after electroporation, the embryos 
were visualised in ovo under fluorescence microscope. The embryos that have 
expressed td Tomato fluorescence in the desired tissues, were harvested and fixed, 
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then visualized under a dissecting microscopy to observe the reporter gene expression 
GFP. 
 
2.24 Harvesting Embryos. 
The embryos were dissected out from the shell by cutting the vitelline membrane and 
the blood vessels from the surrounding tissue using sharp forceps. The embryo was 
then scooped up with curved-shank tweezers. The embryos were then washed with 
Hank’s Balanced Salt Solution (Thermo Fisher Scientific). The embryos were then 
cleaned up using sharp forceps, by removing any unwanted tissue and remnants of 
blood vessels or vitelline membrane. 
 
2.25 Fixing Embryos  
The embryos were immersed in 4% paraformaldehyde fixative, with the fixing period 
being dependent on the size and age of the embryo. Typically embryos at E4-E5 would 
need from 1 to 2 hours to maintain the tissue integrity.  
 
2.26 Mounting chick embryo neural tubes and cerebella on cork discs  
In order to cryo-protect, the trunk of the embryo was dissected out from the whole 
embryo and all unwanted material was removed. The remaining tissue was submerged, 
until it sank, in the succession of 6%, 12% and 18% sucrose in Millonig’s Phosphate 
Buffer (0.125 M, pH 7.4) with 0.1% NaN3. 
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The required area of a cryo-protected embryo was located in the desired orientation, 
and mounted in a dome of optimal cutting temperature (OCT)-type embedding 
compound (Bright Cryo-M-Bed medium) on a cork disc. 
Iso-pentane was placed in a plastic beaker which was suspended over liquid nitrogen 
in a Dewar’s flask to cool it. The cork disc was then placed in the ultra-cold iso-
pentane for about 1 min to allow the OCT and tissue to freeze, at which point it was 
dipped in liquid nitrogen. The tissue always stored at -80 °C 
 
2.27 Antibody-staining of chick embryos  
Sections (10 micron) of chick neural tube (E5), cerebellum (E17) were cut using the 
cryostat. These sections were collected and mounted on gelatine-coated slides and a 
circular mark was drawn with a DAKO pen around the section. Paraformaldehyde was 
quenched for 15 min in 0.2 M glycine pH 7.4, non-specific antibody sites blocked with 
diluent consisted of 1% BSA, 0.12 M (Millonig’s), 0.1% Triton, 0.1% NaN3 give for 
15-30 min at room temperature. The section was stained with primary antibody at the 
appropriate concentration (see Table A4 Appendix) in diluent (30 min to 1 hour at 
room temperature), dip washed (three times in HBSS), stained with secondary 
antibody at 1:250 in diluent (1 hour at RT), dip washed (three times) in HBSS and 
once in de-ionized water and cover-slipped using a DAKO mount as adhesive.  
Nuclear staining was achieved by co-application of DAPI (1:1000 from 0.1µg/ml 
stock) with the secondary antibody. A list of primary and secondary antibodies used 
in the immunofluorescence staining of the chick embryo neural tube and cerebellum 
is provided in Table 4 in the Appendix. 
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2.28 Culturing of the SK-N-AS cell line  
SK-N-AS cells (human neuroblastoma cell line) were grown in media as outlined in 
2.1.6 in T175 flasks. When the cells’ confluency reached 70-80% they were passed 
into a new T175 flask. To passage the cells, the medium was removed from the flask 
and the cells were washed with 10 ml sterile PBS. 5 ml of 1x trypsin (Sigma) was 
added, washed over the cells and then removed. The flask was placed in the incubator 
at 37 ºC for 3-4 min until the cells started to detach from the surface. The cells were 
washed away from the surface flask with 10 ml of media, the cell clumps were broken 
up by pipetting and 1-2 ml of the cell suspension (approximately 1-2.4 million cells, 
depending on the cell type) was then placed in a new T175 flask with 40 ml of fresh 
media appropriate for the cell line. To detect infection with mycoplasma the cell lines 
were tested with Myco Alert mycoplasma detection kit (Lonza) every six months. 
 
2.29 Cell counts using a haemocytometer  
To determine the number of cells per ml of media a haemocytometer was used for cell 
counts. A T175 flask of cells at 70% confluency was passaged as stated in 2.36 up to 
when the cells were washed with 10 ml of media. The cover slip and haemocytometer 
were washed with ethanol before use. The haemocytometer has a grid which consists 
of 25 squares (5x5) bounded by three parallel lines each containing 25 smaller squares 
(5x5). The cover slip was placed over the counting surface of the haemocytometer and 
20 µl of the media with cells were inserted under the cover slip. The counting surface 
was visualised under a light microscope on a 10x objective and the number of cells 
within 25 large squares bounded by three parallel lines were counted. Any cells located 
on the top or left hand borders of 25 squares were included in the count while any cells 
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on the right or bottom border were excluded. This area corresponds to 0.1 mm³ and 
therefore the number of cells were multiplied by 104 (10000) to give the number of 
cells in 1 cm³ which is equivalent to 1 ml. This gave the number of cells per ml of 
media. 
 
2.30 Transfection of SK-N-AS cells  
Using Turbojet transfection Reagent (ThermoScientific/Fermentas, R0531) according 
to the manufacturer’s protocol, the cells were counted (as in 2.31) and then plated into 
24-well plates at a concentration of 66,000 cells per well with 1 ml media 24 hours 
before transfection. 1 µg of the test reporter gene plasmid and 2 µl of Turbofect were 
mixed in a total volume of 100 µl of serum free media, vortexed and incubated at room 
temperature for 20 min. SK-N-AS cells were transfected with 100 µl of the 
transfection mixture, equal to 1/10 of the volume of the media. After 4 hours of 
incubation in 5% of CO2 at 37 °C, the medium was exchanged with a fresh medium 
to reduce cell death. After 48 hours incubation the transfected cells were photographed 


















Evolutionary conserved regions of the human FUS gene can 







3.1 Introduction  
Comparative genome analyses can highlight regions of the genome that have been 
conserved during evolution that might play an important role in regulating gene 
expression. One of the previous projects in this laboratory utilised this approach to 
predict potential domains regulating FUS gene expression that might underlie its 
association as a candidate gene in ALS. The regulatory domains identified spanned 
the major transcriptional start site of the FUS gene and had a high degree of 
conservation between chimpanzees, dogs, mice and rats. These ECRs, and the putative 
FUS promoter, were initially selected for in vitro studies and subsequently analysed 
at embryonic day 5 (E5) of the chick embryo model in vivo, in order to address their 
potential regulatory functions in an appropriate anatomical location, specifically in the 
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3.2 Chapter Aims  
 
 To develop a methodology using the chick embryo model to test the activity 
of potential regulatory elements in the human FUS gene. In this chapter, these 
regulatory elements are presented as evolutionary conserved regions (ECRs). 
ECRs were cloned into the reporter vector and transfected into the chick 
embryo neural tube at HH12-14 in order to assess their activity via reporter 
gene expression in the transfected area.  
 
 To develop a reporter gene system using a combination of two fluorescent 
plasmids. The td Tomato plasmid was used to determine electroporation 
efficiency and a promoter-less phrGFP plasmid was used as the reporter gene. 
This dual plasmid system has potential advantages including that transfected 
embryos can be observed without embryo sacrifice, therefore enabling them to 
be cultured in ovo for 48-72 hours and thus giving a longer window of 
visualisation. Furthermore, this will allow gene expression to be visualised 





3.3 Endogenous gene expression of KIFAP3, FUS, and ELP3 in chick embryo 
tissue at E5.  
3.3.1 Introduction  
An initial experiment was conducted to confirm that KIFAP, FUS, ELP3 genes are 
expressed endogenously in motor neurones at this stage of development (E5). These 
genes were initially selected for their important association with MND, as  a conducted  
study by (Landers et al., 2009) identified a SNPs residue within the KIFAP3 gene 
associated with reduced KIFAP3 expression can increase the survival rate of ALS, 
furthermore, ALS causal mutations were found in the FUS gene (Kwiatkowski et al., 
2009), finally work by (Simpson et al., 2008) was identify ELP3 gene in ALS patients. 
At the early stages of this project it was planned to test putative regulatory elements 
in the form of evolutionary conserved regions (ECRs) from several genes known for 
their association with MND. When the ECR browser was applied to KIFAP3 and FUS 
genes, however, it showed that both genes contain evolutionary conserved regions, 
and these ECRs have been addressed for their activity in the in vitro study. The ELP3 
gene, meanwhile, contains two SNPs located in the intronic region that have been 
associated with motor neurone disease. For this reason it was important first to confirm 
that KIFAP, FUS and ELP3 genes are expressed in motor neurones at this stage of 
development. At E5 specifically, the motor column cells in the chick neural tube are 
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3.3.2 Optimisation of RT-PCR assay to confirm KIFAP3, FUS, and ELP3 genes 
expression in chick embryo tissue at E5  
The optimised RT-PCR was used to confirm the expression of genes mentioned above 
at E5 in the chick embryo central nerve system tissue. In brief, total RNA was prepared 
from the E5 chick neural tube, E15 forebrain and E17 cerebellum using the RNeasy 
mini kit (Qiagene). First a strand of cDNA was produced from the total RNA 
preparations. Platinum Taq DNA Polymerase (Promega) and primers were used for 
the amplification. The primers are described in detail in the table 1 Appendix. The 
annealing temperature was optimised while varying the cDNA concentration in the 
neural tube and cerebellum. The correct band sizes were amplified at the following 
annealing temperatures: 55 °C for KIFAP3, 57 °C for FUS and 59 °C for ELP3. The 
PCR products were visualised by agarose gel electrophoresis using a 1 kb fragment of 
KIFAP (Figure 3.1), a 994 bp fragment of FUS (Figure 3.2) and a 997 bp fragment of 


















Figure 3.1: Endogenous expression of chick KIFAP3 gene. Expression was detected 
in the chick CNS. Total RNA was purified from the E5 neural tube, E15 forebrain, 
reverse transcribed to cDNA and then used as a PCR template.L1 1kb ladder, L2 
KIFAP3 in neural tube, L3 KIFAP3 in forebrain, L4 1kb ladder. 
  L1      L2                     L3      L4 













L1         L2            L3             L4         L5          L6              L7        L8            L9 
L1      L2          L3      L4         L5        L6       L7       L8       L9 
Figure 3.2: Endogenous expression of FUS and ELP3 genes in the chick CNS. 
Total RNA was purified from E5 neural tube, E17 cerebellum, reverse transcribed to 
cDNA and then used as a PCR template. L1 1 kb ladder, L2 negative control, L3 FUS 
in neural tube 2 µl, L4 FUS in neural tube 1 µl, L5 FUS in Cerebellum, L6 negative 
control, L7 ELP3 in neural tube 2 µl, L8 ELP3 in neural tube 1 µl, L9 ELP3 in 
cerebellum.   
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3.3.3 Selection of FUS gene in an analysis of potential regulatory domains that 
regulate gene expression  
Putative regulatory elements in the form of ECRs from KIFAP3, FUS and ELP3 were 
tested in vitro. The activity of KIFAP3 and ELP3 genes were not strongly supported 
in vitro, but a positive result was achieved from the evaluation of FUS gene ECRs in 
vitro (Khursheed et al., 2015). For this reason it was decided to concentrate on FUS 
gene analysis both in vivo and in vitro and not to continue the initial work with 
KIFAP3 and ELP3 (data not shown).  
 
3.3.4 Injection and transfection of the chick embryo neural tube with the GFP 
reporter vector alone  
 
Many elements of in vivo injection and the electroporation technique were developed 
and refined during this project in order to obtain the best results. This included egg 
incubation, embryo maintenance, and modification of injection and electroporation 
parameters such as the microinjection technique and electrode positioning.  
Initial experiments were conducted to assess the GFP-reporter vector expression in the 
chick embryo neural tube. Although previously conducted in the lab, these 
experiments are technically demanding. For this reason, trial transfections were 
conducted to ensure consistency with data obtained from previous similar studies in 
the lab. This involved  in vivo injection  to determine the electroporation efficiency by 
demonstrating the expression of IRES-GFP (Figure 6.8 Appendix) driven under a 
constitutive promoter in the chick embryo (Yaneza et al., 2002). Injection mixtures 
consisted of Fast Green dye dissolved in PBS to allow visualisation of the injection 
site under bright-field microscopy, mixed with the GFP-reporter vector. The lumen of 
the chick embryo neural tube at HH12-14 was microinjected with the mixture and two 
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3 mm electrodes were placed over the neural tube. For electroporation, 5 square-wave 
electric pulses were applied at a fixed voltage of 15.5V with a pulse length of 50 ms 
duration and a gap of 100 ms. Determining the optimum electrode position in relation 
to the injected area was of paramount importance, but this was difficult because of the 
instability of the embryo and its environment. Achieving good electrical contact with 
the egg yolk was essential and this was ensured by removing the vitelline membrane 
and placing a few drops of PBS over the embryo. It was found that the electrodes 
needed to be positioned such that the injected area was centred between the two 
electrodes in a parallel orientation. To ensure that the embryo was not disturbed, and 
to avoid bleeding through contact with the major blood vessels, this process was 
carried out with extra diligence. Optimal electroporation was confirmed by detecting 































As shown in Figure 3.3 this vector drives the extensive expression of GFP in the rostral 
(A) and caudal (B) regions of the neural tube. A cross-section of the neural tube (C) 
shows that most of cells located proximally to the positive electrode expressed 
detectable GFP, whereas no expression was detected on the contralateral side, 
meaning it could act as a negative control. Strong GFP expression was detected in 
>90% of the samples at 48 hours, indicating the effectiveness of this method for 
introducing exogenous DNA. The bright field microscopy image (D) illustrates the 
rostral and caudal regions of the chick embryo neural tube at E5. This experiment 
established that the proposed electroporation system works well when GFP plasmid is 











Figure 3.3: Representative images of Chick embryo transfected with GFP. Whole 
mount (A, B) and cross-section of the dissected neural tube using a lab blade (C) of 
embryonic day 5 chick showing fluorescence (A,B) indicating the location of 
electroporation in the rostral region (A) and caudal region (B) of the neural tube following 
successful micro-injection and electroporation of  the neural tube. (C) Showing 
fluorescence in dorsal root ganglia, motor neuron cells and motor column; (D) whole 
mount chick embryo under bright field microscopy. Images are representative of 3 similar 
experiments using 10 embryos. 
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3.3.5 Chick embryo neural tube at E2-3 was transfected with Hb9 enhancer as a 
positive control  
The electroporation technique was now used to transfect the motor neurone cells from 
the chick embryo neural tube at HH 12-14. For this, the p1229 vector reporter gene 
system was used (a kind gift from Dr Michael Lyons) (Figure 6.7 Appendix), which 
contains the LacZ coding sequence driven by the human β-globin minimal promoter. 
An Hb9 enhancer sequence from the HOXb9 gene was cloned in the p1229 vector to 
confer detectable expression in motor neurone cells (Nakano et al., 2005). The 
transcription factor binding to the Hb9 enhancer activates the human β-globin minimal 
promoter driving LacZ gene expression and resulting in the expression of β-
galactosidase (β-gal) in the cell. β-gal is therefore expressed only where the Hb9 
enhancer is active. Hb9 is also only expressed in developing spinal motor neurones 
and is considered to be a strong marker for motor neurone cells (Tanabe et al., 1998, 
Arber et al., 1999).  
A mixture of 1 µg/µl of GFP plasmid and 2 µg/µl of Hb9 enhancer plasmid with 1 µl 
of Fast Green were dissolved in PBS and microinjected into the neural tube of chick 
embryos. 14 embryos were successfully injected and electroporated. Following 
incubation for 48 hours at 37 °C three of these embryos showed strong GFP expression 
in the neural tube (Figure 3. 4, B) and were processed as described in the material and 
methods chapter embryo staining section, remaining embryos has GFP expression in 
superficial tissues that allocated around the neural tube were excluded from the 
experiments as the transfected tissue has no motor neuron cells After incubation for a 
further five hours at 37 ºC all three embryos showed a blue staining in the neural tube 














The chromogenic signal of β-gal expression can only be visualised following sacrifice 
of the embryo. For β-gal stain development the tissue must be incubated in X-gal 
staining solution for 5 hours at 37 ˚C. This process is time-consuming, however, 
making β-gal reporters a less than ideal choice for expression studies in the chicken 
neural tube. 
3.3.6 Development of dual plasmid system using a combination of two fluorescent 
plasmids  
Rather than use the p1229 Hb9 enhancer as a reporter gene system, therefore, a new 
reporter gene system was introduced. This new system used a combination of two 
plasmids, both of which expressed fluorescent proteins so that the transfected embryo 
could be monitored and observed using florescent microscopy in vivo. This new 
system consisted of a plasmid expressing td Tomato under the control of a 
constitutively active chick β-actin promoter and shows strong red fluorescent 
illumination when observed under a fluorescent microscope with a red filter. td 
A B 
100µm 100µm 
Figure 3.4: Representative images of Chick embryo transfected with Hb9 enhancer. 
Whole mount (A,B) dorsal view showing the Hb9 enhancer LacZ-driven  blue staining in the 
spinal motor neurons of a chick embryo at E5 (A) GFP (B) following successful micro-
injection and electroporation Scale bar 100 µm.  Representative of 3 similar experiments. 
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Tomato plasmid has td Tomato sequences and is genetically modified from Discosoma 
striata (DsRed). It has a bright fluorescent protein (FP), and has tandem repeat dimer 
FP. This was created by coupling two td Tomato units with a 12 amino acid linker. td 
Tomato has many advantages, including compatibility with the existing lab 
microscope and Leica red filter set. It also has a fluorescence excitation spectrum peak 
at 554 nanometres and an emission spectrum peak at 581 nanometres along with a 
high photostability region. td Tomato was constructed was used as a marker protein to 
indicate successful microinjection and  electroporation (Strack et al., 2009) . With td 
Tomato plasmid a phrGFP plasmid was used as an alternative to the p1229 Hb9 
enhancer and acted as a reporter gene plasmid. This dual plasmid system has many 
advantages, including the fact that transfected embryos could be observed without 
embryo sacrifice and, therefore, can be cultured in ovo for 48-72 hrs giving a longer 
window of visualisation. Furthermore, gene expression can be directly visualised 




3.3.7 Testing of the fluorescent overlap between the GFP channel and red channel  
A set of three experiments were conducted to observe the fluorescent properties of 
GFP as a reporter and td Tomato as a marker (Figure 6.9 Appendix) and to confirm 
that there were no potential artefacts or fluorescence overlaps between the green and 
red channels when visualising plasmid expression. To test fluorescence overlap or 
artefacts related to the td Tomato plasmid, an injection mixture containing Fast Green 
dye in PBS and td Tomato plasmid was introduced into the chick embryo neural tube 
at development stage HH 12-14. When visualised under the red filter, a strong red 
fluorescence was observed in the neural tube of successfully electroporated embryos. 
When samples were observed under fluorescence it is very important to avoid the loss 
of signal through photo-bleaching. In my study it didn’t seem to affect the tested 
samples under the conditions I followed. Photo-bleaching was avoided by reducing 
the illumination intensity, and by the use of robust fluorophores. Given these results, 
the td Tomato plasmid could act as suitable marker in chick embryo tissue with 
sustained florescent intensity maintained for >48 hours, and even up to E5 (Figure 
3.5A). Moreover, when the same image was viewed under the green filter there was 
no fluorescence, indicating an absence of fluorescent overlap or artefacts (Figure 
3.5C).  
  










To test for fluorescence overflow or artefacts when the IRES GFP plasmid alone was 
electroporated into the chick embryo neural tube, the IRES GFP has a major excitation 
peak at 488 nm, and peak emission at 509 nm. An electroporated embryo was 
visualised under the green filter and a strong green fluorescence was apparent in the 
transfected area, whereas when viewed under the red filter, no fluorescence was 
observed, indicating that IRES GFP could be used as a marker plasmid without any 





Figure 3.5: Representative image of Chick embryo transfected with td Tomato 
plasmid in the neural tube. Chick trunk (A, B) At E5 showing fluorescence (A) the 
expression of the tdTomato is detected in the neural tube by a red filter indicating the 
location of the electroporation. td Tomato has expressed under the beta actin promoter and 
has a strong red fluorescence, therefore needing short exposure times, usually around 500 





A B C 
1mm 
Figure 3.6: Image of Chick embryo transfected with GFP in the neural tube. Whole 
mount (A, B, C) of embryonic day 5 chick showing fluorescence; (A) the expression of 
GFP is detected in the neural tube by green filter indicating the location of the 
electroporation. GFP was detected with long exposure times usually between 1-1.5 s. (B) 
Same image under bright field microscopy (C) with no fluorescence under a red filter (D) 
Schematic representation of GFP reporter gene vector.  
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Finally, the td Tomato and IRES GFP plasmids were tested together in chick embryos. 
Both exhibited strong fluorescence under their corresponding filter. The transfected 
embryo in (Figure 3.7) shows td Tomato expression in the neural tube (A) and GFP 
expression in (C). These findings suggest that both plasmids could be co-injected for 
subsequent visualisation experiments; that both exhibited strong expression in the 






Figure 3.7: Chick embryo transfected in the neural tube with both td Tomato and 
GFP. Whole mount (A, B, C) of embryonic day 5 chick showing fluorescence (A, C) 
The expression of td Tomato and GFP are detected in the neural tube; the former by a 
red filter and the latter by a green filter, indicating the location of the electroporation. 
(B) The same image under bright field microscopy. 
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3.3.8 Promoter-less phrGFP cannot drive GFP expression without a suitable 
promoter  
When the regulatory domains from the human FUS gene were observed, it was 
decided to use another type of GFP as a reporter gene. This type was called humanised 
recombinant GFP (hrGFP). It has a humanised recombinant GFP gene and a SV40 
polyadenylation signal. This version does not have a promoter and thus provides an 
ideal option to clone the promoter/enhancer of interest in extensive multiple cloning 
sites (Figure 6.10 Appendix). In addition, it has a major excitation peak at 500 nm and 
an emission peak at 506 nm. This vector has been tested in different cell lines and 
shows a high level of expression of functional fluorescent protein, and is more 
consistent, less toxic than EGFP, and the GFP produced from transfected cell lines is 
more efficient (Dardalhon et al., 1999). ECRs from the FUS gene were cloned into 
phrGFP so that the regulatory activity of these FUS ECRs could subsequently be tested 
on our own minimal promoter. To achieve this, the phrGFP was first tested alone to 
confirm that this plasmid cannot drive GFP expression without a suitable promoter. 
Chick embryos at HH12-14 were microinjected with phrGFP and td Tomato plasmids 
and these were electroporated into the neural tube. 48 hours post transfection; 
successful embryos exhibited td Tomato expression under a red filter, but did not show 
any GFP expression under a GFP filter, confirming that in the absence of a promoter, 
the phrGFP alone cannot drive GFP expression in the chick embryo neural tube. td 
Tomato was included as an internal control to ensure successful electroporation 
(Figure 3.8).   
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Figure 3.8: Chick embryos transfected in the neural tube with phrGFP plasmid with 
absent promoter and presence of td Tomato. Trunks of chick embryos at  embryonic 
day 5 showing no GFP fluorescence (A) no expression of the GFP is detected in the neural 
tube by green filter indicating the phrGFP with no promoter has no ability to drive 
expression. (B) The same image under bright field microscopy (C) td Tomato fluorescence 
under a red filter.  
A B C 
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3.3.9 The FUS gene was expressed ubiquitously in the chick E5 neural tube and 
E17 cerebellum  
To establish the validity of analysing reporter gene expression in embryonic day 5 
(E5) embryos, it was important to validate endogenous chick FUS expression in the 
chick embryo neural tube at E5. Endogenous of FUS expression was detected 
previously in the neural tube and forebrain by RT-PCR, thus this experiments was 
done by immunohistochemistry to confirm FUS gene expression in the cells of neural 
tube and specifically in the motor neurone cells. Cross-sections of the neural tube at 
E5 and the cerebellum at E18 were stained with an anti-FUS antibody (Abcam ab 
23439). Neural tube stained sections demonstrated that FUS had ubiquitous expression 
in the embryo at these stages (Figure 3.9 A). Cell nuclei were detected by DAPI 
staining in Figure 3.9 B and D. The E18 cerebellum cross-section also exhibited 
ubiquitous FUS expression in cells of all regions including cells of the molecular layer, 
Purkinje, and granular layers (Fig. 3.9 C). The negative control, lacking a primary 
antibody, did not show any staining (Fig. 3.9 E).   




Figure 3.9: FUS is expressed in the neural tube of E5, and in the cerebellum of 
E18 chick embryos. Frozen section of chick embryo E5, E18 stained with (A, C) 
FUS antisera, (B, D). DAPI. FUS is ubiquitously  expressed in all cells in the 
section, including cells in  the developing motor column and all cells in the 
cerebellum section molecular layer, Purkinje layer (PL), granular layer (GL). (E) 




















3.3.10 The location of motor neurone cells was identified in the chick neural 
tube by Hb9 antibody staining  
Prior to testing the regulatory propriety of FUS ECR in the chick embryo it was 
important to identify the region of the developing motor column and motor neurones 
in the chick embryo neural tube, so as to address the location and site that should be 
transfected with FUS regulatory domains. To achieve this aim 
immunohistochemically staining of frozen sections of E5 chick embryo neural tube 
was carried out using a Hb9 antibody (obtained from the University of Iowa) (Nakano 
et al., 2005, Ovcharenko et al., 2004); a secondary antibody was used –goat anti-mouse 
Alexa 488 (Invitrogen). The stained section demonstrated Hb9 expression specifically 
in the nuclei of motor neurone cells (Figure 3.10 A). The negative control, lacking a 
primary antibody, did not show any staining (Fig. 3.10 B).  
  
Figure 3.10: The region of the developing motor column was identified by the Hox 
gene family. (A) A cross-section of chick embryos unlabelled neural tube at E5 stained 
for a motor neuron marker protein HB9. The white arrow indicates motor neuron cells 
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3.3.11 An upstream (ECR) and intronic (INT) region are conserved during 
evolution  
In silico and functional in vitro analysis of the potential regulatory elements of the 
FUS gene was undertaken by my colleague Dr Thomas Wilm at the University of 
Liverpool. This data has been presented in a published paper (Khursheed et al., 2015). 
The data from the in vitro experiments has been summarised here to show the 
functional properties of the ECRs. Comparative genome analysis was conducted using 
the UCSC genome browser and the ECR browser (Ovcharenko et al., 2004, Kent et 
al., 2002).  
Comparisons of genomic sequences between distant organisms using UCSC genomic 
and ECR browsers can highlight candidate regions of the genome that have been 
conserved over a long period. This analysis can identify noncoding elements that may 
have critical biological functions. When this analysis was applied to the FUS gene a 
high degree of conservation was identified both 5’ and 3’ of the predicted major 
transcription start site (MTSS), located at Chr16: 31,191,429 (Figure 3.12) The 
highlighted area showed more than 70% conservation between human, chimpanzee, 
dog, and mouse species, but this region was not conserved in the chicks and the peak 
height corresponded to the percentage conservation with over 100 bp regions. The 
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Firs predicted domain identified was termed the proximal promoter (PP) a predicted 
domain continuous with MTSS. This region contained 137 bp upstream of the MTSS 
and 106 bp of untranslated parts of exon 1. The FUS promoter has no TATA box 
sequence but does have stretches of a G C rich region, and has several transcription 
binding sites for transcription factors AP2, Sp1 and GCF (Åman et al., 1996). The 
FUS promoter is involved in the initiation and or elongation of transcription by 
interacting with the RNA polymerase II and the TFIID complex (Bertolotti et al., 
1998). Additional conserved region was observed; further upstream of the proximal 
promoter 311 bp sequences in length and located 29 bp 5’ to PP; co-ordinates 
Ch16:31,190,954 -31,191;264. The last identified region was observed at 5’ portion 
of the first intron continuous with exon 1 this domain termed as INT (704 bp). This 
showed the most conserved region between compared species and thus potentially 
represents an important regulatory domain (Figure 3.11).  
Now that these key regions have been identified, they will be cloned into the 
expressions systems that have been developed and verified so far in the thesis, and 
then evaluated to see if they have regulatory functions or not. These domains are 
shown to have activity in vitro, and their regulative function in both neuroblastoma 
and the hybrid neuroblastoma/motor neurone cell line NSC-34 cells is briefly 
demonstrated (paper ref). First, constructs containing ECR and INT were both 
maintained contiguously with the predicted MTSS of FUS and they are in the same 
order as they appear in the genome. These constructs were tested in the neuroblastoma 
cell line, SK-N-AS. The in vitro experiments were undertaken in the lab by Dr Thomas 
Wilm and compiled into a published (Khursheed et al., 2015). The data of the in vitro 
experiments has been summarised here in order to demonstrate the regulation activity 
of FUS domain. Previously, SK-N-AS had been confirmed as exhibiting endogenous 
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FUS gene expression. Construct containing PP (243 bp) was shown to act as strong 
promoter and drove the expression of the luciferase marker gene when it tested in the 
promoter-less pGL3b vector (p< 0. 002). Constructs that contained INT PP, or ECR 
PP are shown to act as regulatory domains (Figure 3.12A). When they cloned up a 
stream of heterologous SV40 promoters in the pGL3p reporter gene vector, these 
regions showed themselves to be positive regulators of expression, with INT having a 
significantly greater effect in this respect (Figure3.12B). When both domains were 
tested in the hybrid neuroblastoma/motor neurone cell line (NSC-34 cell with pGL3) 
they were both shown as being able to act as positive regulators. Furthermore, the INT 
domain showed a greater activity than that observed in SK-NA-S, while the ECR was 
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Figure 3.12: Demonstration of FUS reporter constructs’ activity in SK-N-AS and NSC-
34 cells. (A) FUS promoter constructs were cloned in the promoter-less pGL3b and tested in 
SK-N-AS cells. The FUS PP drove strong expression of the luciferase marker gene (p<0.002) 
while constructs with either ECR or INT in combination with the PP increased levels of 
expression and showed higher levels of transcription activity (p<0.04, p<0.03 respectively) 
than PP alone. (B, C) the upstream ECR and intron INT from the FUS regulatory domain 
when cloned into the SV40 promoter pGL3p and expressed in SK-N-AS cells (B) and NSC-
34 (C) increased levels of luciferase activity compared to the SV40 promoter in SK-N-AS 
cells (p,0.02, p<0.004). Bars represent the fold change in firefly luciferase activity normalized 
against renilla luciferase activity, and means were calculated from a number of experiments. 
Transfection experiments were performed in double triplicates taken from (Khursheed et al., 
2015) 
3.3.12 FUS regulatory domains enhance expression in a chick embryo in vivo 
model  
To test the functional activity of the FUS regulatory domains with their own proximal 
promoter in the chick embryo neural tube, FUS fragments PP (243 bp) and ECR PP 
(582 bp) were excised from their original vectors using sacI and bglII and 
subsequently cloned into the Bam HI/SacI sites of the MCS of the promoter-less 
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phrGFP vector (Stratagene, UK) upstream of the GFP reporter gene. The constructions 
of both plasmids were described in detail in Chapter 2 section 2.15.15.1 and were a 
kind donation from Dr Vivien J. Bubb University of Liverpool). The resulting 
constructs were named FUS PP phrGFP and FUS ECR PP phrGFP.   
3.3.13 Construction of INT PP phrGFP and INT ECR PP phrGFP reporter gene 
vectors  
To generate the above plasmids the INT1 704 bp fragment was PCR-amplified using 
proofreading Phusion DNA polymerase (NEB, UK); the primers and PCR reaction 
conditions used were described in Chapter 2 section 2.15.15.2 The PCR reaction 
product was visualised by 1.2% agarose gel electrophoresis (Figure, 3.13 lane 2).  
The band at 704 bp was excised, purified, and digested with BglII and Nhel. This 
fragment was subsequently ligated into FUS PP phrGFP and FUS ECR PP phrGFP 
vectors. The resulting vectors were transformed, and minipreps analysed by double 
digestion with restriction enzymes/endonucleases BglII and EcoRV resulting in 
partially cut products.  The digested minipreps were screened on a 0.8% agarose gel. 
If the desired plasmid was successfully constructed, it would give expected fragment 
sizes of 1300 bp and 950 bp (Figures 3.14 and 3.15). Clones containing the expected 
inserts were expanded overnight, purified and sequenced for perfect homology and 






 122   
 
  
Figure 3.13: 1.2% agarose gel showing FUS intron1 
amplicon. L1 is the negative control; L2 is, 
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Figure 3.14: The 1300 bp band size of INT ECR PP. Double 
digestion of FUS INT ECR PP from the phrGFP vector with 
EcoRV and Bglll restriction enzymes. Vector of phrGFP 3.7 
kb L1 1kb ladder, L2 digested colony with the insert, L3, L4, 
L5 are empty colonies. 
L1 L2              L3              L4              L5             





    
1kb 
Insert fragment 
of 950 bp  
1kb 
Figure 3.15: The 950 bp band size of INT 
PP. Double digested of INT PP from 
phrGFP with Bglll, EcoRV Vector of 
phrGFP 3. 700 bp L1 1kb ladder, L2 empty 
colony, L3 digested colony with insert, L4 
empty colony, L5 1kb ladder  
L1                L2        L3          L4      L5 
 125 
 
3.3.14 Demonstration of the FUS regulatory domains’ activity in the chick 
embryo neural tube at E5  
The potential activity of the predicted FUS gene regulatory regions was assessed in 
the cell model and the data generated from FUS domains activity show to act as 
activators of the expression. The order of the regulatory regions where switched to 
enable the activity of each region to be tested individually. The results were able to 
demonstrate the activities of the FUS regulatory domains in the targeted anatomical 
location, specifically in the motor neurones of the chick embryo neural tube. The FUS 
regulatory domains that were tested in chick embryos were (FUS PP, FUS ECR PP, 
FUS INT PP, and FUS INT ECR PP Figure 6.11, 6.12, 6.13, 6.14 Appendix) in each 
transfection the total DNA of the FUS constructs were maintained to the 
recommendation range that adopt from Cold Spring Harbor Manual (Sambrook et al., 
1989). 
 
3.3.15 FUS ECR PP phrGFP can act as activator in the chick embryo neural tube  
To test the activity from FUS ECR PP phrGFP plasmid in the chick embryo (Figure 
3.16J), the lumen of the developing chick embryo neural tube at HH 12-14 was 
injected with 1µl each of FUS ECR PP phrGFP plasmid at (3.6 µg), of tomato plasmid 
(1 µg/µl), 1µl PBS, and of Fast Green (1 µg/µl) and then transfected by 
electroporation. In each transfection the total DNA of FUS ECR constructs were 
maintained to the recommended range that adopted from (Hogan et al., 1986). 
Reporter gene constructs were co-injected with a plasmid containing chick -actin 
promoter driving td Tomato expression as an internal control for successful 
electroporation. In order to allow the reporter gene expression to develop fully, and to 
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allow differentiation of motor neurone cells, the expression was not assessed until 48 
hours post transfection. The 25 successfully transfected embryos number from the 
three experiments had strong td Tomato in the neural tube (Figure 3.16A) and strong 
GFP in the same location (Figure 3.16B). Frozen sections of one of the transfected 
embryos showed the extent of successful electroporation in the left-hand neural tube 
since the DNA within this neural tube is directed to the cathode (Figure 3.16D). Figure 
3.16E shows that the ECR PP can drive GFP expression in all the electroporated cells, 
including the developing motor neurones. These frozen sections were stained with 
DAPI (Figure 3.16F). Some frozen sections of the transfected embryos were also 
immunohistochemically stained using an Hb9 antibody (obtained from the University 
of Iowa) and a secondary antibody of goat anti mouse IgG Alexa 350. The stained 
section demonstrates Hb9 expression; specifically in the nuclei of motor neurone cells 
in the frozen section of the E5 chick embryo neural tube the Hb9 antibody stain shows 
a pale blue approaching violet fluorescence. Since the staining here was quite pale, 
however (Figure 3.16I) and since it was even harder to see with red and green 
fluorescence (Figure 3.16G and 3.16H), this experiment was not repeated for 
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Figure 3.16: FUS ECR PP phrGFP activity in chick embryos. (A, B) and (C) show 
embryos that have been electroporated with 1 µg/µl td Tomato, 3.6 µg/µl ECR PP GFP, (A) 
td Tomato fluorescence indicating successful electroporation. (B) GFP fluorescence 
indicating the activity of ECR PP in the neural tube. (C) Bright field showing the location 
of electroporation in four successfully electroporated chick embryos. The arrow indicates 
the electroporated trunk region of one of the embryos. Scale bar 2 mm. D, E, and F are 
frozen sections of one of the embryos: D shows the extent of successful electroporation in 
the neural tube. It is restricted to the left hand side since the DNA within the neural tube is 
directed to the cathode. (E) Shows that ECR PP drives GFP expression in all the 
electroporated cells including the developing motor neurons. (F) Shows Dapi staining.(G, 
H, I) are the same frozen cross-section showing td Tomato (G), (H) motor neuron cells 
transfected with ECR PP phr GFP reporter gene, indicted by the white arrow (I) motor 
neuron cells demonstrating Hb9 expression specifically in the nuclei of motor neurons  (J) 
Schematic representation of FUS ECR PP phrGFP reporter gene vector. Scale bar 100 µm 
    PP GFP J     ECR 
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3.3.16 FUS PP phr GFP cannot drive reporter gene expression in chick embryo 
neural tubes  
The functional activity from FUS PP phr GFP plasmid was tested in chick embryo 
neural tubes (Figure 3.17F). 1 µl each of FUS PP phr GFP at (11 µg/µl), of tomato 
plasmid (1 µg/µl), and of Fast Green (1 µg/µl) were transfected into the lumen of chick 
embryo neural tubes at stage HH 12-14. The ten successfully transfected embryos had 
strong red expression in the neural tube (Figure 3.16A) but no GFP expression was 
observed in any of the transfected samples, indicating that PP alone could not drive 
the detectable reporter gene (Figure 3.17B). Frozen sections from one of the embryos 
that were transfected with the FUS PP shows td Tomato expression, indicating 
successful transfection (Figure 3.17D). Figure 3.17E, meanwhile, shows no GFP 
expression in the neural tube, indicating that FUS PP alone cannot drive reporter gene 
activity in chick embryo neural tubes. Figure 3.17F Schematic representation of the 



























Figure 3.17: FUS PP phrGFP activity in chick embryo neural tube. All panels show 
embryos that have been electroporated with 1 µg/µl td Tomato, 3. 6 µg/µl PP GFP. (A) td 
Tomato, (B) PP GFP and (C) bright field microscopy image.. Scale bar 2 mm. The white 
arrow indicates the electroporated trunk region of the embryo. (D, E) are frozen sections of 
the embryo from (A, B and C). (D) Shows the extent of successful electroporation in the 
neural tube. It is restricted to the left hand side since the DNA within the neural tube is 
directed to the cathode. (E) Shows no fluorescence, indicating that PP alone cannot drive 
GFP expression in the neural tube, including in the developing motor neurons. (F) Schematic 
representation of FUS PP phrGFP reporter gene vector. Scale bar 100 µm.  
A B C 
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D E 100µm 
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3.3.17 FUS INT PP phrGFP acts as a positive activator in chick embryo neural 
tubes  
The FUS INT PP 1phrGFP plasmid shown in (Figure 3.18F) was tested in chick 
embryo neural tubes. 1 µl each of FUS INT PP phr GFP at (3.6 µg), of tomato plasmid 
(1 µg/µl), and of Fast Green (1 µg/µl) transfected to the lumen of chick embryo neural 
tubes. After 48 hours the successfully transfected embryos were showed to have td 
Tomato expression when observed under the red filter and showed GFP expression 
under the GFP filters. In the three experiments 14 embryos had strong td Tomato 
(Figure 3.18A) and strong GFP expression in the chick embryo neural tubes at the 
same location (Figure 3.18B). Figure 3.18 D, E, meanwhile, show sections of the 
embryo neural tube transfected with the INT PP phrGFP. These section have been cut 
with a lab blade to observe the expression activity in more detail, Figure 3.18D shows 
td Tomato expression, indicated by the white arrow, and Figure 3.18E shows 
expression of IN PP phrGFP, indicated by the blue arrow. Motor neurone cell locations 


































Figure 3.18: FUS INT PP enhances expression in chick embryo neural tube. (A, B and C) show 
embryos that have been electroporated with 1 µg/µl td Tomato, 3.6 µg INT PP GFP. (A) td Tomato 
fluorescence indicating successful electroporation. (B) GFP fluorescence indicating the activity of 
INT PP in the neural tube. (C) Bright field microscopy image. (D, E) Cross-sections of the neural 
tube from the transfected embryo in (A), (D) shows td Tomato in the neural tube cells and (E) shows 
FUS INT PP activity indicated by GFP in most neural tube cells, indicated by the white arrow and 
including motor neuron cells indicated by the purple arrow (F) Schematic representation of FUS 
INT PP phrGFP reporter gene vector. Scale bar 1 mm  
 
GFP     PP F    INT 
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3.3.18 FUS INT ECR PP phrGFP can act as activator in chick embryo neural 
tubes  
FUS INT ECR PP phr GFP was tested in chick embryo neural tubes (Figure 3.19F). 
The test plasmid mixture at a final concentration of 4.4 µg, 1 µg/µl of td Tomato, 
1 µg/µl Fast Green, and 1 µl of PBS was injected and transfected to the chick embryo 
neural tubes. 48 hours post transfection the 14 successfully transfected embryos 
showed both strong td Tomato (Figure 3.18A) and strong GFP expression (Figure 
3.19B) in the same location of the neural tube. Frozen sections were taken from the 
neural tubes of transfected embryos and Figure 3.19D shows the expression of td 
Tomato in these sections, indicated by white arrow, while Figure 3.19E shows the 
expression of the INT ECR PP in the transfected area, indicated by the blue arrow; 
motor neurone cells are indicated by the purple arrow. 
Overall, the promoter/ enhancer properties of these various regulatory regions (ECR 
PP, INT PP, and INT ECR PP) were consistent with the results obtained in the cell 
line model, except that PP alone showed no activity in vivo. Differences of FUS PP 
behave between SK-N-AS and chick embryo neural tube at E5 is most likely due to 
transcription factors that are active in vitro but not active in vivo at this development 
stage of neural tube ; or they might have a tissue specific activity and not active in the 
developing neural tube cells. These differences could play a crucial role in the 
response to regulatory elements.  
The transfected neural tubes were excised and fixed and frozen cross-sections were 
prepared. In the FUS ECR PP phr GFP transfected specimen, the majority of GFP 
positive cells were located in the ventral region, specifically in the motor column and 
motor neurone cells. In the INT PP and INT ECR PP specimens, strong GFP signals 
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were apparent in the dorsal and ventral regions including the motor column. PP alone 
did not show fluorescence in the dorsal or ventral axes.  
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Figure 3.19: FUS INT ECR PP activity in chick embryos. (A, B, and C) show embryos that have 
been electroporated with 1 µg/µl td Tomato and 4.4 µg/µl INT ECR PP. (A) td Tomato fluorescence. 
(B) GFP fluorescence indicating the activity of INT ECR PP in the neural tube. (C) Bright field 
microscopy image. Scale bar 2 mm (D) frozen section of transfected neural tube showing td Tomato 
expression (E) the same section showing expression of GFP in the neural tube and specifically in the 
motor neurone cells MNC (F) Schematic representation of FUS INT ECR PP phr GFP reporter gene 
vector. Scale bar 100 µm.  











3.3.19 Transfection of S K- NA-S cell line with FUS regulatory domains 
The activities of the predicted regulatory regions from the FUS gene were assessed in 
the FUS-expressing neuroblastoma SK-NA-S cell line. This experiment was 
conducted particularly to test whether FUS PP plasmid alone was constructed 
correctly and to affirm that there was no problem with the construction of the plasmid. 
The activity of the constructs was measured using the hr GFP reporter gene system as 
a traceable marker and a scoring system based on the number of cells expressing GFP. 
The td Tomato was included as a positive control and promoter-less phrGFP alone as 
negative control. Construct activity was determined 24 hours after transfection by 
counting the number of GFP-positive cells as a proportion of the total number of cells, 
as viewed by fluorescent and phase-contrast microscopy, respectively. All predicted 
regulatory regions showed significant marker gene expression (Figure 3.20), table 5 
in the appendix. The cells transfected with INT ECR PP phrGFP showed the highest 
level of GFP expression among all FUS ECR constructs, while cells transfected with 
ECR PP phrGFP showed the lowest level of GFP expression. Cells transfected with 
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Figure 3.20: Transfection of SK-NA-S cells with FUS ECR phrGFP constructs. The red cells 
in the fluorescence image (A) are transfected cells with td Tomato plasmid represented as a positive 
control (B) phase picture of the same image. The green cells in the fluorescence (C) are transfected 
cells with FUS ECR PP construct (D), phase picture of the same image. The green cells in the 
fluorescence (E) are transfected cells with FUS PP (F) phase picture of the same image. (G) 
Fluorescence of cells transfected with FUS INT ECR PP (H) phase pictures of the same image. (I) 
fluorescence of cells transfected with FUS INT PP (J) phase pictures of the same image. (K) No 
fluorescence is seen in cells transfected with phr GFP alone, represented as a negative control (L) 





The LacZ reporter system works well in the chick embryo model but the long 
processing time meant that it was not an ideal technique for the current study. It was 
therefore replaced with an alternative reporter gene system using GFP and td Tomato 
markers. The GFP plasmid functioned as a reporter gene, whereas td Tomato 
functioned as an internal electroporation efficiency control. Furthermore, 
electroporation drives the DNA in one direction and GFP was not expressed at the site 
contralateral to injection, demonstrating successful microinjection and 
electroporation. This dual fluorescent protein system has many advantages including: 
the transfected embryos can be observed under a fluorescent microscope without 
embryo sacrifice; the GFP fluorescence spectrum did not overflow into red filters and 
vice versa; embryos can be cultured in ovo for 48-72 hrs or much longer therefore gene 
expression can be monitored over a longer time scale with no leakage of proteins into 
surrounding tissues or background; and, finally, gene expression is directly visualised 
under fluorescent microscopy without the need for staining.  
Comparative genome analyses helped in the identification of domains in the human 
FUS gene that have been conserved across species which we postulated were 
potentially important regulatory domains. This analysis identified putative domains 
including a 704 bp domain located in the first intron of the FUS gene, a minimal 
promoter domain contiguous with MTSS, and a 311 bp ECR fragment upstream of the 
proximal promoter (see Figure 3.11).  
These regulatory regions were tested with SV40 minimal promoter in the 
neuroblastoma cell line, SK-N-AS. ECR and INT were shown to act as transcriptional 
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activators and drove expression of the luciferase marker gene in this cell line for 
example ECR increased the level of expression activity by two fold and INT1 
increased the level of expression four time more (Figure 3.12B). Same regions were 
tested with hybrid neuroblastoma/motor neuron cell line NSC-34 cells, ECR increased 
the level of activity two fold and INT1 showed to increase the level of activity 8 time 
more (Figure 3.12C). 
Both INT and ECR when linked with FUS PP in the phrGFP plasmid had 
transcriptional activity in the chick embryo neural tube, INT PP expression were 
observed in 14 transfected embryos and ECR PP expression were observed in 25 
transfected embryos, while PP alone had no activity in the in vivo environment. When 
the same plasmids were tested in vitro they show GFP expression, and PP alone shows 
enhancer activity. These experiments were conducted to ensure that the plasmids were 
constructed correctly; they showed that there is no difference in the plasmid 
construction but that there are differences between the chick and SK-N-AS 
environment and / or sensitivity of detection. The difference is most likely due to 
differences in the cellular environment or phenotype; for example SK-N-AS cells are 
human cancer, transformed cells with a lot of mutations and might have different 
transcription factors. The differences might also be due to transcription factors that are 
active in vitro but not active in vivo; or they might have a tissue specific activity and 
not transcript in the developing neural tube cells. These differences could play a 









Identification of the regulatory domains that regulate FUS gene expression in motor 
neurones can help us to understand the genetic features that may promote these 
diseases. For example, the INT domain was shown to have enhancer activity in the in 
vitro experiment with the pGL3b vector (Figure 3.12A). The INT domain in 
combination with PP, when maintained after MTSS, was shown to affect the 
transcriptional activity of the luciferase marker gene and act as an activator of 
transcription; specifically, the INT domain when located after MTSS can modulate 
through post-transcriptional activity and demonstrate a significant increase in the 
transcription level. When it has been cloned upstream of PP (Figure 3.21) or upstream 
of ECR PP (Figure 3.22) meanwhile, strong GFP expression can be detected in the 




























Figure 3.21 FUS INT PP sequences. INT1 sequences from human FUS gene labelled with sequences1, were 
cloned upstream of FUS promoter labelled with sequences 2, red font of sequences1 indicates the start of 























  Sequences 3 
Figure 3.22 FUS INT1 sequences cloned upstream of FUS ECR PP in reporter plasmid phrGFP. INT1 labelled 
with sequences1, were cloned upstream of FUS  ECR promoter labelled with sequences 2 and sequences 3 for FUS 
promoter, red font of sequences1 indicates the start of INT1sequences, red font of sequences2 indicates the start of 




It has been shown that mutation within cis regulatory domains or 3’UTR mutations of 
FUS gene may have a profound effect on the gene expression spatially and temporally 
that might lead to changes in FUS gene location in the gene in the cell and cause 
globular and granular inclusions, eventually leading to loss of motor neurones 
(Sabatelli et al., 2013a, Gal et al., 2011, Kryndushkin et al., 2011, Ito et al., 2011). 
These ECR domains may now be added to the list of regions of the gene to be 
considered for study when undertaking mutational analysis of samples from patients 
with MND. Furthermore, they are also regions of interest in view of recent results that 
correlated regulation of FUS expression with motor neurone degeneration (Vance et 
al., 2013).  
The results presented here suggest that chick embryos can be used as a model system 
to confirm the role of the human FUS regulatory domains in the motor neurones of 
chick embryo neural tube. These human regulatory domains were selected on the basis 
of their conservation across phyla from fish to chick to man. The approach used here 
can be applied to analysis of other genes whose expression is implicated in the 
development and progression of ALS and other neurodegenerative diseases (Abe et 
al., 2004)  
Although the FUS ECRs used are human sequences and their conservation in chicks 
is not known, they have responded well to the chick environment in vivo and, 
specifically, their activities were observed in the motor neurones of the neural tube. 
These results demonstrate that the chick embryo model can be used to investigate 
potential regulatory elements that may function in the adult human diseases.  
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In summary, this chapter has demonstrated a novel human regulatory domain, INT, 
located within the MTSS of the FUS gene, which could play a role in FUS gene 
regulation in the form of ECR. The positive results generated from the FUS domain’s 
activity in the chick embryo neural tube and the success achieved from using this 
model system provides an incentive to test other putative regulatory domains that are 
located upstream of two genes FUS and PARK7. These domains are SVAs and are 
classified as subtype D, a subtype that is only found in primates and is not conserved 






































4.1 Introduction  
In the previous chapter it was demonstrated using a chick embryo model that the 
regulatory domain resides in the evolutionary conserved regions (ECRs) of the human 
FUS gene. In this chapter, the study is extended to investigate the role of another 
domain or region located upstream of the FUS gene. This region is a SVA, and has 
been demonstrated to be important in FUS gene regulation (Savage et al., 2014a). This 
region was identified using the genome browser UCSC and ENCODE data (the 
Encyclopaedia of DNA elements). This aided the identification of the regulatory 
elements that might have an influence on FUS gene regulation. Specifically, when the 
UCSC genomic browser (http://genome.ucsc.edu/index.html) was applied to the FUS 
gene locus, a large repetitive region was identified located within 10 kb of the 
transcription start site (TSS) from the FUS gene and 20 kb away from the 5’ end of 
the PRSS36 gene. This repetitive region was called VNTR and was found to be a 
central region of a large repetitive region known as SVA (see Figure 4.1). The 
ENCODE data further identified many elements that might suggest that this SVA 
could be involved in gene regulation. These are: 1) DNase 1 clusters were found on 
both sides of the SVA. 2) regions with active histones and H3K4Met were found, 
which are always found near to the transcription factor binding and 3) human 
expressed sequences tags (ESTs) were found to originate and be transcribed in both 
directions of this region (Figure 4.3) (Doolittle, 2013, Kavanagh et al., 2013). SVAs 
are non-autonomous, non-LTR retrotransposons, named according to their 
composition SINE-R, VNTR (variable number of tandem repeats), and an Alu-like 
sequence (Wang et al., 2005). SVAs are actively mobilised in the human genome, 
using the LINE 1 machinery in order to replicate and expand through the genome by 
a copy and paste mechanism (Wang et al., 2005). 2700 copies of SVAs are present in 
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the human genome (Wang et al., 2005). The general structure of the SVA and the 
classification of its subtypes were described in the Introduction chapter, section 1.8.3. 
The FUS SVA is classified as subclass D which is found only in humans and 
chimpanzees. The structure of FUS SVA differs to the structure of the canonical SVA 
by the absence of two elements (see Figure 4.1). First, FUS SVA has no hexamer 
repeat CCCTCT at the 5’ end. Second, it has no poly A-tail after the SINE. FUS SVA 
has an Alu–like sequence, and a central repetitive region consisting of tandem repeat 
(TR) and VNTR and followed by SINE. The structure of the canonical SVA is 
illustrated in Figure 1.8 in the Introduction chapter 
 
Figure 4.1: Structure of the SVA located upstream of the FUS gene. 
A diagram illustrating the structure of the SVA D located upstream of FUS gene. It consists 
of an Alu-like sequence, then a TR followed by VNTR and a SINE. FUS SVA is missing the 
hexamere repeat CCCTCT at the 5’ end of a canonical SVA and has no poly A-tail after the 
SINE, this image is taken from (Savage et al., 2014b). 
 
The estimated rate of the insertion of SVAs insertion into the human genome is 1 in 
every 916 births (Xing et al., 2009)). To date, it is known that eight of the inserted 
SVAs have a correlation with diseases (Hancks and Kazazian, 2012). Global analysis 
of the SVAs has identified another SVA located upstream of the PARK7 gene (Figure 
4.2) (Savage et al., 2013a). This SVA is important for, the fact that it is located 
upstream of the PARK7 gene is significant since the gene is known for its association 
to neurodegenerative disease and in some cases ALS (Buée-Scherrer et al., 1995, Hof 
et al., 1994) and also in two types of breast cancer, and in non-small cell lung 
carcinoma (MacKeigan et al., 2003a). PARK7 SVA shares similarities with the FUS 
SVA feature as it is located 10 kb upstream of PARK7 gene, it is human specific and 
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is classified as sub class D. PARK7 SVA, however, differs from FUS SVA in that it 
contains all the domains of the canonical SVA, for example it has a CCCTCT 
hexamere repeat at 5’ end.  
 
 
Figure 4.2 the human specific PARK7 SVA located 10 kb upstream, of the PARK7 gene. 
SVA has a hexamer repeat CCCTCT, VNTR, Alu-like sequence, TR, VNTR, SINE and poly 
A-tail (redrawn from (Savage et al., 2013a)  
 
In summary, previous work has identified two SVAs, located upstream of the FUS and 
PARK7 genes as regulatory elements in an in vitro model (Savage et al., 2014b), 
(Savage et al., 2013a). This chapter will demonstrate the potential functional activity 
of both FUS SVA and PARK7 SVA in vivo using the chick model established and 




4.2 Aims  
 Analyse the endogenous expression of chick PARK7 gene in chick embryo brain 
at E5. 
 To study in the developing chick central nervous system the regulative properties 
of the SVAs in FUS and PARK7 genes known for their association with 
neurodegenerative disease. This will be achieved by cloning the sequences of the 
SVA and VNTR from FUS gene, SVA from PARK7 and insert into a reporter 
plasmid; then to inject the generated  plasmids into neural tube, midbrain region  
of developing chick embryo at E2-3 and then electroporated to test their regulation 
activity by driving the expression of phr GFP  
4.3 Methods  
 Bioinformatics analysis of the FUS, PARK7 gene locus in the UCSC genomic 
browser (http://genome.ucsc.edu/index.html) was used in order to provide 
information about the function and structure of important repetitive regions that 
have potential regulatory function. 
 Develop a methodology in order to inject and electroporate chick embryo mid 
brain at E5 with FUS SVA, PARK7 SVA constructs and analyse their regulatory 




4.3.1 Construction of human FUS SVA and VNTR reporter plasmid domains 
for in vivo experiments  
The generation of FUS proximal promoter reporter plasmid has been described in 
Chapter 2, section 2.15.15.1. The FUS SVA and FUS VNTR plasmids were provided 
by Dr Vivien J. Bubb University of Liverpool). They contain the intact FUS SVA and 
the isolated TR/VNTR sequences and were PCR amplified from SVA and VNTR 
reporter plasmids used for the in vitro analysis and cloned upstream of the promoter 
into either FUS PP phr GFP or FUS ECR PP phr GFP, which have already been used 
in Chapter 3 section 3.3.15 and section 3.3.16 The resulting constructs were named 
SVA PP phrGFP and VNTR PP phrGFP SVA ECR PP phrGFP, VNTR ECR PP 
phrGFP. The constructions of these four plasmids were described in Chapter 2, section 





4.4 Results  
4.4.1 Identification of a SVA D upstream of FUS gene  
When the UCSC genome browser analysis was applied on the FUS gene locus aided 
by utilisation of ENCODE (the Encyclopaedia of DNA elements) it illustrated the 
structure of the gene in the region under examination, highlighting an active chromatin 
area and binding site of transcription factors (Figure 4.3). A large GC- rich repetitive 
region located 10 kb away from FUS gene transcriptional start site (TSS) was 
identified when the FUS gene loci were analysed. The ENCODE data suggested that 
this repetitive region had many features indicating that it might be active; these 
features included: 1) being flanked by a DNase 1 hypersensitivity cluster, and 2) the 
transcription factor binding sites. This repetitive region was found to be part of larger 
repetitive region called an SVA (Figure 4.3). This SVA is present in humans and 
chimpanzees only and was classified as a SVA subtype and conservations were 



















































































































































































































































































4.4.2 FUS SVA D, VNTR act as transcriptional regulator in reporter gene 
constructs in vitro  
 The functional analysis of the FUS SVA or VNTR in vitro was addressed in the 
laboratory by Dr Thomas Wilm. The data generated by the experiments have been 
summarised here to demonstrate the functional properties of both FUS SVA and 
VNTR in vitro (Khursheed et al., 2015). The regions encompass the SVA, and within 
the central VNTR were PCR amplified and cloned in the firefly luciferase reporter 
gene pGL3P, a vector containing a SV40 minimal promoter element. These constructs 
containing the complete SVA sequences or the VNTR were tested in the human 
neuroblastoma cell line SK-N-AS. The level of reporter gene expression showed 
significant differences between SVA and VNTR compared to the minimal promoter 
SV40 promoter alone in the pGL3P vector. The complete SVA repressed reporter gene 
and showed decreased in the level of expression by p<0.05, whereas the TR/VNTR 
were showed enhanced properties and increased the level of reporter gene expression 
by p<0.001 for short alleles and by p<0.05 for long alleles in this cell line. It may 
demonstrate that SVA may contain distinct regions that act as regulatory domains and 





4.4.3 FUS SVA and VNTR can act as regulatory domains in the chick embryo 
neural tube  
Previous chapter we have discussed the activity of the FUS ECR in chick embryo 
neural tube and showed these regions have a regulator activity. Here, the functional 
activity of SVA and VNTR from FUS gene will be tested in chick embryo neural tube. 
Interestingly, previous work by (MacKenzie and Quinn, 1999) showed that specific 
VNTRs can have a regulator property and  support tissue specific expression in 
developing mouse transgenic models. To investigate the repression activity of the FUS 
SVA in chick neural tube at development stage E5, the FUS SVA was analysed and 
cloned in to the FUS ECR PP plasmid, the expression properties of which were studied 
in detail in Chapter 3, and showed to act as a strong regulator. The ECRPP FUS SVA 
plasmid at 2-5 µg DNA at final concentration with 1 µg/µl of tomato plasmid were 
injected into the chick neural tube 48 hours after electroporation, strong tomato 
expression was observed in 6 embryos, (Figure 4.4A) table 4.4.15 specifically in the 
neural tube. When these samples were analysed for GFP expression, all were seen to 




Figure 4.4: Activity of ECR PP FUS SVA in chick embryo neural tubes at E5. (A) Embryos 
electroporated with tomato plasmid as marker for successful transfection. (B) Bright field 
microscopy image. (C) Expression of ECR PP FUS SVA in chick embryos’ neural tubes 
indicated by reporter gene GFP (D) Schematic representation of ECR PP FUS SVA phrGFP 
reporter gene vector. Scale bar 1 mm  
 
 
GFP PP  D  ECR FUS SVA 
154 
 
Next, tested plasmid was FUS SVA cloned into FUS PP plasmid.  Previously FUS PP 
plasmid was observed, and shown to have no activity in chick embryos. In each 
transfection the total DNA of FUS SVA PP, FUS SVA ECR PP, FUS VNTR PP, and 
FUS VNTR ECR PP constructs were maintained to the recommended range that 
adopted from (Hogan et al., 1986). FUS SVA PP plasmid at ( 2-5 )µg DNA 
concentration with 1 µg/µl  of td tomato plasmid were injected into the chick neural 
tube, after 48 hours electroporation, FUS SVA PP expression was indicated by 
phrGFP and the electroporation efficiency was indicated by tomato reporter 
expression. td Tomato plasmid was found to be expressed strongly along the dorsal 
and ventral axis of the neural tube in 14 embryos (Figure 4. 5A)  
  
A C 1mm B 
Figure 4.5: Representative image of FUS PP SVA phrGFP activity in the chick 
embryo neural tube at E5. (A) Expression of tomato plasmid in the chick embryo neural 
tube, indicating successful electroporation. (B) Bright field microscopy image. (C) 
Expression of the GFP reporter gene indicating activity of the FUS SVA as a 




When analysed for GFP reporter gene expressions. Only four out of these 14 embryos 
were found to express the GFP reporter gene (Figure 4.6C), table 4.4.15. Figure 4.6C 
shows weak GFP expression in the neural tube of four embryos indicated by white 
arrows, it seems that SVA works in chick embryos as a weak regulator. Embryos show 
very strong td Tomato expression under the β-actin promoter (as in Figure 4.6A).   
Figure 4.6: Representative image of the FUS PP SVA activity in chick embryo neural 
tubes at E5. Strong td tomato expression was observed in the chick neural tubes (A). (C) 
Weak GFP expression indicated by white arrows, showing that SVA can act as weak 
enhancer. (B) Same image in bright field microscopy. (D) Schematic representation of FUS 
PP SVA phrGFP reporter gene vector. Scale bar 1 mm  
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To test the activity of the FUS VNTR alone in the chick embryo neural tube, the same 
methods were followed as before and after 48 hours’ incubation embryos were 
analysed for reporter gene expression.  In contrast with the intact SVA, all embryos 
which expressed tomato plasmid strongly had GFP expression in the same location. 
All seven of the embryos that expressed tomato plasmid also expressed GFP in both 







Figure 4.7: Representative image of the FUS VNTR activity in chick embryo neural 
tubes at E5. (A) Embryos electroporated with tomato plasmid as a marker for successful 
transfection. (B) Bright field microscopy image. (C) Expression of ECR PP FUS SVA in chick 
embryo neural tubes indicated by reporter gene GFP (D) Schematic representation of FUS 
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FUS VNTR ECR PP phrGFP was tested to determine the VNTR transcription activity. 
Expression of the reporter gene construct was seen in the neural tube, and this 
expression indicated the strong enhancer activity of the FUS VNTR ECR PP phrGFP 
(Figure 4.8) by expression of GFP (C) and tomato plasmid (A) in the three 
electroporated embryos table 4.4.15. ECR PP is known for its strong activity 
(Khursheed et al., 2015) and this experiment confirmed that VNTR can elevate the 







Figure 4.8: Representative image of FUS ECR PP VNTR expression in chick embryo 
neural tubes at E5. (A) Tomato plasmid (B) bright field microscopy image (C) Reporter gene 
expression FUS ECRPP VNTR (D) Schematic representation of ECR PP FUS VNTR phrGFP 
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4.4.4 Characterisation of a SVA located upstream of the PARK7 gene  
The PARK7 SVA was identified during global analyses of SVAs in the human genome 
(Savage et al., 2013a). This SVA is located 10 kb upstream of the PARK7 gene. 
According to the repeat masker track on the UCSC genome browser (Hg 19) this SVA 
has features that are similar to FUS SVA as both are human specific, and subtype D, 
but differs from FUS SVA in having a hexamer repeat allocated at the 5’ end. 
ENCODE data showed that active histone marks and DNase1 hypersensitivity clusters 
are located near to the promoter locus (Takahashi et al., 2001). Thus, this region has 
been identified as a major transcription start site. Another region was also identified 7 
kb away from the TSS of the PARK7 gene. This region has similar features of 
identified TSS for PARK7 gene, including the CpG Island, DNase 1 hypersensitivity 
clusters and active histone marks, and this region is therefore referred to as a minor 
transcription start site.  Furthermore, a human specific SVA was identified 8 kb 







































































































































































































































































4.4.5 Endogenous PARK7 expression in E5 chick embryo brain  
It was important to confirm the endogenous expression of the PARK7 gene in the 
chick brain at the development stage E5 since the analysis of reporter expression had 
to commence at this stage. This was confirmed by RT-PCR in the E5 chick brain. An 
expected band of 550 bp was obtained at 62.5 ºC annealing temperature by PARK7 
primers using gradient PCR (temperature range 55 ºC to 65 ºC) (Figure 4.10).  
   
Figure 4.10 PARK7 is expressed in the brain tissue of E5 chick embryos. 
Total RNA was purified from E5 brain reverse transcribed to cDNA and then used as a 
PCR template. 1.5% agarose gel showing a band at approximately the expected 550 bp. 
The MW marker is 100 bp with the white arrow pointing to 500 bp. The next lane was the 





4.4.6 Generation of PARK7 SVA FUS PP phrGFP construct  
The PARK7 SVA fragment was cloned into the FUS PP phrGFP plasmid, which was 
chosen to act as a minimal promoter. The original vector Zero Blunt PCR vector from 
Invitrogen) containing the PARK7 SVA fragment was a kind donation from Dr 
Abigail Savage. For the detail of the plasmid construction see Chapter 2, section 
2.15.15.4 The PARK7 SVA fragment was released from the original vector PCR Blunt 
II by restriction enzyme digestion (Figure 4.11A). The PARK7 SVA was also run on 
the 0.8% gel electrophoresis and was shown to have a band size of 5 kb (Figure 4.11B). 
Meanwhile, the uncut FUS PP phrGFP and digested FUS PP phrGFP with Nsil were 
run on 0.8% gel electrophoresis, visualised by ethidium bromide nucleic stain and 
found to have a 4 kb band size (Figure 4.11C L1), digested FUSPP phrGFP ran lower 
than the uncut one (Figure 4.11C L2). The PARK7 SVA band at 1.6 kb was excised 
and cleaned over an SV column then dephosphorylated.  
4.4 7 Ligation of the PARK7 SVA sequence into reporter vector FUS PP phrGFP 
to generate the PARK7 SVA FUS PP phrGFP  
Ligation of the PARK7SVA into the FUSPPSVA phrGFP vector was performed. 
Selected colonies were mini-prepped and digested with Bgl1 for the presence of 
plasmid (Figure 4.11D). The PARK7 SVA FUS PP phrGFP was located in the forward 
orientation (Figure 4.11D L1), as the arrows indicate from the top at 2697 bp, 1724 bp, 
1229 bp; and reverse orientation: 3075 bp, 1347 bp, 1229 bp (Figure 4.10D L2).The 
empty vector has two band at 2471bp, and 1229bp (Figure 4.11 (D) L3). The colonies 
with forward orientation were purified by plasmid prep, sequenced and then expanded 
in an overnight culture, PARK7SVA FUS PP phrGFP, was purified and concentrated 
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Figure 4.11: Steps of cloning PARK7 SVA into the reporter gene vector phrGFP. (A) 
L1 M W marker 1 kb, L2 cut of PARK7SVA with Nsil result band at 1.7 kb indicated by 
the white arrow. (B) L1 M W marker 1 kb, L2 uncut of PARK7SVA. (C) Digestion of 
phrGFP with Nsil. L1 shows a band of uncut of phr GFP. L2 show band of cut of phrGFP 
with Nsil result band at 4 kb. L3 M W marker 1 kb. (D) Digested minipreps with BglI. L1 
M W marker 1 kb, L2 PARK7SVA in forward orientation, L3 PARK7SVA in reverse 






4.4.8 The activity of the PARK7 SVA as a transcriptional regulator in reporter 
gene construct in vitro  
The functional analysis of the PARK7 SVA in vitro was undertaken in the laboratory 
by Dr Abigail Savage and compiled in a published paper (Savage et al., 2013a). The 
data of the in vitro experiment are summarised here to demonstrate the functional 
activity of the PARK7 SVA in both SK-N-AS and MCF-7 cell lines. The PARK7 SVA 
in the forward orientation was cloned into the multiple cloning site of the pGL3P 
reporter gene vector upstream of the SV40 minimal promoter, when transfected into 
the SK-NA-S cell line no alteration in the level of expression was observed when 
compared with the minimal SV40 promoter alone. In the MCF-7 cell line, however, 
PARK7 SVA acted differently in the forward orientation. Here it significantly elevated 
the level of reporter gene expression. This indicated that intact PARK7 SVA 





4.4.9 PARK7 SVA can act as a functional regulatory domain in an in vivo model  
Injection and transfection of the PARK7SVA FUS PP phrGFP construct into chick 
neural tube.  
The activity of the PARK7 SVA phrGFP construct in the forward orientation was 
tested in vivo. The neural tubes of chick embryos were injected and transfected by 
electroporation with an injection mixture containing PARK7 SVA at a final 
concentration of 4.2 µg, td Tomato 1 µg /µl and 1 µg/µl of Fast Green. After 48 hours 
of incubation, embryos which had been electroporated successfully in the neural tube, 
as evidenced by tomato plasmid expression, were tested for the PARK7 SVA PP 
phrGFP reporter gene by fluorescent microscopy. Three embryos were expressing 
tomato plasmid in the neural tube co-localised with GFP expression. The PARK7 
SVA, therefore, exhibits reporter gene expression and demonstrates that PARK7 SVA 
has an activator property in chick embryo neural tubes compared with FUS SVA 













Figure 4.12: PARK7SVA FUSPP phrGFP activity in chick embryo neural tubes at E5. 
PARK7 SVA can enhance the expression of FUS PP.  (A, B and C) show an embryo that has 
been electroporated with 1 µg/µl td tomato and 4.2 µg/µl PARK7SVA.(D) Schematic 
representation of PARK7 SVA phrGFP reporter gene vector 
A B C 500µm 
GFP  D        PP PARK7 SVA 
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4.4.10 Develop a methodology to establish electroporation of chick brain with td 
Tomato at E5  
Once it had been demonstrated that PARK7 had activity in the chick embryo neural 
tube at E5 it was decided to extend the investigation of the activity of the PARK7 SVA 
in the chick brain at E5. To obtain this data, the electroporation technique had to be 
modified to determine the optimum position and type of electrode. The linear wire 
electrode was substituted with a gold plated electrode. The position of the electrode 
was manipulated to obtain the best result. Different regions of the chick brain were 
transfected at HH stage 14, namely the hind brain, midbrain and forebrain. All three 
regions were transfected efficiently (data not shown), however the midbrain region 
was chosen for several reasons. First, the midbrain has a big cavity and can be injected 
very easily; second, the midbrain region at E2-3 consists of a thin layer of cells which 
allows exposure of a large area of cells to the plasmid mix meaning that many cells 
can be electroporated. Third, the midbrain can be positioned between the two 
electrodes and there is no tissue or blood vessels around to obstruct the electrode.  
Initial experiments tested the td Tomato in the chick brain region as a positive control 
experiment. The midbrain or tectum region was injected with the td Tomato plasmid 
at HH stage 14. After 48 hours of incubation the chick embryos were observed under 
fluorescence microscopy for evidence of expression. The successfully transfected 
embryos showed strong red fluorescent protein at the site of injection and 
electroporation (Figure 4.13). Consequently, the midbrain region was used for 
transfection of the reporter gene construct and detection of the expression of the FUS 











250µm A B C 1mm 
Figure 4.13: Chick embryo midbrain was transfected with td Tomato at E5. (A) 
Expression of td Tomato was detected in the midbrain region of chick embryos in vivo, 
indicated by the white arrow (B) bright field microscopy image. The midbrain region 
of a chick embryo was transfected with 1 µg /µl of tomato plasmid at HH 12-14. (C) A 
section from the transfected midbrain was dissected with a laboratory blade and placed 
under dissecting microscopy, showing the expression of tomato plasmid in the 




4.4.11 FUS PP phrGFP alone act as weak regulator in chick midbrain at E5  
In the previous chapter the FUS PP phrGFP reporter gene construct was tested in the 
neural tube, where no expression activity was demonstrated. Now the FUS PP phrGFP 
plasmid in the chick embryo midbrain was tested to observe the activity of FUS PP 
alone in the brain tissue. A plasmid mix of 1 µg/µl of tomato plasmid and PBS with 
Fast Green and FUS PP phrGFP at a final concentration 4.4 µg was microinjected and 
then transfected by electroporation to the chick embryo midbrain at HH 12-14. The 
transfected embryos were incubated for 48 hours and viable embryos were analysed 
for td Tomato plasmid expression and then observed for GFP expression. All five 
embryos that had strong tomato expression also showed weak GFP expression in the 
midbrain; furthermore, the FUS PP was found to be active in the tectum cell sub type 
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Figure 4.14: FUS PP phrGFP activity in the midbrain region of a chick embryo 
at E5. (A) td Tomato expression in chick midbrain, (B) bright field microscopy image, 
(C) FUS PP has weak expression in the midbrain, indicated by the white arrow. (D) 
Cross-section of the midbrain with weak FUS PP phrGFP expression observed in a 





4.4.12 PARK7 SVA acts as activator in the chick brain at E5  
The PARK7 SVA was tested in the chick embryo midbrain. A mixture of the td 
Tomato at 1 µg/µl and the PARK7 SVA phrGFP at a final concentration 3.2 µg/µl was 
prepared and transfected into the cavity of the midbrain and then the embryos were 
incubated for 48 hours at 38 ºC in order to allow the reporter gene expression to 
develop (Figure 4.15) table 4.4.15. The PARK7 SVA FUS PP construct served as an 
activator and enhanced the expression of FUS PP in chick brain embryos, whereas in 
the previous experiment FUS PP alone was shown to have only a weak expression in 
the chick midbrain. Strong td tomato and GFP expression was observed in five 
embryos under fluorescent microscopy. PARK 7 SVA can therefore demonstrate 
activator behaviour in chick brains and neural tubes in vivo, and in the human 



















C  1mm 
200µm 
D E 
Figure 4.15: PARK7 SVA phrGFP activity in the midbrain region of a chick embryo 
at E5. (A) td Tomato expression, (B) bright field microscopy image, (C) PARK7SVA 
expression in the midbrain indicated by a white arrow. (D) Cross-section of the midbrain 
with GFP. (E) The same section with td tomato expression. (F) Schematic representation 
of PARK7 SVA phrGFP reporter gene vector 
GFP  F  PP PARK7 SVA 
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4.4.13 FUS SVA PP serves as an activator in chick brains at E5  
FUS SVA PP phrGFP was tested in the chick embryo neural tube, to see if FUS SVA 
sequences can drive reporter gene expression in neural tubes. In this experiment the 
FUS SVA was tested in the midbrain region of chick embryo at E5. The plasmid mix 
of 1µg/µl of tomato plasmid and 1µl PBS with Fast Green and FUS SVA PP phrGFP 
at a final concentration 4.4 µg/µl was microinjected and then transfected by 
electroporation to the chick embryo midbrain at HH 12-14. Transfected embryos were 
incubated at 38 ºC for 48 hours before being tested for td Tomato expression and 
reporter gene expression of GFP. All three embryos that had td Tomato expression in 
the midbrain table 4.4.15 (Figure 4.16A) showed GFP expression in the same region 
(Figure 4.16C). Successful samples were fixed, then with a clean laboratory blade the 
transfected area of the midbrain was dissected (Figure 4.16B) and the site of the cut 
was indicated with a white line and white arrow, as in Figure 4.16 (D, E, and F). The 
dissected tissue from the midbrain was placed under a fluorescent microscope and it 
was evident that most tectum region cells have a strong td Tomato expression (Figure 
4.16 (D). Strong FUS SVA expression was also observed under a GFP filter (Figure 
4.16F), indicating the activation behaviour of the FUS SVA domain in the chick 
midbrain. Specifically, the expression of FUS SVA was found to be strong in a 



























Figure 4.16: FUS SVA PP phrGFP activity in the midbrain region of a chick embryo at 
E5. (A) td Tomato expression, (B) bright field microscopy image, (C) FUS SVA PP has strong 
expression in the midbrain, indicated by the white arrow. (D) Cross-section of the midbrain 
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4.4.14 Comparison of functional activity between FUS SVA, VNTR, PP and 
PARK7 SVA in the chick embryo central nervous system at E5  
Comparing the overall functional activity of FUS SVA, FUS VNTR, and PARK7 SVA 
and FUSPP reporter Table 4.4.15, the results indicate that FUS SVA can act as weak 
enhancer in the neural tube since four embryos only show weak GFP expression in the 
neural tube out of 14 embryos with strong td Tomato expression. The same construct, 
however, has stronger enhancer activity in the chick brain. PRAK7 SVA, meanwhile, 
has enhanced activity in both the neural tube and chick brain. FUS PP alone is shown 





Table 4.4.15: Summary of findings (Location of injection (NT-neural tube, B- 
brain) HH -the Hamburger-Hamilton stage)  
 
















F SVA PP NT 22 14 4 weak 
GFP 
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PP 
NT  3 3 
PPARK7 SVA 
PP 
B  5 5 
FUS SVA PP B  3 3 
FUS PP B  5 5 weak 
GFP 






4.5 Discussion  
When the FUS gene locus was analysed for potential regulatory domains, an SVA 
retrotransposon was identified located 10 kb upstream of the MTSS of the gene. The 
FUS SVA, and its central VNTR, were tested in vitro and, interestingly, while the 
intact SVA was a repressor in the human neuroblastoma SK-N-AS cell line, the central 
VNTR region showed enhancer activity (Savage et al., 2014b). This data demonstrates 
the enhancer activity of the VNTR and the strong repressor element of the SVA that 
flanks this repetitive central VNTR region when analysed in the neuroblastoma cell 
line.  
The SVA domain was then selected to be tested for its regulatory properties in the 
chick embryo neural tube and it was interesting to test a primate specific SVA D that 
was not conserved in chickens. From the previous results in Chapter 3 it was 
demonstrated that human FUS ECRs functioned very well in the chick embryo neural 
tube. This region of the neural tube contains the motor neurons, which are the 
appropriate cell type to test the regulatory properties that might be involved in ALS. 
To observe the regulatory properties of the FUS SVA this domain was first tested in 
the construct that works as a strong activator, namely the FUS ECR PP. When the 
SVA was cloned into the above plasmid and tested in the chick embryo neural tube 
for expression, the result showed that all embryos that have td Tomato expression also 
have GFP expression in the neural tube. Then the SVA was cloned in the FUS PP, it 
having already been shown in this research that this FUS PP when applied alone has 
no activity in the chick embryo neural tube. Fourteen embryos with the SVA FUS PP 
showed strong red fluorescence but only four out of these 14 embryos exhibited weak 
GFP expression in the neural tube. This demonstrates that this SVA functioned as 
weak activator for expression whereas a repressor activity was observed when SVA 
176 
 
was tested in vitro with the SV40 promoter. When the plasmid containing the FUS 
VNTR ECR PP was tested in the chick embryo neural tube, however, the transfected 
embryos showed strong red and green fluorescence in the neural tube and hence 
provided evidence for potential regulator activity.  
In order to dissect further the activity of the components of the SVA, the VNTR was 
cloned in the FUS PP and tested in the chick embryo model. This showed that all 
transfected embryos were expressing td Tomato and GFP in the neural tube, indicating 
that VNTR has positive regulator properties. Since SVA has weaker activity than the 
VNTR this implies that there may be a repressor element in the SVA. These results 
reveal that there is more than one regulatory element in SVA perhaps an enhancer 
VNTR and a repressor in the remaining elements. This data suggests that there is a 
different balance of activity in human and chicks. This particular system of analysing 
the transcriptional properties of the domain is not quantitative, however, and therefore 
changes in the level of expression have not been determined here. Nonetheless, the 
fraction of transfected embryos that also fluoresce with GFP gives an indication of 
weak rather than strong expression. Furthermore, VNTR shows stronger activity in 
the chick neural tube, while the SVA containing VNTR is weaker, suggesting that an 
element within the SVA might have a repressor activity, and this partially matches 
what was seen in vitro in human cells. In the chick, the VNTR activation overwhelms 







It was interesting to test the regulatory activity of another SVA located near the PARK 
7 gene. This gene is known to be implicated in neurodegenerative diseases and breast 
cancer. This SVA is also of the subtype D and was located near to active histone 
markers and, according to the data obtained from both the UCSC Browser and 
ENCODE it might have regulatory properties. A previous study conducted by (Savage 
et al., 2013a) addressed human PARK7 SVA in vitro in SK-N-AS and breast cancer 
cell lines. The central VNTR from the PARK7 was analysed in the forward orientation, 
and showed different reporter gene expression in these two cell lines. The VNTR, 
when tested in the SK-N-AS, shows no activity when compared to the pGL3P SV40 
minimal promoter. While SVA showed no activity in the SK-N-AS cell line it can 
enhance the reporter gene expression in MCF-7 cells (Savage et al., 2013a). This 
showed that SK-NA-S and breast cancer cells can respond differently to SVA and 
VNTR domain, undoubtedly because of the different cell environment; for example 
through transcription factors that get activated in the MCF-7 cells but not in the SK-
N-AS ones (Savage et al., 2013b).  
Functional analysis of the PARK7 SVA in the chick embryo model was conducted by 
selecting the PARK7 SVA in a forward orientation. This was cloned into the FUS PP 
phr GFP plasmid. The FUS PP plasmid was tested previously and showed no activity 
in chick embryo neural tubes, and this promoter can therefore act as a minimal 
promoter. When the plasmid PARK7 SVA FUS PP phrGFP was tested in chick 
embryo neural tubes the PARK7 SVA enhanced the reporter gene expression. Five 
embryos were shown to have GFP and td Tomato in the neural tube. After that, the 
function of the FUS SVA, VNTR and PARK7 SVA were tested in the chick embryo 
neural tube at E5. Then the investigation was extended into another region of central 
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nervous system; the chick brain. After many attempts to transfect the chick brain 
regions at stage HH12-14, it was shown that the midbrain or tectum can be transfected 
effectively with td Tomato alone. Strong red fluorescent can be observed under the 
fluorescent microscope at E5, indicating that this technique can be conducted 
successfully. A series of constructs were tested in chick brains at HH stage 12-14. The 
successfully transfected embryos were analysed for reporter activity at E5. The first 
plasmid tested was FUS PP alone, this plasmid was shown to have weak expression 
in chick embryo midbrains compared to no expression at all in chick neural tubes (see 
discussion above). PARK7 FUS PP was tested and shown to drive GFP expression in 
chick midbrains. Finally, FUS SVA PP also showed strong expression in chick 
midbrains and acts as an activator. In contrast, this plasmid was shown to act as a weak 
regulator in chick embryo neural tubes.  
The work carried out in this chapter demonstrates the activity of two SVAs located 
upstream of two genes, FUS and PARK7, known for their implication in 
neurodegenerative disease and cancer. The activity of the SVA was previously 
addressed in vitro using human cell line neuroblastoma SK-N-AS and MCF-7 cells 
and here in vivo using chick embryo neural tubes and midbrains at E5. SVAs have 





























98% of the human genome consists of DNA that does not code for proteins, and it is 
now becoming apparent that this should not be dismissed as ‘junk’ DNA, as it was 
formerly termed, but that these regions have domains that are vital in the regulation of 
gene expression. Gene expression is controlled in both spatial and temporal ways that 
operate at many levels; identification of new elements that regulate gene expression 
were the main aims of this project.  
 In the past identifying these regions was difficult for researchers, but the development 
of the Evolutionary Conserved Region (ECR) browser, the UCSC human genome 
browser and the utilisation of bioinformatics analysis now serve as useful tools in 
conjunction with the wealth of information available from the ENCODE project 
(much of which is on UCSC genome browser).   
In the first part of this thesis, the ECR browser and UCSC genomic browser were used 
to predict important cis-acting DNA regulators of the FUS gene promoter that direct 
transcription (Khursheed et al., 2015). Putative regulatory domains were identified by 
cross-species comparison of the genomes; these domains were tested for function in 
reporter gene cassettes in the neural tube of a chick embryo model at E5 to address 
their potential as transcriptional regulatory domains. Two of the domains, located in 
the genome in intron 1 and a region upstream of the TSS of FUS directed reporter gene 
expression when they were adjacent to both the SV40 promoter and with the FUS 
proximal promoter, indicating that they can work with both heterologous and 
homologous promoters.  The intronic domain INT1 is able to act as a transcriptional 
activator when it is cloned upstream of SV40 or phrGFP. Interestingly, INT1 shows 
the greatest activity in the hybrid neuroblastoma/ motor neurone cell line NSC-34, and 
could be involved in the expression of the FUS gene. The third domain (PP) identified 
in chapter 3, which encompassed the region Chr16: 31,191,429 had no intrinsic 
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activity in the chick neural tube at the stage of development analysed, and was used 
as a minimal promoter in later experiments in the neural tube. When (PP) domain was 
tested in the chick brain, however, it did show activity, suggesting there were essential 
differences in the cell environment or the cell phenotype enabling it to respond to the 
regulatory domain. Such differences could include transcription factors that were 
expressed in brain cells from those found in the motor neurone cells within neural 
tube.  
In summary, ECRs were identified and can highlight important regulatory domains by 
using the ECR Browser and the UCSC genomic Browser. This approach can quickly 
highlight important putative regulatory domains of the human FUS gene based on in 
vitro reporter gene assays using comparative genomics of range of species such as 
chimpanzee, dog, rat, and mouse using 70% identity across a length of 100 bp as a 
parameter to identify the conserved regions in ECR browser. This analysis 
encompasses 4 kb upstream and downstream, coordinates of conserved regions were 
obtained from the UCSC genome browser (Hg19). Upon transcription factor analyses 
of the FUS gene using the ECR Browser linked rVista 2.0. The region spanning 
chr16:3119182-31192141 has 50 conserved transcription factors binding sites (TFBS) 
arranged into five groups, SP1, PAX5, E2F, E2F1, and E2F1DP1. Further analyses of 
the transcription factors coordinated to ch16:31191334-31191759 in the region of 
426 bps showed 81 transcription factors were arranged in four groups, PAX5, SP1, 
E2F, and E2F1DP1. Further analyses of the transcription factors locates 
ch16:31191334-31191759 in the region of 426 bps showed 81 transcription factors, 
were arranged in four groups, PAX5, SP1, E2F, and E2F1DP1. Furthermore, ECRs in 
other genes often demonstrate important regulatory properties for example, studies 
have demonstrated the role of seven ECRs selected from MIR137 locus. MIR137 
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containing the micro RNA known for its significant associations with schizophrenia, 
these ECRs can regulate reporter expression in neuroblastoma cell line, SH-SY5Y 
(Gianfrancesco et al., 2016). 
 
5.1 SVA domains upstream of the FUS and PARK7 gene play a role in regulation 
of gene expression  
In the second part of this thesis another class / type domain was analysed, the SVA. 
This domain differs from an ECR by being primate specific, one of the most recent 
transposable elements to enter into the human genome. SVA SVA insertions have 
been identified in 96 diseases as of 2012 (Hancks and Kazazian, 2012). Furthermore, 
SVA insertions can have an impact in normal brain function and pathologically in 
tumours (Richardson et al., 2014). Retrotransposition in general can act as 
transcriptional or cause epigenetic modulation, specifically alterations in methylation 
patterns which may cause variation in cancer progression (Szpakowski et al., 2009). 
Many studies have demonstrated that the retrotransposons and SVAs lose their 
silencing property in cancer and the aging brain (Szpakowski et al., 2009, Baillie et 
al., 2011). Somatic retrotransposon has been demonstrated in the ageing brain and 
might play a role in ageing (Baillie et al., 2011, Faulkner, 2011). SVA has also been 
postulated to control the brain size in specific regions that are responsible for learning, 
muscle movement, balance and memory (Vasieva et al., 2016, Pulvers and Huttner, 
2009). SVA insertions can have implications in human gender-related brain function 
through hormonal sensing; for example, SVA F insertion in the BRACA1 gene has 
been demonstrated to have a crosstalk function with oestrogen receptor ESR1(Gorrini 
et al., 2014, Kang et al., 2012) Furthermore, SVAs are present in genes that have been 
associated with a range of psychiatric conditions such as intellectual disability, 
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epilepsy and bipolar disorder (Cirlugea and O’Donohue, 2016). Interestingly, SVAs 
insertions have been suggested to act as impact factor on evolution and cognition in 
human. For example, the older SVA subtypes A-C has occurred in genes associated 
with primitive characteristics while SVA subtypes D-F1were occurred in genes 
involved with complex behavioural characteristics. SVA sub type F and F1 were found 
to occurred in genes that involved with immune system and accounted as a major 
modulator of CNS function, and psychiatric disorders for example schizophrenia, 
depression, and autism (Thakur et al., 2015). Therefore, SVAs were chosen from the 
FUS and PARK7 genes known for their association to neurodegenerative disease.  
Both of these SVAs are found approximately 10 kb, 8 kb upstream of the TSS of FUS 
and PARK7 genes. Although FUS SVA and Park7 SVA share similarity such as both 
being members of subtype D they also have differences: PARK7 SVA considered as 
human specific whereas FUS SVA is found in primate genome, PARK7 SVA has all 
domains of a canonical SVA while FUS SVA is missing both the CCCTCT repeat at 
its 5’ end and the poly A tail at the 3’ end. The ability of both FUS, PARK7 SVAs to 
affect gene expression were tested in a reporter gene vector, with a minimal promoter. 
FUS SVA  showed to repress the expression in the SK-N-AS cell line (Khursheed et 
al., 2015). While intact PARK7 SVA, in forward orientation has no alteration in the 
level of the reporter gene activity when, tested in the SK-N-AS cell line, but it’s can 
significantly increase the reporter gene activity in MCF-7 (human breast 
adenocarcinoma) cell lines (Savage et al., 2013a). Suggesting, that SVA encompass a 
repressor element such as SINE domain was acting as a repressor domain. The final 
aspect of the research involved exploring the regulatory function of the SVA further. 
The VNTRs domain and their ability to regulate gene expression has been, 
investigated in both FUS, and PARK7 genes. Which showed to be polymorphic in the 
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number of repeats of their VNTRs. Since a large tandem repeat domain was identified 
at 10 kb 5’ of major transcriptional start sites of FUS genes using the UCSC genomic 
bioinformatic site (http:// genome.ucsc.edu). VNTRs domain within the FUS SVA 
was therefore chosen for further study. FUS VNTRs were increase the transcription 
activity of the reporter gene in the SK-N-AS cell line (Khursheed et al., 2015). 
Whereas, PARK7 VNTRs can demonstrated a repressor activity in neuroblastoma cell 
line SK-N-AS and in MCF-7 cells showed a similar activity to that observed with the 
minimal promoter alone (Savage et al., 2013a). Both, FUS SVA, PARK7 SVAs ability 
to affect gene expression were tested in an in vivo chick embryo model. FUS SVA, 
demonstrates as weak activator for expression in chick embryo neural tube (Figure 
4.5) and as a strong activator in chick mid brain (Figure 4.16). PARK7 SVA in forward 
orientation enhanced the expression in chick embryo neural tube (Figure 4.12) and 
mid brain region (Figure 4.15). FUSVNTR shows to act as activator in chick embryo 
neural tube (Figure 4.7).  
In summary our data suggests that SVA domains upstream of the FUS gene can 
potentially contribute to ALS by modulation of gene expression at the FUS gene locus 
and that variation of the VNTR can also regulate gene expression in accordance to the 
challenge that the cell receives.  
Chick embryos have been used as a model system in this project to understand the role 
of the novel regulatory elements in regulating gene expression among genes important 
for their implication in motor neuron disease. This model system can interpret the 
results in a qualitative form and can define the repressor activity of the regulatory 
domains but they do not quantify the results since such quantification is dependent on 
several factors such as the efficiency of the electroporation, the sub set of transfected 
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cells, the development stage of the embryo and the rate of transfected cells. In order 
to use this system effectively, a program such as Image J software should be used to 
calculate the exact number of the transfected cells with internal control and with the 
reporter gene construct. Furthermore, the ratio of cells that are transfected with the 
control plasmid and the reporter plasmid can be employed. This model system has 
many advantages including accessibility, ease of tissue manipulation, and lack of cell 
death during electroporation, quick analysis just 48 hours after electroporation, 
comparable with in vitro methods. Our results have shown that the chick embryo 
model is useful and can be used to corroborate and extend in vitro reporter gene assays 
findings provided the gene of interest is expressed in the differentiating cells in the 
embryo. This model can work well particularly with comparative genome analysis 
where the human regulatory sequences are identified according to their conservation 
with chick or even fish genomes. To understand the role of regulatory regions on gene 
expression it is extremely valuable to employ efficient methods for gene transfer into 
living embryos because i) tissue architecture and the relationship between different 
cell types are maintained and ii) the normal physiological regulatory pathways and 
mechanisms are intact. Here we successfully used the application of an in ovo 
electroporation technique to analyse the regulation of gene expression in genes known 
for their implications in neurodegenerative disease. 
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5.2 Proposed Future experiments and directions  
The dual fluorescent system used in this thesis, are qualitative and very subjective. 
This system cannot quantify the results for several reasons, for example the success of 
the electroporation, the development stage of the embryo, subset of transfected cells. 
In order to use this system effectively and capture the effect of the regulatory elements 
on gene expression, it would be important to employ methods to quantify the level of 
expression directed by the reporter gene. There are several approaches, such us, using 
dual fluorescence protein assay. In this system a marker protein (red fluorescence) can 
be driven by a constitutive promoter and compared with the amount of GFP directed 
by the test promoter (ECR/ VNTRs or SVA). The results can then be quantified using 
Image J software to measure the green: red fluorescence ratio.   
Mutations or polymorphisms, within the cis-acting regulatory domains or 3’ UTR 
mutations of FUS gene may have a major effect on the expression and potential 
dysregulation of FUS gene expression. Based on analysis of both FUS SVA and FUS 
VNTR reporter gene constructs in vivo chapter 4, we could assign differential 
regulatory properties to these regions in vivo; specifically, the long variant from FUS 
SVA has worked as a weak regulator, whereas when the FUS VNTR region of the 
long variant was as activator, indicating the multiple regulatory regions within the 
SVA as previously shown for the PARK7 SVA (Savage et al., 2013b). Conversely 
when comparing these same domain in vitro, it was the short variant that had higher 
activity in both cases. This would suggest distinct factors in both models are 
differentially modulating the activity, consistent with their ability to act as tissue 
specific and stimulus inducible manner.   
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 Furthermore, based on analysis of the PARK7 SVA directed reporter gene expression 
when cloned in the forward orientation in vivo chapter 4, the PARK7 SVA was a 
positive regulator. In the in vitro model complete PARK7 SVA and its central VNTR 
can support differential   reporter gene expression (Savage et al., 2013a).  The PARK7 
SVA, supports no reporter gene activity in SK-N-AS cells, but has activity in MCF-7 
cells. Further dissection of the SVA, demonstrates that removal of the SINE element 
from PARK7 SVA, can increase the reporter gene expression, thus would be acting as 
a repressor domain. This would suggest testing regions from PARK7 SVA represented 
by VNTR, SINE, CCCTCT and Alu-like sequences individually, and study their 
distinct activity in vivo. The level of the PARK7 SVA reporter gene activity in the 
reverse orientation differs from PARK7 SVA activity in forward orientation in vitro. 
It would be useful to test the activity from PARK7 SVA in reverse orientation and 
study their regulatory function in vivo. The in vivo approach used in this thesis would 
be applicable to study several genes whose over expression is a key element in 
developing ALS, neurodegenerative disease, as it may give insight into regulation not 





























6.1 Chicken primers were used for generating PARK7, FUS, ELP3, KIFAP3, 





















































































































Table 6.1: Details of primers used in amplification of FUS, KIFAP3, ELP3, PARK7, and 
GAPDH. The sequence of the forward and reverse primers, melting temperatures, the primer 




6. 2 information regarding the injection and electroporation of chick embryo in the 






Electroporation  Electrode  Conditions 
and plasmid 
mix  
12-14 HH Neural tube Position the 
electrode on 
both side of 
neural tube  
Straight wire 
electrode of 5 
mm length 
100 – 200 nl 
12-14 HH Mid brain  Position of the 
electrode on 
both side of 
embryo head 
precisely on 
both side of mid 








to the cathode  
Same  
 
Table 6.2: Information regarding the injection and electroporation of the chick embryo 
in the neural tube and brain region. Embryo stage, site of the conditions and type of 






6. 3 Information regarding the plasmid used in transfection of chick embryo 
central nerve system.  
FUS PP phr GFP Neural tube 
FUS ECR PP phrGFP Neural tube 
FUS PP int phrGFP Neural tube 
FUS ECRPP int phrGFP  Neural tube 
FUS SVA PP phrGFP Neural tube and midbrain  
FUS SVA ECR PP phrGFP Neural tube  
FUS VNTR PP phrGFP Neural tube  
FUS VNTR ECR PP phrGFP Neural tube 
PARK7 SVA FUS PP phrGFP Neural tube and midbrain 
P1229 Hb9 enhancer Neural tube 
  
 
Table 6.3: The reporter gene constructs used in vivo. This table shows names of the reporter 
gene constructs that have been used in vivo and the electroporated regions of the central nerve 






6. 4 Information regarding the antibodies used in immunofluorescence staining  
 
 
Table 6. 4: Details of the antibodies used in immunofluorescence staining of neural tube 
cross section protocol. Company the antibody was obtained from and the amount used in the 










Primary antibodies Dilution used 
 anti FUS raised in rabbit 1:500,Abcam ab 23439 
 Hb9 raised in mouse (1:5,Developmental Studies Hybridoma 
Bank, 
Department of Biology, University of 
Iowa). 
Secondary antibodies   
Goat anti mouse Alexa 488 1:250 (Invitrogen) 
Goat anti rabbit Alexa 488 1:250 (Invitrogen) 
Goat anti mouse IgG Alexa 350 1:500 (Invitrogen) 
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6. 5 Information regarding the transfection of S K- NA-S cell line with FUS 
regulatory domains 
FUS ECR constructs Number of transfected SK-N-AS that 
has GFP expression for the reporter gene 
and tomato expression as a marker 
Tomato plasmid act as positive control 47-50 cells transfected 
FUS PP 10-11 cells transfected 
FUS ECR PP 7-8 cells transfected 
FUS INT PP 10-11 cells transfected 
FUS INT ECR PP 16-17 cells transfected 
phrGFP act as negative control No transfected cells 
 
Table 6.5: Information regarding the transfection of SK-NA-S cell line with FUS 
regulatory domains. FUS ECR constructs used in the cell transfection, number of transfected 




6.6 Alignment between predicted and sequenced INT PP, INT ECR PP, and 
PARK7 SVA 
A  INT PP 
Score=1301 bits (704), Expect=0.0, Identities= 704/704 (100%), Gaps= 0/704 
Strand=Plus/plus 
Query 37        ATGGCCTCAAACGGTAGGTAAGGGCGCGAGGCGACGGCGGCGGCGCACCCGGCCGAGGCC 96 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509253  ATGGCCTCAAACGGTAGGTAAGGGCGCGAGGCGACGGCGGCGGCGCACCCGGCCGAGGCC 32509312 
 
Query 97        TCCCAGCTGGGCTTTTCGTTTTCAGTGGGACCGGGGCGGCGATCCCGTGTGGGATTTTTT 156 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509313  TCCCAGCTGGGCTTTTCGTTTTCAGTGGGACCGGGGCGGCGATCCCGTGTGGGATTTTTT 32509372 
 
Query 157       GGCGCCCCTGTGGCGGGAAGCCGCGGAGAAGAGTAACTGGAGGAGGCTGGTGTCGCCATT 216 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509373  GGCGCCCCTGTGGCGGGAAGCCGCGGAGAAGAGTAACTGGAGGAGGCTGGTGTCGCCATT 32509432 
 
Query 217       TTGTTTCGCTCCTCTGGCCCTCGCGCGCGGGGCGGGAAGTCTTTTCTTTGCAGTCCGTTT 276 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509433  TTGTTTCGCTCCTCTGGCCCTCGCGCGCGGGGCGGGAAGTCTTTTCTTTGCAGTCCGTTT 32509492 
 
Query 277       GCTTGGGGTGGGCGTTGGGAGGGACGCTTCTTAGGGGTTTGAAGCGTCAGGTGAGGGTGG 336 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509493  GCTTGGGGTGGGCGTTGGGAGGGACGCTTCTTAGGGGTTTGAAGCGTCAGGTGAGGGTGG 32509552 
 
Query 337       AAAACGCCCATTCTCCGTGGCCTCGCCTCCCCCAACTCCCGGCCCCGCGCTCGAGCCCGC 396 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509553  AAAACGCCCATTCTCCGTGGCCTCGCCTCCCCCAACTCCCGGCCCCGCGCTCGAGCCCGC 32509612 
 
Query 397       TTTGTCGCAGTGCTGCATCCGGGCACTCGCGGCGCGCACGCGCTCTGCGGGCCCCTCCCC 456 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509613  TTTGTCGCAGTGCTGCATCCGGGCACTCGCGGCGCGCACGCGCTCTGCGGGCCCCTCCCC 32509672 
 
Query 457       CTTCGCGGCGCGGGTACCCCTTCCCCGCCTCGTGTTGGTTCAGCTTTCTGTCGCGAGACC 516 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509673  CTTCGCGGCGCGGGTACCCCTTCCCCGCCTCGTGTTGGTTCAGCTTTCTGTCGCGAGACC 32509732 
 
Query 517       CTTCGCGGAAGACTCGGCGGCGCGCGTCCGGTGTGAGCCTTGTCCCTCAGTGGTCCTTCG 576 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509733  CTTCGCGGAAGACTCGGCGGCGCGCGTCCGGTGTGAGCCTTGTCCCTCAGTGGTCCTTCG 32509792 
 
Query 577       CGAATGGGCGGGACCGCTCCGTTCCCGCCTGGGTTGCCACGCGGCTGGGGGCGGAGGCTC  636 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509793  CGAATGGGCGGGACCGCTCCGTTCCCGCCTGGGTTGCCACGCGGCTGGGGGCGGAGGCTC 32509852 
 
Query 637       GGGATCGGGGCCGCCCTCTAGCTTAACGGTTTGGCGGCGGTGGTCAGGGTTCGACCAACG  696 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509853  GGGATCGGGGCCGCCCTCTAGCTTAACGGTTTGGCGGCGGTGGTCAGGGTTCGACCAACG 32509912 
 
Query 697       GACTTGGGGACGGCCCGAGAGTTTTTCCCGCCTAAATTTCTTTC  740 
                |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  32509913 GACTTGGGGACGGCCCGAGAGTTTTTCCCGCCTAAATTTCTTTC  32509956 
 
 
Range 2: 32508764 to 32509192GenBankGraphics Next Match Previous Match First Match  
Alignment statistics for match #2 
Score Expect Identities Gaps Strand Frame 
641 bits(710) 0.0 397/429(93%)  5/429(1%) Plus/Plus  
Features: 
29691 bp at 5' side: polyserase-2 isoform 1 precursor61 bp at 3' side: RNA-binding protein FUS isoform 2 
Query 786       GCCATCCTGGGTGAAAGCGGGGCCCAGCGAAGGGGCCCGGCCACAGGAATCTCGGTTCCA  845 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32508764  GCCATCCTGGGTGAAAGCGGGGCCCAGCGAAGGGGCCCGGCCACAGGAATCTCGGTTCCA 32508823 
 
Query 846       CCCCGCTACTCCCGGCTGTGACTCCAGTTTCGTccccagccgccgggaccgccccctcgc  905 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32508824  CCCCGCTACTCCCGGCTGTGACTCCAGTTTCGTCCCCAGCCGCCGGGACCGCCCCCTCGC 32508883 
 
Query 906       cccgcccccAGCGGGCACTCNN-CCGTACCACTGTGCCTTCATGGGGGTGGAGATAGATC  964 
                ||||||||||||||||||||   ||||||||||||||||||||||||||||||||||||| 
196 
 
Sbjct 32508884  CCCGCCCCCAGCGGGCACTCAGGCCGTACCACTGTGCCTTCATGGGGGTGGAGATAGATC 32508943 
 
Query 965       GTGGGCTAGTCCTGCCGAGGAGAGAGGGGTTCTTCCTCAAAAAATATGATTATGTATAGT  1024 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32508944  GTGGGCTAGTCCTGCCGAGGAGAGAGGGGTTCTTCCTCAAAAAATATGATTATGTATAGT 32509003 
 
Query 1025      ATTCGCATGATTCTAGTTAACTTGTTTCCCTTCTGCCTGCTCGGACCCTCTACCTGCCCT  1084 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509004  ATTCGCATGATTCTAGTTAACTTGTTTCCCTTCTGCCTGCTCGGACCCTCTACCTGCCCT 32509063 
 
Query 1085      ACGAAGGGGGCGGAGTGCGTTCCTGCCTCCCCCTGCTCTT-CGCNTTTGGNGCGCGCCNG  1143 
                |||||||||||||||||||||||||||||||||||||||| ||| ||||| ||||||| | 
Sbjct 32509064  ACGAAGGGGGCGGAGTGCGTTCCTGCCTCCCCCTGCTCTTCCGCGTTTGGTGCGCGCCTG 32509123 
 
Query 1144      CGCGGNNCGT--NNNNNGNANCGTACTTNAGCTTCGAC-NNNNNGNNNGGGNTGCTCANN  1200 
                |||||  |||       | | ||||||| |||||||||      |   ||| ||||||   
Sbjct 32509124  CGCGGTGCGTAGGCGGCGGAGCGTACTTAAGCTTCGACGCAGGAGGCGGGGCTGCTCAGT 32509183 
 
Query  1201      CCTCCNGGC  1209 
                 ||||| ||| 





B  INT ECR PP 






     
 


















     684/684(100%)  0/684(0%)     Plus/Plus  
 
Query 37        ATGGCCTCAAACGGTAGGTAAGGGCGCGAGGCGACGGCGGCGGCGCACCCGGCCGAGGCC 96 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509253  ATGGCCTCAAACGGTAGGTAAGGGCGCGAGGCGACGGCGGCGGCGCACCCGGCCGAGGCC 32509312 
 
Query 97        TCCCAGCTGGGCTTTTCGTTTTCAGTGGGACCGGGGCGGCGATCCCGTGTGGGATTTTTT 156 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509313  TCCCAGCTGGGCTTTTCGTTTTCAGTGGGACCGGGGCGGCGATCCCGTGTGGGATTTTTT 32509372 
 
Query 157       GGCGCCCCTGTGGCGGGAAGCCGCGGAGAAGAGTAACTGGAGGAGGCTGGTGTCGCCATT 216 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509373  GGCGCCCCTGTGGCGGGAAGCCGCGGAGAAGAGTAACTGGAGGAGGCTGGTGTCGCCATT 32509432 
 
Query 217       TTGTTTCGCTCCTCTGGCCCTCGCGCGCGGGGCGGGAAGTCTTTTCTTTGCAGTCCGTTT 276 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509433  TTGTTTCGCTCCTCTGGCCCTCGCGCGCGGGGCGGGAAGTCTTTTCTTTGCAGTCCGTTT 32509492 
 
Query 277       GCTTGGGGTGGGCGTTGGGAGGGACGCTTCTTAGGGGTTTGAAGCGTCAGGTGAGGGTGG 336 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509493  GCTTGGGGTGGGCGTTGGGAGGGACGCTTCTTAGGGGTTTGAAGCGTCAGGTGAGGGTGG 32509552 
 
Query 337       AAAACGCCCATTCTCCGTGGCCTCGCCTCCCCCAACTCCCGGCCCCGCGCTCGAGCCCGC 396 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509553  AAAACGCCCATTCTCCGTGGCCTCGCCTCCCCCAACTCCCGGCCCCGCGCTCGAGCCCGC 32509612 
 
Query 397       TTTGTCGCAGTGCTGCATCCGGGCACTCGCGGCGCGCACGCGCTCTGCGGGCCCCTCCCC 456 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509613  TTTGTCGCAGTGCTGCATCCGGGCACTCGCGGCGCGCACGCGCTCTGCGGGCCCCTCCCC 32509672 
 
Query 457       CTTCGCGGCGCGGGTACCCCTTCCCCGCCTCGTGTTGGTTCAGCTTTCTGTCGCGAGACC 516 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509673  CTTCGCGGCGCGGGTACCCCTTCCCCGCCTCGTGTTGGTTCAGCTTTCTGTCGCGAGACC 32509732 
 
Query 517       CTTCGCGGAAGACTCGGCGGCGCGCGTCCGGTGTGAGCCTTGTCCCTCAGTGGTCCTTCG 576 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509733  CTTCGCGGAAGACTCGGCGGCGCGCGTCCGGTGTGAGCCTTGTCCCTCAGTGGTCCTTCG 32509792 
 
Query 577       CGAATGGGCGGGACCGCTCCGTTCCCGCCTGGGTTGCCACGCGGCTGGGGGCGGAGGCTC 636 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509793  CGAATGGGCGGGACCGCTCCGTTCCCGCCTGGGTTGCCACGCGGCTGGGGGCGGAGGCTC 32509852 
 
Query 637       GGGATCGGGGCCGCCCTCTAGCTTAACGGTTTGGCGGCGGTGGTCAGGGTTCGACCAACG 696 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32509853  GGGATCGGGGCCGCCCTCTAGCTTAACGGTTTGGCGGCGGTGGTCAGGGTTCGACCAACG 32509912 
 
Query  697       GACTTGGGGACGGCCCGAGAGTTT  720 
                 |||||||||||||||||||||||| 
Sbjct  32509913  GACTTGGGGACGGCCCGAGAGTTT  32509936 
 
Score 652 bits(722) , Expect=0.0    Identities Gaps Strand Frame 
                          403/435(93%)       5/435(1%)       Plus/Plus  
Features: 
29685 bp at 5' side: polyserase-2 isoform 1 precursor61 bp at 3' side: RNA-binding protein FUS isoform 2 
Query 767       GAGCTCGCCATCCTGGGTGAAAGCGGGGCCCAGCGAAGGGGCCCGGCCACAGGAATCTCG 826 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32508758  GAGCTCGCCATCCTGGGTGAAAGCGGGGCCCAGCGAAGGGGCCCGGCCACAGGAATCTCG 32508817 
 
Query 827       GTTCCACCCCGCTACTCCCGGCTGTGACTCCAGTTTCGTccccagccgccgggaccgccc 886 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32508818  GTTCCACCCCGCTACTCCCGGCTGTGACTCCAGTTTCGTCCCCAGCCGCCGGGACCGCCC 32508877 
 
Query 887       cctcgccccgcccccAGCGGGCACTCNN-CCGTACCACTGTGCCTTCATGGGGGTGGAGA 945 
                ||||||||||||||||||||||||||   ||||||||||||||||||||||||||||||| 
Sbjct 32508878  CCTCGCCCCGCCCCCAGCGGGCACTCAGGCCGTACCACTGTGCCTTCATGGGGGTGGAGA 32508937 
 
Query 946       TAGATCGTGGGCTAGTCCTGCCGAGGAGAGAGGGGTTCTTCCTCAAAAAATATGATTATG 1005 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
198 
 
Sbjct 32508938  TAGATCGTGGGCTAGTCCTGCCGAGGAGAGAGGGGTTCTTCCTCAAAAAATATGATTATG 32508997 
 
Query 1006      TATAGTATTCGCATGATTCTAGTTAACTTGTTTCCCTTCTGCCTGCTCGGACCCTCTACC 1065 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 32508998  TATAGTATTCGCATGATTCTAGTTAACTTGTTTCCCTTCTGCCTGCTCGGACCCTCTACC 32509057 
 
Query 1066      TGCCCTACGAAGGGGGCGGAGTGCGTTCCTGCCTCCCCCTGCTCTT-CGCNTTTGGNGCG 1124 
                |||||||||||||||||||||||||||||||||||||||||||||| ||| ||||| ||| 
Sbjct 32509058  TGCCCTACGAAGGGGGCGGAGTGCGTTCCTGCCTCCCCCTGCTCTTCCGCGTTTGGTGCG 32509117 
 
Query 1125      CGCCNGCGCGGNNCGT--NNNNNGNANCGTACTTNAGCTTCGAC-NNNNNGNNNGGGNTG 1181 
                |||| ||||||  |||       | | ||||||| |||||||||      |   ||| || 
Sbjct 32509118  CGCCTGCGCGGTGCGTAGGCGGCGGAGCGTACTTAAGCTTCGACGCAGGAGGCGGGGCTG 32509177 
 
Query 1182      CTCANNCCTCCNGGC  1196 
                ||||  ||||| ||| 
Sbjct 32509178  CTCAGTCCTCCAGGC  32509192 
 
C  PARK7 SVA 
 
 
                                                        
 
                                                       Identities Gaps Strand Frame 
Score=1738 bits(941), Expect=0.0                                                         954/964(99%)           2/964(0%)     Plus/Plus  
Features:  
Query  70       GGCTTTTTGATAACCCCTGACTGAAACCCTAAGTAATGGGATCTTACTCTCACTTCAAGA  129 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7999801  GGCTTTTTGATAACCCCTGACTGAAACCCTAAGTAATGGGATCTTACTCTCACTTCAAGA  7999860 
 
Query  130      AATAAGAtcctctccctctccctctccctctccctctccctctctctccacggtctcctt  189 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7999861  AATAAGATCCTCTCCCTCTCCCTCTCCCTCTCCCTCTCCCTCTCTCTCCACGGTCTCCTT  7999920 
 
Query  190      ccacggtctccctctgatgccgagccaaagctggacggtactgctgccatctcggctcac  249 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7999921  CCACGGTCTCCCTCTGATGCCGAGCCAAAGCTGGACGGTACTGCTGCCATCTCGGCTCAC  7999980 
 
Query  250      tgcaacctccctgcctgattctcctgcctcagcctgccgagtgcctgcgcacgccgccac  309 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7999981  TGCAACCTCCCTGCCTGATTCTCCTGCCTCAGCCTGCCGAGTGCCTGCGCACGCCGCCAC  8000040 
 
Query  310      gcctgactggttttcg--ttttttttttgtggagacggggttttgctgtgttggccgggc  367 
                ||||||||||||||||  |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8000041  GCCTGACTGGTTTTCGTTTTTTTTTTTTGTGGAGACGGGGTTTTGCTGTGTTGGCCGGGC  8000100 
 
Query  368      tggtctccagctcctaaccacgagtgatccgccagcctcggcctcccgaggtgccgggat  427 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8000101  TGGTCTCCAGCTCCTAACCACGAGTGATCCGCCAGCCTCGGCCTCCCGAGGTGCCGGGAT  8000160 
 
Query  428      tgcagacggagtctcgttcactcagtgctcaatggtgcccaggctggagtgcagtggcgt  487 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8000161  TGCAGACGGAGTCTCGTTCACTCAGTGCTCAATGGTGCCCAGGCTGGAGTGCAGTGGCGT  8000220 
 
Query  488      gatctcggctcgctacaacctccacctcccagccgcctgccttggccccccaaagtgccg  547 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8000221  GATCTCGGCTCGCTACAACCTCCACCTCCCAGCCGCCTGCCTTGGCCCCCCAAAGTGCCG  8000280 
 
Query  548      agattgcagcctctgcccagccgccaccccgtctgggaagtgaggagcgtctctgcctgg  607 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8000281  AGATTGCAGCCTCTGCCCAGCCGCCACCCCGTCTGGGAAGTGAGGAGCGTCTCTGCCTGG  8000340 
 
Query  608      ccccccatcgtctgggatacgaggagcctctctgcctggctgcccagtctggaaagtgag  667 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8000341  CCCCCCATCGTCTGGGATACGAGGAGCCTCTCTGCCTGGCTGCCCAGTCTGGAAAGTGAG  8000400 
 
Query  668      gagcgtccctgcccggccgccatcccatctaggaagcgaggagcgcctcttccccgccgc  727 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8000401  GAGCGTCCCTGCCCGGCCGCCATCCCATCTAGGAAGCGAGGAGCGCCTCTTCCCCGCCGC  8000460 
 
Query  728      catcccatctaggaagtgaggagcgtctctgcccggccacccatcgtctgagatgtgggg  787 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8000461  CATCCCATCTAGGAAGTGAGGAGCGTCTCTGCCCGGCCACCCATCGTCTGAGATGTGGGG  8000520 
 
Query  788      agcacctctgccccgccgccctgtctgggatgtgaggagcgcctctgctgggccgcaacc  847 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




Query  848      ctgtctgggaggtgaggagcgtctctgcccggccgccccgtctganaagtgagaaaaccc  907 
                ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
Sbjct  8000581  CTGTCTGGGAGGTGAGGAGCGTCTCTGCCCGGCCGCCCCGTCTGAGAAGTGAGAAAACCC  8000640 
 
Query  908      tctgcctggcaaccgccccgtctganaantgaggancccctccgtccggcagccaccccg  967 
                ||||||||||||||||||||||||| || |||||| |||||||||||||||||||||||| 
Sbjct  8000641  TCTGCCTGGCAACCGCCCCGTCTGAGAAGTGAGGAGCCCCTCCGTCCGGCAGCCACCCCG  8000700 
 
Query  968      tctgggaantgaggancgtctccgcccggcagccaccccgtctggganggaggtnggggg  1027 
                |||||||| |||||| ||||||||||||||||||||||||||||||| |||||| ||||| 
Sbjct  8000701  TCTGGGAAGTGAGGAGCGTCTCCGCCCGGCAGCCACCCCGTCTGGGAGGGAGGTGGGGGG  8000760 
 
Query  1028     gggg  1031 
                |||| 
Sbjct  8000761  GGGG  8000764 
 
 
Figure 6.6:.Alignments between predicted and sequenced (from FUS proximal promoter) of (A) INT 














Figure 6.7: Map of P1229. The location of the Ampicillin resistance gene 
(AmpR) and minimal human β-globin promoter (hβglobin), LacZ gene and 
SV40 (Poly A generation) insertion into the pBluescript backbone. DNA 
sequence supplied by Alasdair Mackenzie. The RE site at the MCS that cut only 
once in the whole sequences are shown. Hb9 enhancer sequence was inserted 





Figure 6.8: Map of ires GFP. The location of the minimal human β-actin Promoter DNA 
sequence, the RE site of the iresglink are shown. Ires GFP sequence inserted between XhoI 
(3099bp) and PstI (3657bp) 
202 
 
A7 Map of td Tomato                                                     
PtdTomato 
PtdTomato 
Figure 6.9: Map of td Tomato plasmid. The location of the β- actin promoter, DNA 
sequence of tdTomato a kind gift from Marco Marcello, University of Liverpool was 

















Figure 6.10: Map of the phrGFP Vector. This vector contains the hrGFP gene and the 
SV40 polyadenylation signal, multiple cloning site, the location of the Ampicillin 






Figure 6.11: Map of phrGFP FUS PP the location of the Ampicillin 
resistance gene (AmpR) and minimal human FUS Promoter (FUS PP), GFP 
gene and SV40 (Poly A generation) insertion into the phrGFP backbone. 




Figure 6.12: Map of phrGFP FUS ECR PP The location of the Ampicillin 
resistance gene (AmpR) and minimal human FUS Promoter (FUS PP), GFP 
gene and SV40 (Poly A generation) insertion into the phrGFP backbone. 





Figure 6.13: Map of phrGFP FUS INT PP The location of the Ampicillin 
resistance gene (AmpR) and minimal human FUS Promoter (FUS PP), GFP 
gene and SV40 (Poly A generation) insertion into the phrGFP backbone. FUS 














Figure 6.14: Map of phrGFP FUS INT ECR PP The location of the Ampicillin 
resistance gene (AmpR) and minimal human FUS Promoter (FUS PP), GFP 
gene and SV40 (Poly A generation) insertion into the phrGFP backbone. FUS 




Figure 6.15: Map of phrGFP FUS SVA PP. The location of the Ampicillin 
resistance gene (AmpR) and minimal human FUS promoter (FUS PP), GFP gene 
and SV40 (Poly A generation) insertion into the phrGFP backbone. FUS SVA PP 




Figure 6.16: Map of phrGFP FUS SVA ECR PP. The location of the Ampicillin 
resistance gene (AmpR) and minimal human FUS promoter (FUS PP), GFP gene 
and SV40 (Poly A generation) insertion into the phrGFP backbone. FUS SVA PP 




Figure 6.17: Map of phrGFP FUS VNTR PP. The location of the Ampicillin 
resistance gene (AmpR) and minimal human FUS promoter (FUS PP), GFP gene 
and SV40 (Poly A generation) insertion into the phrGFP backbone. FUS SVA PP 




Figure 6.18: Map of phrGFP FUS VNTR ECR PP, the location of the Ampicillin 
resistance gene (AmpR) into the phrGFP backbone.FUS VNTR ECR PP sequence 












Figure 6.19: Map of phrGFP FUS PP PARK SVA, the location of the Ampicillin 
resistance gene (AmpR) into the phrGFP backbone.FUS VNTR ECR PP sequence 
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